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Abbreviations 
 
A 
aa   Amino acid 
AIDS   Acquired immune deficiency syndrome 
APC   Antigen presenting cell 
AR   Acute rejection 
ART   Anti-retroviral therapy 
 
B 
BCIP   5-Bromo-4-chloro-3-indolylphosphate 
BFA   Brefeldin A 
BKV   BK virus (Polyomavirus BK) 
BSA   Bovine serum albumin 
 
C 
CD   Cluster of differentiation e.g. CD4+ 
CDV   Cidofovir 
CMV   Cytomegalovirus 
CsA   Cyclosporin A 
CSF   Cerebrospinal fluid 
CTL   Cytotoxic T lymphocyte 
 
D 
D   Donor 
DC   Dendritic cell 
DMSO  Dimethylsulfoxid 
DNA   Deoxyribonucleic acid 
 
E 
EBV   Epstein Barr Virus 
EDTA   Ethylene diamine tetraacetic acid 
ELISA   Enzyme-linked immunosorbent assay 
EM   Electron microscopy 
ESA   Enzyme-linked immunospot assay (Elispot) 
 
F 
FACS   Fluorescence activated cell sorting 
FK506  Tacrolimus, also see “Tac” 
 
G 
gB   Glycoprotein B 
GCV   Ganciclovir 
G-CSF  Granulocyte colony-stimulating factor 
GM-CSF  Granulocyte and macrophage colony-stimulating  
   factor 
GranB   Granzyme B 
GvHD   Graft versus host disease 
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H 
HAART  Highly active anti-retroviral therapy 
HC   Haemorrhagic cystitis 
HD   Healthy blood donor 
HEK   Human embryonic kidney (cell line) 
HHV6   Human Herpes virus 6 
HHV8   Human Herpes virus 8 
HIV   Human immunodeficiency virus 
HSCT   Hematopoietic stem cell transplantation 
 
I 
i.v.   Intravenous 
IE   Immediate early (phase of cytomegalovirus gene  
   expression) 
IFN   Interferon e.g. alpha, beta, or gamma 
Ig   Immunoglobulin 
IL   Interleukin e.g. IL-17 
IRIS   Immune reconstitution inflammatory syndrome, also IRS 
ISG   Interferon stimulated genes 
 
J 
JCV   JC virus (Polyomavirus JC) 
 
K 
KCl   Potassium chloride 
KIV   KI virus, Polyomavirus KI (Karolinska Institute) 
KT   Kidney transplant patient 
 
L 
LPS   Lipo-polysaccharide 
LT   Large T (early protein) 
Lys   Lysate 
 
M 
Mφ   Macrophage 
mDC   Mature dendritic cell 
MHC   Major histocompatibility complex 
MPyV   Merkel cell carcinoma associated Polyomavirus 
MPA   Mycophenolate acid 
mRNA  Messenger RNA 
mTOR  Mammalian target of rapamycin 
 
N 
NaCl   Sodium chloride 
NBT   p-Nitroblue Tetrazoliumchlorid 
NCCR   Non-coding control region 
NK cell  Natural killer cell 
NOD   Nucleotide-binding oligomerization domain, NOD-like  
   receptors 
NLS   Nuclear localization signal 
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O 
OD   Optical density 
 
P 
PBMC   Peripheral blood mononuclear cell 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
Perf   Perforin 
PML   Progressive multifocal leukoencephalopathy 
pp   Phosphoprotein 
pp65   CMV capsid protein (late protein) 
pp72   CMV immediate early 1 protein (immediate early  
   protein) 
PVAN   Polyomavirus associated nephropathy 
PyV   Polyomavirus 
 
R 
R   Recipient 
Rapa   Rapamycin, also see “Sir” 
Rb   Retinoblastoma susceptibility protein 
RNA   Ribonucleic acid 
RPMI   Roswell Park Memorial Institute (cell medium) 
RPTEC  Renal proximal tubular epithelial cells (cell line) 
 
S 
SEB   Staphylococcal enterotoxin B (super antigen) 
SFU   Spot forming unit 
Sir   Sirolimus, also see “Rapa” 
siRNA   Small interfering RNA 
SOT   Solid organ transplantation 
sT   Small T antigen (early protein) 
SV40   Simian virus 40 
 
T 
Tac   Tacrolimus, also see FK506 
TCR   T-cell receptor 
TEM   Effector memory T-cell 
Th1   T helper cell type 1 
Th2   T helper cell type 2 
TMB   Tetramethylbenzidine 
TLR   Toll like receptor 
TREC   T-cell receptor excision cycle 
T-reg   T regulatory cells 
TRIS   Tris-hydroxymethyl-amino methane 
 
U 
UL   Unique long domain, gene  sequence in CMV genome 
    e.g. UL97 
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V 
VLP   Virus like particle 
VP1   Viral capsid protein 1 (late structural protein) 
 
W 
wt   Wild-type 
WUV   WU virus, Polyomavirus WU (Washington university) 
 
Miscellaneous 
+   Positive 
-   Negative 
3D   3 dimensional 
PhD thesis: CMV and BKV immunity, Adrian Egli                                      11/196 
 
1. Introduction 
 
The deceptively small size and simple structure of viruses feints their diverse 
and fascinating interactions with the infected host cells and the corresponding 
antiviral host responses. During my PhD thesis, I focused on three main 
aspects of these complex interactions for Cytomegalovirus (CMV) and 
Polyomavirus BK (BKV): 
(I) Measurement of CMV and BKV-specific immune response in 
healthy individuals and kidney transplant recipients 
(II) Determination of immunological risk factors associated with virus 
replication and development of virus-associated diseases 
(III) Identification of immuno-dominant responses to CMV and BKV 
protein and epitopes 
 
 CMV and BKV have an significant impact on transplantation with 
considerable morbidity, graft dysfunction or loss, and even mortality (Hirsch 
and Steiger 2003; Egli, Binggeli et al. 2007; Fishman 2007). 
 
A deeper understanding of the basic mechanisms of virus recognition by the 
immune system and the nature of the resulting immune response in healthy 
individuals vis-à-vis immunosuppressed patients may help (i) to improve 
current immunological monitoring assays; (ii) to further identify risk groups for 
virus replication; (iii) to quantify risks for progression to virus diseases; (iv) to 
guide antiviral and immunosuppressive therapies; and (v) to develop new 
therapeutic strategies such as vaccines and adoptive T-cell transfer 
(Hoffmeister, Kiecker et al. 2003). 
 
1.1. General aspects of virus and host interaction 
 
According to Darwin’s principle “survival of the fittest”, viruses require 
sufficient replication for transmission to new potential hosts. The host cells 
have developed respective defence mechanisms to prevent damage from 
virus replication. Adaptation of the virus and host occurred co-evolutionary 
over time and our current view of virus infections result from old evolutionary 
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established companionship and new challenges due to new opportunity 
regarding transmission as well as gaps in the immune defence.. 
  
Viruses are obligate intracellular pathogens. Importantly, the host and 
particularly cell tropism are dependent on several factors:  
 
(I) Availability of cell surface receptors for virus entry. 
(II) The specificities of the replication machinery in infected cells, built 
through a conglomerate of the hosts’ transcriptome, proteome, 
and cytokinome. 
(III) The immunological pressure presence at the site of replication. 
 
Interestingly, viral cell tropism is not static. Tropism can adapt during the 
course of infection, to recruit further replication seites or to establish latency 
(Este, Babrera et al. 1999; Mosier, Picchio et al. 1999).  
 
The first step is viral entry into a host cell. In case of a lytic infection, the 
cellular replication machinery is redirected for production of more virus 
particles. The viral genome is replicated, required proteins are built, 
assembled, and packaged into the newly formed viral particles. Finally, 
viruses exit cells either via lytical or non-lytical mechanisms. In the case of an 
abortive infection, the virus may not replicate in the cell due to suboptimal 
tropism or killing by the host immune response. In the case of a latent 
infection, viruses only express latency associated proteins and the host cell 
remains intact. 
 
Figure 1 shows the described pathways of virus replication from cell entry to 
production and assembly of virus proteins, and virus exit during CMV and 
BKV infection (Figure 1, further details can be found in chapter 1.3.1. and 
1.3.2.).  
 
The virus either (I) replicates actively with high viral loads and it becomes 
cleared by the host immune response. Or, (II) after the primary round of 
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replication the virus establishes latency or a low replicating state with no 
clearance, and builds equilibrium together with the host immune response. 
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Figure 1. Replication cycle of Cytomegalovirus (A) and Polyomavirus BK (B). 
Left text box indicates: entry receptor, host cells infected and transcription 
factor binding site, and exit mechanisms. 
Right scheme shows: cellular mechanism of replication with time scale for the 
key processes. 
1.1.1. Virus latency and reactivation 
 
A virological definition of latency is the infection of host cells with harboured 
full-length virus genomes, but without replication. During latency, viruses need 
to avoid immune recognition and initiation of defence mechanisms. This can 
be achieved by significantly lower antigen presentation and expression of a 
special set of latency associated proteins. As a cost, no active virus 
transmission occurs during the latent phase. 
From the clinical point of view, latency is infection of a person without disease. 
 
When the host is in “danger” for example during sepsis, trauma, or elective 
surgery, higher levels of transcription factors are expressed. These 
transcription factors bind to host gene promoters, but may activate viral 
promoter and reactivate replication of latent viruses (Sinclair and Sissons 
2006; Miller, Rashid et al. 2007; von Muller, Klemm et al. 2007; Limaye, Kirby 
et al. 2008; Sharma, Gerlitz et al. 2008; Yan, Huang et al. 2008). 
Examples of important transcription factors are NFkB and AP-1 (Ha, Park et 
al. 2004; Lopez-Maury, Marguerat et al. 2008; Montalvo-Jave, Escalante-
Tattersfield et al. 2008). These factors may also be activated in the setting of 
transplantation, either in the donor due to brain damage and ischemia, or in 
the recipient by the condition leading to failure of the organ to be transplanted 
or by the surgical procedure. Down-modulation of host cell transcription 
factors pre-transplantation with siRNA may be a promissing future treatment 
option to avoid virus reactivation in ischemic phases (Zhen, Lian et al. 2007). 
 
The general course for virus reactivation in transplantation results from 
activating factors (cytokines, ischemia, etc) and loss of adwquate immune 
control. 
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1.1.2. Host immune response 
 
Throughout evolution, viruses and hosts have been engaged in an 
evolutionary arms race (Domingo 2007). From the evolutionary standpoint, 
viral infection places host cells under an important pressure to build up an 
efficient defence mechanism against these obligate intracellular parasites 
(Cooper 1976; Klein 1982; Tarikudanathan and Sayegh 2007; Cooper 2008; 
Ferrer.Admetlla, Bosch et al. 2008; Lanier 2008; Tarlinton 2008). 
Differentiation of self from non-self is the key function of the immune system 
and executed through the innate and adaptive immune response by inducing 
an inflammatory reaction (Metchnikoff 1883; Zinkernagel and Doherty 1974). 
1.1.2.1. Innate immune response 
 
The hallmark of the innate immunity is its limited but predefined specificity to 
divide between self and non-self, allowing fast responses yet without 
immunological memory. 
 
The innate immune response is built upon cellular and humoral effectors. 
The first line of cellular defence is the epithelial barrier on skin, in the 
respiratory and gastrointestinal tract. These barriers contain anti-microbial 
proteins and more specialized cells (Gallo, Murakami et al. 2002). 
Most host cells, but especially professional antigen presenting cells (APC) 
such as DCs, B-cells and macrophages, can recognize pathogen-associated 
molecular patterns (PAMPs). Typical pathogen structures (non-self) such as 
basic lipids and sugar structures or characteristic DNA and RNA motives are 
recognised by Toll like receptors (TLR, (Arancibia, Beltran et al. 2007; Bowie 
2007; Schröder and Bowie 2007)), Mannose-binding-lectin, scavenger 
receptors, NOD-like receptors (Rietdijk, Burwell et al. 2008), and the 
inflammosome complex (Lee and Kim 2007; Muruve, Petrilli et al. 2008). 
 
The activation of PAMP receptors lead to a release of humoral effectors of the 
innate immune system such as interferon alpha or beta, and other 
inflammatory cytokines leading to a anti-viral or -bacterial state of 
neighbouring cells (Barton and Medzhitov 2002). Additionally co-stimulatory 
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molecules for T-cells are up-regulated and antigens processed via MHC. 
Thereby, the APC builds an important bridge from the innate to the adaptive 
immune response (Figure 2 for overview of factors of the innate immune 
system). 
Other humoral effectors of the innate immune system consists of soluble 
factors such as kinin-, coagulation-, and complement-system, which have an 
antimicrobial effect (Tomlinson 1993; van der Poll 2001). Especially the 
complement system is able to recruit further inflammatory cell, is part of the 
opsonization process and able to induce killing via building the membrane 
attack complex in antibody-marked pathogens (Bhakdi and Tranum-Jensen 
1991). 
 
 
Figure 2. Overview of adaptive (T-cell) and innate (APC) interactions of the 
immune system. 1st signal: MHC/peptide presentation to T-cell receptor. 2nd 
signal: Co-stimulation. The central role of dendritic cells between innate and 
adaptive immune mechanisms is shown. 
PhD thesis: CMV and BKV immunity, Adrian Egli                                      17/196 
 
Another important factor is RNA interference (siRNA) expressed in almost 
every host cell. Cellular siRNA is already found in prokaryotic cells (Lu, Gan et 
al. 2008). Within the host cell, siRNA down-modulates foreign viral DNA or 
RNA via dimer formation (Gottwein and Cullen 2008). 
 
1.1.2.2. Adaptive immune response 
 
The hallmark of the adaptive immune system is its high specificity and its 
ability to build up an immune response (non-self) faster upon reencounter 
(immunological memory). 
 
The adaptive immune response is built on cellular and humoral effectors. 
 
Cellular adaptive immune response is engaged by T-cells and B-cells. Two 
main subset of T-cells exist: CD8+ cytotoxic and CD4+ helper T-cells. 
Every host cell constantly presents intra-cellular 9mer peptides via major 
histocompatibility complex I (MHC I) to CD8+ T-cells. Professional APCs 
additionally present extra-cellular 15mer peptides via MHC II to CD4+ T-cells. 
 
Peptide presentation is a highly complex process, and also very important for 
the understanding of epitope mapping in general, therefore the main features 
are summarized in the next paragraphs. 
 
The main steps of peptide processing are (i) cleavage of the antigen, (ii) 
loading on the MHC molecule, and (iii) presentation and interaction with a 
corresponding T-cell receptor (see Figure 3). 
 
In the cytosol, a large multi-catalytic protease complex, the proteasome, 
performs protein degradation of cytosolic proteins. The proteasome consists 
of 28 sub-unites, arranged in four stacked rings, each of seven subunits. 
Interferons induce parts of the proteasome (KNP2 and LMP7). An interferon-
induced proteasome switches its specificity to an increased cleavage of 
polypeptides after hydrophobic residues, and reduced cleavage after acidic 
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residues (Goldberg, Cascio et al. 2002; Rock, York et al. 2002). This may lead 
to an epitope switch during infection and therefore has important 
consequences for diagnostic and therapeutical targeting. 
For extracellular proteins, protein cleavage happens in the endosome, which 
becomes increasingly acidic. The endosomes contain cysteine proteases as 
cathepsins B, D, S, and L.  
 
 
 
Figure 3. Function of the antigen presenting cells during peptide processing: 
(i) Protein cleavage, (ii) epitope loading on MHC and (iii) processing on the 
cell surface (adapted from Felix and Allen, 2007 Nature Review Immunology) 
 
As the MHC molecule trans-locates during synthesis into the lumen of the 
endoplasmic reticulum (ER) and on the one side, and all proteins are 
produced and cleaved in cytosol on the other side, there is the requirement for 
transport of peptides from cytosol to the ER. This transport system is called 
transporters associated with antigen processing -1 and -2 (TAP-1 and -2). The 
TAP complex prefers peptides between 8 and 16 amino acids with 
hydrophobic or basic residues at the carboxy-terminus, and has a bias against 
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proline in the first three amino terminal residues (Uebel and Tampe 1999; 
Lankat-Buttgereit and Tampe 2002). 
 
Binding of a peptide to MHC is an important step for the assembly of a stable 
MHC molecule. For MHC I, following steps through the cascade of peptides 
(calnexis, calreticulin, and tapsin), the MHC I complex finally binds to TAP 
with the cytosolic cleaved peptide. Only the fully folded trimmed MHC class I 
molecule and its bound 9mer peptide are then stable and leave the ER via 
Golgi to the cell surface. 
For MHC II molecule, the peptide is also important for stabilisation. However, 
before binding a 15mer sequence, the MHC II needs to avoid unspecific 
binding within the ER. This is mediated by the MHC class II-associated 
invariant chain. The invariant chain lays within the MHC binding grooveand is 
then cleaved within the less acidic endosome to be replaced by a 15mer 
peptide fragment. Finally the MHC II-peptide complex is transported to the cell 
surface (Lagaudriere-Gesbert 2002; Williams, Peh et al. 2002). 
 
 
 
Figure 4. Peptide binding to MHC I (green), and MHC II (orange). 
 
The binding of peptides to the MHC molecule is mediated through specific 
amino acid anchor residues. The amino acid side chain anchors the peptide 
by binding to pockets that lie in the peptide-binding groove. Polymorphisms in 
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the MHC molecule define the amino acid chain structure of the pockets and 
the pockets’ binding specificities. Thus, these polymorphisms determine the 
particular HLA type and the consequent peptide to be presented (see Figure 
4). For example HLA A0201 prefers a leucin and valine at the 2nd and 9th 
position of a 9mer epitope for binding into a MHC I molecule, whereas HLA 
B0702 prefers a prolin at the second position. 
 
T-cells recognize MHC-bound peptides via their T-cell receptor (TCR) 
(Zinkernagel and Doherty 1974). The TCR is highly specific for only one 
determined self or non-self amino acid sequence. 
 
Stimulated T-cells engage several functions in dependance of their subtype: 
CD8+ T-cells may induce killing of APCs via Granzyme B and Perforin. CD4+ 
T-cells mainly produce supporting cytokines. Three subtypes of CD4+ T-
helper cells exist: Th1-cells release mainly IL2, TNFα and INFγ, which support 
CD8+ T-cells; and Th2-cells release IL4, 5, and 13 leading to stimulation of B-
cells, IgG switch to IgE and inhibition of macrophage activity. Newly 
discovered Th17-cells release IL17, although their role in infection control is 
yet controversial (Jin, Zhang et al. 2008). 
 
The role of dedicated anti-viral T-cells in controlling virus replication is 
important and development of posttransplant virus disease was correlated to 
reduced amounts of virus-specific T-cells (Zinkernagel and Althage 1977; 
Sester, Gartner et al. 2005). The in vivo function of virus-specific T-cells and 
the protective effect normally is linked to in vitro induced cytokine production. 
Cytokines can be measured as a release with Elispot assay, or the 
intracellular accumulation with flow cytometry. Epitope-specific T-cell can be 
stained with tetramers (see Figure 6).  
As the immune responses may lead to dangerous collateral damage to the 
host, it must be tightly controlled. 
(i) In the thymus, T-cells with an auto-reactive or excessively strong binding 
TCR are positive selected by induction of apoptosis. Negative selection 
acts on T-cells with weakly binding TCR (Plamer 2003; Miosge and 
Zamyska 2007; Naeher, Daniels et al. 2007). 
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(ii) In the periphery the expanded pathogen-specific T-cell clone fraction 
needs to constrict and differentiate into a smaller set of memory T-cells 
after clearing the pathogen. (Lan, Mackay et al. 2007; Sakaguchi, 
Yamaguchi et al. 2007). The contraction phase is influenced by the 
eradication of the pathogen and therefore anergy to T-cells due to less 
stimulation, induction of apoptosis and external control through 
regulatory T-cells (T-regs). Similar to cytotoxic T-cells, T-regs also carry 
a pathogen-specific TCR, but produce down-modulating cytokines such 
as IL10 or TGFbeta. 
 
Another important part of the adaptive immune response is the production of 
antibodies by B-cells. The membrane-bound immunoglobulin (B-cell receptor) 
may also be released into plasma or tissue. Depending on the maturation 
state of the B-cell, the location of the B-cell and cytokine profile present, IgA, 
IgD, IgE, IgG or IgM are produced. Mature B-cells release antibodies with a 
higher binding affinity to an epitope (affinity) (Davies and Chacko 1993). 
Immunoglobulins may bind to viruses and inhibit infection of new host cells 
(neutralizing) or binding to bacteria and help during phagocytosis 
(opsonization). Although, not all antibodies produced are neutralizing. 
1.1.3. Virus adaptation 
 
Like pointed out before, the host’s immune responses place viruses under 
pressure to adapt. In general terms, adaptation to a new biological 
environment is based on the accumulation of mutations over a specific time-
span (Thommes and Hubscher 1990; Drake and Holland 1999; Domingo, 
Biebricher et al. 2001; Friedberg, Walker et al. 2006). During continuous 
infection, antiviral treatment and antiviral immune response, a heterogeneous 
pool of viral genomes (quasi species) evolves in the host. This enables 
selection for various elegant escape mechanisms (Smith and Inglis 1987; 
Lopez-Bueno, Mateu et al. 2003; Domingo 2006). This viral positive selection 
includes complement activation blockade, inhibition of MHC presentation, 
interference with ubiquitin-dependent proteolysis, interaction with apoptosis 
pathways, production of cytokines, chemokines and receptor homologues 
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(Ploegh 1998; Alcami 2003) 
Escape mutations from neutralizing antibodies and from T-cell recognition can 
even be observed in vivo (Borrow, Lewicki et al. 1997; Ciurea, Klenerman et 
al. 2000). 
Due to its random nature, most mutations lead to a severe loss of function, 
known as viral negative selection(Müller and Bonhoeffer 2003). This is 
reflected in the frequency of any particular mutant among all possible variants 
depending on its replication capacity (Domingo 2006). The reduced fitness of 
a mutated strain can revert to the original sequence, when the selective 
antibody or T-cell pressure is no longer present (Borrow, Lewicki et al. 1997). 
However, this possibility only occurs rarely in complex genomic 
rearrangements, in accordance with Muller’s ratchet hypothesis (Chao 1990).  
 
The rate of evolution can be indicated as nucleotide substitutes per year in an 
organism (Shankarappa 1999). A lower rate of evolution probably indicates a 
better adaptation to the host, and potentially is higher in latency-associated 
pathogens. 
 
Over the course of evolution, latent viruses perfectly adapt to the response of 
the immune system and vice-versa. Nowadays, transplantation medicine 
challenges the equilibrium of host and virus by putting the graft as a new 
player into the game. The impact of immune suppression and the presentation 
of self and non-self peptides via allogenic MHC molecules shifts the 
established balance between virus and host. 
 
1.2. Aspects of virus and host interaction in the transplant setting 
 
The potent and long lasting immunosuppression in solid organ transplantation 
has led to a reduction of acute rejection episodes in recent years (Meier-
Kriesche, Li et al. 2006). Most probably due to a reduction of virus-specific 
immune control, in transplant recipients a higher virus-associated morbidity 
and mortality has been observed (Fishman 2007). Registry data of paediatric 
kidney transplant patients showed an increase of infections from 20.4% to 
30.8% from 1982 to 2002 (Dharnidharka, Stablein et al. 2004). Similarly, in 
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adults above 50 years of age, infection rates during the first year post-
transplant increased from 48% to 69% (Dharnidharka, Caillard et al. 2006). 
Important players beside viral characteristics are the host and graft. All three 
form a complex interactive unit, influenced by external factors as trough levels 
of immunosuppression, antiviral treatment, or co-infections (Figure 5). 
 
 
 
Figure 5. Host-Graft-Virus interaction. Yellow circle: Host factors; red circle: 
virus factors; blue circle: graft factors. Interacting fields are indicated with 
colour changes. 
 
1.2.1. Risk profiling 
 
Pre- and post-transplantation the donor, recipient and graft are screened for 
their respective contribution to infection risk depending on recipient and donor 
patient history, epidemiological situations of pathogens, patients age, type of 
transplantation, and signs and symptoms of deceased donors ((Fishman 
2007), see Table 1). The risk profiles define post transplantation surveillance 
strategies such as anti-viral prophylaxis or preemptive strategies (Preiksaitis, 
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Brennan et al. 2005), and limitations or exclusion to transplantation programs 
(ID Community of Practice 2004). 
 
Recipient  
 Patient history 
 Vaccination 
 Epidemiology 
 Immune defects: humoral or cellular syndromes, 
splenectomy, thymectomy 
 Diagnostics 
 Chest x-ray 
 Serological immune response (IgG and IgM) 
 T. pallidum 
 HIV 
 Herpes viruses: CMV, EBV, HSV, VZV 
 Hepatitis viruses: HBV, HCV 
 (Polyomaviruses BK and JC) 
 Strongyloides, Coccoides, Histoplasmosis 
 Cellular immune response (INFγ positive T-cells) 
 Viruses: CMV, EBV, BKV 
 TBC (T-spot or Mantoux skin test) 
  
Donor  
 Patient history 
 Epidemiology 
 Diagnostics 
 Serological immune response (IgG and IgM) 
 T. pallidum 
 HIV 
 Herpes viruses: CMV, EBV, HSV, VZV 
 Hepatitis viruses: HBV, HCV 
 (Polyomaviruses BK and JC) 
 Toxoplasmosis 
 West nile virus 
 Microbiological testing of blood and urine 
 
Table 1. Screening parameter for graft recipient and donors pre- and post 
transplant (adapted from Fishman, NEJM 2007) 
 
The patient’s risk assessment for infection is based on serology and genome 
detection of the pathogen in urine, plasma or biopsy material. However, this is 
often inaccurate and shows the following problems (Fishman 2007). 
 
First, serological responses are three to four weeks delayed to acute infection, 
often are not directly correlated with protection from virus replication, may 
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cross-react to other similar viruses, and even may be false negative. 
Additionally, for newer pathogens standardized ELISA assays, clear definition 
of cut-offs, and baseline characteristics in healthy and immunosuppressed 
individuals are missing, and sero- or genotype specific gaps may be present. 
The influence of immunosuppression on serology data is not yet sufficiently 
examined. 
Second, genome amplification methods, on the other hand, require sufficient 
isolation of DNA or RNA in a sample. A “latent” virus, which is not replicating 
can be difficult to detect. The present amount of viral loads does not allow to 
fortune future dynamics. 
If an actively replicating virus is found, a graft usually disqualifies for 
transplantation. Unknown pathogens can show fatal outcomes as recently 
shown with LCMV infection (Allander, de Lamballerie et al. 2008). Without 
sequence information available, only high throughput techniques may be able 
to identify the unknown pathogen in reasonable time. 
 
Due to these problems, new testing methods are needed to further assess the 
risk of posttransplant reactivation and progression to virus disease. Virus-
specific cellular immune assays may answer several of the open questions, 
and in combination an accurate risk assessment may be performed 
(Ljungman 2006). 
1.2.2. Virus-specific immune assays 
 
In general, three immunological assay types can be used to quantify and 
characterize a virus-specific immune response after stimulation of peripheral 
blood mononuclear cells (PBMC) with antigens: 
(i) Elispot assay to measure secretion of cytokines by detecting spot 
forming units (SFU) per million PBMC 
(ii)  Intracellular cytokine staining and flow cytometry to detect 
accumulated cytokines in T-cells with addition of surface 
phenotyping with CD4+/CD8+, memory or effector marker 
description 
(iii) Tetramer assays to detect single virus-epitopes T-cells depending 
on the HLA context (also flow-cytometry based).  
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For Elispot and FACS assays usually lysates from infected cell cultures or 
overlapping peptide libraries are used to stimulate the virus-specific immune 
responses in vitro (Figure 6). 
 
 
 
Figure 6. Overview of assays used to measure virus-specific T-cells. Upper 
part: Difference between natural processed epitopes via APCs and artificial 
tetramer loading. Lower part: Three read out systems to measure - (i) Elispot, 
(ii) FACS and (iii) Tetramer binding. 
 
In Tetramer-assays streptavidin-fluorophore labeled MHC-I with a single 9mer 
bound can be used to stain T-cells harbouring the respective T-cell receptor. 
In this case, the precise epitope for one particular HLA-type must be known.  
 
A literature research on established cellular immune assays in daily clinical 
routine to assess the risk of patients for virus replication and progression to 
disease was rather disappointing (PubMed search September 2008). Hardly 
any laboratory has defined, published and in routine used cut-off levels, above 
which patients were protected. Such a cut-off, similar to a viral titer, would be 
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indeed very useful for assessing patients risk. Exceptions are CMV and BKV-
specific immune monitoring assays (see later in chapter 1.3.1. and 1.3.2.). 
 
Designing or improving a virus-specific immune assay requires cautiousness 
at several points. Generally, for a stimulatory antigen-pool, not all viral 
proteins or potential epitopes can be used. Mainly for cost reasons, a peptide 
library usually shows a 4aa gap between peptides. Therefore some important 
HLA relevant epitopes may be missed (HLA gap). Even in commercial tests 
such as the QuantiferonTM or T-spotTM assay for CMV or tuberculosis, no 
manufacturer information is available on this topic (http://www.cellestis.com/, 
http://www.oxfordimmunotec.com/eu/). The identification of immuno-dominant 
peptides could further reduce the amount of peptides used (Sylwester, 
Mitchell et al. 2005). Similar to serological test, cellular immune assays may 
also show a cross-reactive potential (Hamilton, Gravell et al. 2000; Kreijtz, de 
Mutsert et al. 2008). 
 
Effects of immunosuppression on the monitoring assay should also be 
considered. The trough level inhibits the allo-reactive and the virus-specific 
immune response. Immune responses should be set into the context with the 
specific immunosuppressive agent of the patient. 
Drugs such as Calcineurin inhibitors (Tacrolimus and Cyclosporin A) have a 
direct effect on the cytokine production of T-cells. Anti-proliferation drugs 
(Mycophenolic acid, rapamycin or leflunomide) act on proliferation capacities 
after stimulation (Halloran 2004) (Figure 7). 
 
Improvement of the current immune monitoring assays could be done, by 
comparison of healthy individuals to immunosuppressed patients, each with or 
without virus replication and progression to disease. This would allow 
identifying patients at risk and guide treatment. Further, immuno-dominant 
regions could be identified and baselines set for vaccine development. 
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Figure 7. Immunosuppressive drugs and their function on antigen presenting 
cells and T-cells. Green: Antigen presenting cell. Blue: Responding T-cell. 
Intracellular signalling pathways are described and interactions with 
immunosuppressive drugs (white arrows) are shown. 
 
1.3. Cytomegalovirus and Polyomavirus BK post-transplantation 
 
1.3.1. Cytomegalovirus 
 
Cytomegalovirus (CMV) belongs to the group of DNA viruses and the family of 
herpesviridae (Baltimore 1971). Beside CMV seven other human herpes 
viruses exist: Herpes simplex type 1 and 2, Epstein-Barr, Varicella zoster, 
Human Herpes virus 6, 7, and 8.  
 
1.3.1.1. Virus genome and proteins 
 
CMV has a linear double-stranded DNA genome of about 235’000 base pairs 
with more than 200 open reading frames, coding for at least 59 proteins. In 
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the nucleus a circular DNA matrix serves as transcription template (Dunn, 
Chou et al. 2003; Dolan, Cunningham et al. 2004). 
 
CMV latency, reactivation and replication is a tightly regulated process with 
coordinated expression of immediate-early, early and late genes (see Figure 
1). Immediate early proteins, such as IE-1 (pp72) or IE-2 are central 
regulators of viral gene expression. Early gene proteins such as UL97 
phosphokinase and UL54 DNA polymerase facilitate viral genome replication. 
Late proteins such as the tegumentum associated pp65 and glycoprotein B 
(gB) include structural proteins found in the viral capsid, matrix and envelope. 
 
CMV is transmitted via saliva, body fluids, cells, and tissues. The 
seroprevalence depends on socioeconomic status and lies between 30-70% 
in Western Europe and North America (Staras, Dollard et al. 2006). Following 
primary CMV replication in seronegative individuals, CMV establishes latency 
in CD34+ myeloid progenitor cells as a major site (Sinclair and Sissons 2006). 
 
CMV reactivation may occur in “danger” situations to the host, due to common 
shared transcription factors of host cells and viruses. Reactivation of CMV as 
a bystander during sepsis is a classical example (Limaye, Kirby et al. 2008). 
Important CMV transcription factors are: NF1, CREB/ATF, NFκB p50, and 
AP1 (He and Weber 2004; Sinclair and Sissons 2006; Lee, Klase et al. 2007). 
In critical ill patients commonly immune functions are severely suppressed 
and a phase of uncontrolled CMV replication may be followed. 
 
CMV has evolved various highly adapted immune evasive strategies against 
almost every key step in host immune responses (see Table 2).  
 
Despite all these fascinating immune evasive strategies, in a healthy 
immunocompetent host reactivation normally does not occur. If the host is 
immunosuppressed, uncontrolled and progressed CMV replication may lead 
to various direct and indirect CMV effects and diseases (Egli, Binggeli et al. 
2007). 
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Principle CMV factors involved Ref 
Cytokine effects IL-10 like cytokine Spencer, 2002 
MHC-I interference • US2 and 11 re-translocate the MHC from ER to cytosol 
• US3 binds MHCI and causes ER retention 
• US6 inhibits peptide transport and ATP hydrosis 
Wal 2002 
Ahn 1996 
Hewitt 2001 
MHC-II interference not known  
DNA CMV DNA around histones mimics host DNA Grassi 2003 
Interference with co-
stimulation 
• UL144 mimics inhibitory co-signalling function of 
herpes simplex virus entry mediator 
• CMV infected cell may up-regulate PD1 ligand 
Poole 2006 
Sester 2008 
siRNA • miRNA of UL112 down modulates MIC-B, a NK cell 
Ligand 
• β2.7 binds to mitochondrial enzyme complex 1 
Grey, 2007 
Reeves, 2007 
Dölken, 2007 
NK cell escape • UL18 decoy MHC-I like molecules 
• UL40 activates the inhibitory CD94/NKG2A receptor 
• UL141 retains CD155, a Ligand for the activating NK 
receptors DNAM-1 and TACTILE 
• UL16 binds ULBP1 and 2 which are NKG2D ligands 
• UL142 down-modulates MIC-A 
Beck, 1988 
Tomasec, 2000 
Tomasex, 2005 
Kubin, 2001 
Wills, 2005 
INF reduction 
ISG interference 
• UL83 (pp65) deletion induces higher INFβ and ISGs 
• IE2 interferences with NFkB 
• HCMV pTRS1 and PIRS1 block PAS mediated eIF2a 
phosphorylation and reduce RNA degradation by 
RNase L 
Browne, 2003 
Abate, 2004 
Tylor, 2006 
JAK/Stat signal-
transduction 
IE 72kDA and Stat2 association prevents ISGF3 DNA 
binding 
Paulus, 2006 
Site of replication almost every cells may replicate CMV  
   
 
Table 2. Viral escape strategies of Cytomegalovirus 
 
1.3.1.2. Risk assessment and immunological monitoring 
 
Management procedures for CMV are well defined (Preiksaitis, Brennan et al. 
2005). CMV seronegative recipients (R-) of a CMV seropositive donor graft 
(D+) and R(+) patients with anti-rejection or T-cell depleting induction 
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treatment are at high risk for CMV primary infection and uncontrolled 
replication of reactivated CMV under immune suppression (Hodson, Jones et 
al. 2005; Kalil, Levitsky et al. 2005; Strippoli, Hodson et al. 2006). 
This is in line with the importance of CMV-specific T-cells to effectively control 
CMV replication and inhibit progression to disease (Sester, Sester et al. 2001; 
Lacey, Gallez-Hawkins et al. 2002; Bunde, Kirchner et al. 2005; Lacey, La 
Rosa et al. 2006; La Rosa, Limaye et al. 2007; Egli, Binet et al. 2008). The 
state of CMV-specific immune controls together with local microenvironment 
determines how CMV causes organ-invasive disease in intestines (40%), liver 
(20%), lungs (10%), kidneys (5%), eyes (1%) and the central nervous system 
(1%). 
Therefore, high-risk patients profit from an intense CMV surveillance with 
prophylactic or preemptive treatment strategy. Both strategies have shown to 
significantly reduce CMV replication and progression to disease (Humar, 
Mazzulli et al. 2005). Interestingly, 25% to 50% of CMV D+R- do not 
seroconvert within one year (Lowance 1999; Humar, Mazzulli et al. 2005; 
Khoury 2006). Low-level CMV replication with insufficient treatment may be 
an important problem, leading to a poor long-term graft outcome because of 
chronic inflammation within the graft (Pérez-Sola, Castón et al. 2008). Still, 
duration and dosage of prophylaxis and preemptive treatment is still an open 
question. 
 
The risk of developing drug resistance is another important aspect of high-risk 
patients with low CMV-specific immune control. Most cases of GCV-
resistance development are described for the D+R- high-risk group (Limaye, 
Corey et al. 2000; Boivin, Goyette et al. 2005). Most mutations (>90%) 
accumulate in the phosphotransferase UL97. The remaining 10% occur within 
the CMV DNA polymerase UL54 (Gilbert, Bestman-Smith et al. 2002; Gilbert 
and Boivin 2005). To avoid resistance, adequate antiviral dosing is critical 
(Boivin, Goyette et al. 2004). The second group of high-risk patients, R+ with 
T-cell depleting treatment, additionally supports the role for sufficient CMV-
specific T-cell control. These patients are often not well enough monitored, 
due to their R+ and thereby wrongly supposed protective state. However, 
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these patients show as well a considerable risk for GCV resistance 
development (see results part (Egli, Binet et al. 2008)). 
 
Important to highlight is the unknown time-span and dosage of prophylactic 
treatment (3 or 6 months), microbiological surveillance after CMV replication, 
and treatment with Ganciclovir (GCV) and ValGCV after eradication of active 
replication. This is where CMV-specific immune response could help to 
identify the risk for future CMV replication, GCV-resistance development and 
progression to disease. 
 
1.3.2. Polyomavirus BK 
 
With the introduction of high dosage immunosuppression regimens in 
transplantation medicine and the onset of AIDS pandemic, polyomaviruses 
BK and JC were no longer under immune pressure. BKV and JCV started 
replicating at higher levels and used there chance to make a “new” pathogen 
(Hirsch 2005). 
1.3.2.1. Virus genome and proteins 
 
The genome of all human polyomaviruses is about 5.3kb in size and builds a 
circular double-stranded DNA encoding early and late proteins (Yang and Wu 
1979; Frisque, Bream et al. 1984; Cubitt 2006; Allander, Andreasson et al. 
2007; Gaynor, Nissen et al. 2007) (Figure 8). Newly discovered human 
polyomavirus WU, KI and Mantel cell carcinoma polyomavirus (MPyV) will not 
be discussed, due to their unclear role in immuno-suppressed hosts (Allander, 
Andreasson et al. 2007; Gaynor, Nissen et al. 2007; Feng, Shuda et al. 2008). 
Early gene proteins are: the regulatory large tumor antigen (LT-ag) and the 
small T antigen. Late gene proteins are: the capsid VP-1, -2 and -3 and the 
agno-protein. 
 
BKV agno protein is degraded by phosphokinase C (PKC), followed by higher 
LT expression with higher viral loads in cell culture (Johannessen, Myhre et 
al. 2008).  
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The transcription of early and late viral genes is driven by the non-coding 
control region (NCCR), which contains also the origin of DNA replication and 
several transcription factor binding sites (Moens, Johansen et al. 1995; 
Gosert, Rinaldo et al. 2008). The replication cycle of BKV is shown in detail in 
Figure 1. 
 
Figure 8. BKV and JCV genome organisation of early and late genes, 
encoded proteins and homology. 
 
Within the NCCR, the main harboured transcription factor binding sites are: 
SP1, GRE, GM-CSF, NF1, p53, and CMV-IE1 (Moens, Johansen et al. 1995). 
In clinical studies, grafts from deceased donors with longer phases of 
ischemia showed persistent Polyomavirus BK replication and poorer graft 
outcomes compared to living donor kidneys (Wadei, Rule et al. 2006). This 
may be due to reactivation based on up-regulation of transcription factors 
during ischemia. 
 
A complex genome adaptation to a new host situation is the development of 
rearrangements in the NCCR (rr-NCCR, deletions or insertions) post-
transplantation. rr-NCCR BKV shows higher transcription of early genes 
followed by increased late genes transcription. Thereby production of viral 
particles (high viral fitness) is increased with faster development of cytopathic 
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effects in cell culture (Gosert, Rinaldo et al. 2008). Interestingly, in 
immunocompetent hosts, rr-NCCR BKV strains can be found only 
exceptionally in cases of primary infection or pregnancy (Flaegstad, 
Sundsfjord et al. 1991; Markowitz, Eaton et al. 1991; Egli, Infanti et al. 2008). 
This implicates a disadvantage within a competent immune system. Probably, 
due to more interference with the host immune system, those viruses are 
cleared faster, not causing harm (Figure 9). 
 
BKV immune evasive strategies might be mediated through siRNA down-
modulation of host immune factors, but also own BK LT early gene transcripts 
for further silencing. Gosert et al. have described a down-regulating effect of 
co-transfected agno DNA on LT expression (Gosert, Rinaldo et al. 2008). 
Grinde et al. analyzed mRNA expression profiles during BKV infection and 
found a down modulation of NFkB, IRF3, ATF2 in HUV-EC cells (Grinde, 
Gayorfar et al. 2007). siRNA activity was described for Polyomavirus SV40 
(Sullivan, Grundhoff et al. 2005; Gottwein and Cullen 2007; Sullivan 2008). 
Another interesting factor might be the up-regulation of co-stimulatory factors 
in infected cells. Starke et al. have described a up-regulation of PD1 ligand in 
BKV-infected RPTECs (Starke, Lindenmeyer et al. 2008). PD1 ligand has a 
inhibitory function on T-cells and thereby probably virus-infected cells are 
protected from killing (for more information on PD1 see results and discussion 
part). 
 
1.3.2.2. Virus transmission and latency 
 
The transmission strategies of polyomaviruses BK and JC are highly efficient. 
Up to 80% of the world population is infected with BKV and 70% with JCV 
(Knowles, Pipkin et al. 2003; Stolt, Sasnauskas et al. 2003; Lundstig and 
Dillner 2006). 
 
Transmission of BKV and JCV happen at different time-points. BKV is usually 
transmitted during childhood within a relative short time period. JCV 
transmission happens until the age of 40 (Knowles, Pipkin et al. 2003; Stolt, 
Sasnauskas et al. 2003). Different routes are suspected: oral and respiratory 
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(Sundsfjord, Spein et al. 1994), vertical (Shah, Daniel et al. 1980; Stolt, Kjellin 
et al. 2005), as well as via cells and tissues, especially in transplantation 
(Sundsfjord, Spein et al. 1994; Dolei, Pietropaolo et al. 2000; Dorries, Sbiera 
et al. 2003). 
 
 
Figure 9. BKV replication in healthy and immunosuppressed hosts. Left part: 
situation of primary infection or reactivation. Right part: Depending on 
competence of the immune system, different virus replication patterns can be 
observed (adapted from Gosert et al. JEM 2008). Red, green and blue bars 
hypothesis expression profiles of BKV proteins. 
 
Most probably BKV and JCV entry happens through inoculation of a sufficient 
dosage of infectious particles into the gastrointestinal tract. BKV most 
probably uses Gangliosides GD1b and GT1b as receptor for host cell entry 
(Low, Magnuson et al. 2006). JCV requires alpha2-6 linked sialic acid 
(Komagome, Sawa et al. 2002) or serotonergic 5HT2AR receptor (Elphick, 
Querbes et al. 2004). Probably JCV enters into circulation via the tonsils. The 
alpha2-6 linked sialic acid has been found in oligodendrocytes, astrocytes, as 
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well as B- and T-cells in spleen and tonsils (Eash, Tavares et al. 2004). In 
about 40% of tonsils samples from children and adults JCV DNA was found 
(Monaco, Jensen et al. 1998; Kato, Kitamura et al. 2004). Most probably 
during primary infection BKV is shed in stool. 38.3% of stool samples from 
children were tested positive for BKV, whereas JCV has not been found 
(Vanchiere, Nicome et al. 2005). 
During primary infection a first phase of BKV and JCV replication leads to the 
establishment of a latent non-replicative infection in the reno-urinary tract 
(Chesters, Heritage et al. 1983; Dorries and ter Meulen 1983). In healthy 
individuals BKV and JCV are intermittently reactivated. In urine BKV can be 
found in 0-31.5% and JCV in 20-57.4% of samples (Kitamura, Aso et al. 1990; 
Ling, Lednicky et al. 2003; Rodrigues, Pinto et al. 2007; Rossi, Delbue et al. 
2007; Zhong, Zheng et al. 2007; Egli, Infanti et al. 2008).  
JCV can be detected especially in older age-groups (Kitamura, Aso et al. 
1990; Zhong, Zheng et al. 2007). In peripheral blood mononuclear cells 
(PBMC) the results are contradictory. Ling et al. did not find virus in PBMC 
(Ling, Lednicky et al. 2003). Dolei et al. found 21.6% of samples positive for 
BKV and 0.9% for JCV using an ultra sensitive nested PCR (Dolei, 
Pietropaolo et al. 2000). Dorries et al. showed that granulocytes may serve as 
the predominant reservoir harbouring JCV DNA in blood cells (Dorries, Sbiera 
et al. 2003). There is a need to further define the baseline characteristics in 
healthy individuals. 
 
BKV or JCV disease in healthy individuals is a rare event. During BKV primary 
infection, single cases of hemorrhagic cystitis and nephrotic syndrome 
occurred (Hashida, Gaffney et al. 1976; Nagao, Iijima et al. 1982; Saitoh, 
Sugae et al. 1993). In a study of 131 children with suspected meningitis or 
encephalitis 3.8% of CSF samples were positive for BKV, 1.5% for JCV. 
Additionally 20 healthy control patients examined for lower back pain were 
negative (Behzad-Behbahani, Klapper et al. 2003). 
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1.3.2.3. Polyomavirus associated nephropathy 
 
With introduction of high dose and prolonged immunosuppression 
polyomaviruses BK and JC came into our focus by causing kidney graft 
malfunction and loss (Shah, Daniel et al. 1974; Jung, Krech et al. 1975; 
Gardner, MacKenzie et al. 1984; de Silva, Bale et al. 1995; Purighalla, 
Shapiro et al. 1995; Bachman 1999; Nickeleit, Hirsch et al. 1999; Randhawa 
and Demetris 2000; Hirsch, Knowles et al. 2002). Polyomavirus associated 
nephropathy (PVAN) is the major complication linked to high-level BKV 
replication affecting up to 10% of kidney transplant recipients with graft loss in 
up to 50% (Hirsch 2005) (Figure 10). 
 
 
 
Figure 10. Histology pictures of PVAN in an autologous kidney after lung 
transplantation. Left picture: PVAN stage B with inflammation, degenerated 
tubuli and cytopathic effects of enlarged cells due to BKV replication. Right 
picture: Immune SV40 LT staining with cross-reactive antibody (brown). (Egli, 
Hirsch and Johnson, unpublished case report) 
 
Virus detection in plasma serves as a surrogate marker for polyomavirus 
associated nephropathy in transplant recipients (Hirsch and Steiger 2003). 
 
BKV shedding can be found in about 30% of kidney transplant recipients with 
about 1000fold higher viral loads compared to healthy individuals (Hirsch, 
Knowles et al. 2002; Drachenberg, Hirsch et al. 2007; Funk, Gosert et al. 
2007). About 1/3 of patients with BKV positive urine sample also show BKV 
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positive plasma samples. BKV in plasma may increase to several logs and 
serves as an important surrogate marker to assess the risk of PVAN (Figure 
11). The negative predictive value for PVAN of BKV in plasma is almost 
100%, the positive predictive value is about 50% (Hirsch and Steiger 2003).  
Not only the presence of BKV is important but also the viral load. Patients with 
PVAN have higher viral loads than patients without PVAN (28000c/mL vs. 
2000c/mL) (Hirsch, Knowles et al. 2002). If BKV in plasma exceeds 4logs 
c/mL, PVAN should be considered (high sensitivity and specificity >95%) 
(Drachenberg, Hirsch et al. 2005). JCV is rarely detected in plasma (14.2%, 
mean 2000 c/mL) (Drachenberg, Hirsch et al. 2007). 
Dynamic examination after surgical removal of PVAN-containing allografts 
showed a rapid drop of plasma BKV loads, suggesting that the majority of 
BKV is derived from replication within the graft. Calculated plasma viral half-
life of 1-2h implies viral turnover of more than 99% per day and a tubular 
epithelial cell loss of about 10e6 cells per day (Funk, Steiger et al. 2006; Funk 
2007). 
Long lasting replication of BKV in an immuno-suppressed host leads to 
accumulation of NCCR rearrangements (R2=0.64, p<0.001). First, 
rearrangements appeared in urine, followed by plasma. In comparison to non-
rearranged transplanted patients, those patients show 20fold higher viral 
loads (medium 20’000 c/mL versus medium 440’000 c/mL), and probably a 
faster progression to PVAN (Gosert, Rinaldo et al. 2008). 
 
After transplantation Polyomaviruses BK uses its chance of reduced BKV-
specific immune control to replicated uncontrolled, and to accumulate 
mutations, thereby gain higher viral fitness with a even increasing replication 
state. 
 
1.3.2.4. Risk assessment and immune monitoring of BKV proteins 
 
Knowledge on the immunological differences of BKV proteins will allow 
improving our current immunological monitoring assays, help to identify 
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patients at risk for prolonged BKV replication an progression to Polyomavirus 
associated nephropathy, and to focus on vaccine target regions. 
 
 
 
Figure 11. Virus replication after kidney transplantation. Different probabilities 
for virus replication in urine and plasma and development of PVAN is shown. 
(adapted from Hirsch et al. NEJM 2002) 
 
1.3.2.4.1. BKV Large T protein 
 
The LT antigen is relative conserved. Probably due to highly important 
functional sites it does not show large sequence differences between virus 
strains (Hatwell and Sharp 2000). 
 
The homology between BKV-LT and JCV-LT is the highest for all 
polyomavirus proteins. This homology also has an impact on cellular immune 
assays (see results (Binggeli, Egli et al. 2007)). Four BKV-LT epitopes have 
been identified with cross-reaction to JCV-LT (see Table 3). 
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BKV large T-antigen 
Position Sequence HLA type Comment Reference 
     
25 GNLPLMRKAYLRKCK B0708  Li 2006 
57 TLYKKMEQDVKVAHQ DRB1 0301  Li 2006 
157 TLTable 4ACFAVYT A0201  Provenzano 2006 
362 MLTERFNHIL A0201  Randhawa 2006 
406 VIFDFLHCI A0201  Provenzano 2006, Randhawa 2006 
410 FLHCIVFNV A0201  Provenzano 2006, Randhawa 2006 
553 IYLRKSLQNSEFLLE B08 JCV cross Li 2006 
557 KSLQNSEFLLEKRIL B08 JCV cross Li 2006 
579 LLLIQFRPV A0201 JCV cross Provenzano 2006, Randhawa 2006 
613 TFSRMKYNICMGKCI DRB1 0901 JCV cross Li 2006 
     
BKV VP1 epitopes 
Position Sequence HLA type Comment Reference 
     
p44 AITEVECFL A0201 JCV cross Sharma 2006, Koralnik 2002, Li 
2006, Chen 2006 
p108 LLMWEAVTL A0201 JCV cross Sharma 2006, Koralnik 2002 
     
Table 3. Confirmed BKV LT and VP1 epitopes 
 
In kidney transplant recipients, the decrease of BKV loads in plasma was 
associated to a higher extent with BKV-specific cellular immune response 
against BKV LT peptide pools compared to VP1 (Binggeli, Egli et al. 2007; 
Ginevri, Azzi et al. 2007). 
 
1.3.2.4.2 BKV capsid proteins 
 
The role of neutralizing antibodies to BKV capsid proteins is controversial. 
In healthy individuals, increasing BKV and JCV urine loads, and in kidney 
transplant recipients also plasma loads, are associated with an increasing 
BKV and JCV VLP IgG responses. This indicates that plasma IgG levels do 
not correlate with a direct protective effect, but a recent exposure to virus 
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antigens (Hariharan, Cohen et al. 2005; Randhawa, Gupta et al. 2006; 
Ginevri, Azzi et al. 2007; Egli, Infanti et al. 2008). 
The theoretically higher immunological pressure on the surface antigens, VP1 
to 3, should be refleted in higher tendency to adapt and mutate. In JCV, 
different genes were compared according to variances between strains. 
Indeed, the VP1 gene showed the highest inter-strain variance (Hatwell and 
Sharp 2000). Therefore, a VP1 based immune assay or vaccine should cover 
a larger spectrum of epitopes within one serotype and also contain epitopes 
from other strains to cover circulating viruses and escape mutants. 
 
BKV VP1-specific T-cells have been used to monitor immune response. 
However, several differences compared to LT-specific immune response have 
been observed (see results). Two HLA A0201 VP1 epitopes (AITEVECFL and 
LLMWEAVTL) have been described (Koralnik, Du Pasquier et al. 2002; 
Sharma, Zhou et al. 2006; Chen, Trofe et al. 2008). Both epitopes show a 
cross-stimulatory effect on JCV (Table 3). 
 
1.3.2.4.3. BKV agno protein 
 
Although, BKV agno protein is abundantly expressed in the host cell during 
latency, the agno-specific immune response is weak. Hardly an antibody or 
cellular response can be detected (Leuenberger, Andresen et al. 2007). 
During latency this may be due to binding to the nuclear membrane protein 
HP1a, which is described for JCV agno (Okada, Endo et al. 2001; Safak, 
Barrucco et al. 2001) or rapid degradation through PKC-associated 
phosphorylation (Johannessen, Myhre et al. 2008). Thereby, probably agno-
epitopes are not bound to MHC molecules and presented on the cell surface 
to T-cells (Figure 12).  
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2. Aims and Hypothesis 
 
The main aim was to characterize in vivo and in vitro immune responses 
against Cytomegalovirus and Polyomavirus BK in healthy individuals and 
kidney transplant recipients. 
 
The three main hypotheses were: 
(i) Healthy blood donors show a high seroprevalence and competent 
virus-directed immune control with no plasma replication. 
(ii) Kidney transplant patients with recent, but cleared reactivation 
show higher humoral and cellular immune response. During virus 
replication, the amount of virus-specific T-cells negatively correlates 
with the amount of virus detected in plasma. 
(iii) Identification of immunodominant regions with virus proteins will 
allow improving current immunoassays. 
 
For CMV, we aimed (i) to compare antigen-specific T-cells in healthy and 
immunosuppressed patients with or without concurrent and/or future CMV 
replication and development to GCV-resistant CMV-replication, (ii) to identify 
a threshold level for protection using CMV-specific T-cells as risk marker. We 
examined (iii) the potential of a single pp65-epitope (RQY) to stimulate 
immune response in kidney transplant recipients. Finally, (iv) cytokine profiling 
was used to further characterize CMV-specific immune response and the 
impact of the co-stimulatory PD1-molecule.  
 
For BKV, we aimed to (i) define the baseline characteristic of virus replication 
and humoral immune response in healthy blood donors, (ii) to compare BKV-
specific immune responses (LT and VP1) in kidney transplant recipients with 
increasing or decreasing plasma BKV loads. A threshold of protection was 
defined. Further, CD4 and CD8 BKV-specific immune responses were 
examined. (iv) The impact of immunosuppressive drugs in CMV and BKV-
specific T-cells was examined. (v) Finally HLA A- and B-associated epitopes 
were identified and corresponding immune response was characterized. 
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3. Patients, Material and Methods 
 
3.1. Patients and healthy blood donors 
 
All healthy blood donors and transplant recipients gave informed consent on 
the study protocols. The ethical committee of Basel approved all protocols 
used. 
 
Healthy blood donors (HD) were recruited from voluntary laboratory personal 
or from blood donation centre in Basel (SRK, swiss red cross). Serology was 
determined and reserve aliquots were stored. HLA type determination was 
done by inclusion to the stem cell donor database in Basel and is based on 
serological and DNA HLA typing (Prof. Dr. Jean-Marie Tiercy, CHUV, 
Lausanne). 
Transplant recipients were recruited at several time points post transplant 
mainly form the nephrology department at the university of Basel (Prof. Dr. J. 
Steiger) and Kantonsspital St. Gallen (Dr. I. Binet). 
Data on HLA type and mismatches, virus serology, past viral replication, 
concurrent trough levels of immunosuppressive drugs, lymphocyte counts, 
and anti-viral treatment was registered in a database for further analysis. 
 
3.2. Material 
 
3.2.1. Chemicals 
 
6 well cell culture plate  Cellstar (Ref:  657160) 
24 well cell culture plate  Cellstar (Ref: 662160) 
aHLA-ABC    DakoCyto (Ref: M0736) anti human  
     cloneW6/32 
aHLA-DP/DQ/DR   DakoCyto (Ref: M0775) anti human clone 
     CR3/43 
Antibodies, all from Becton Dickinson (Allschwil, Switzerland), except 
otherwise marked 
 a7-AAD   PerCP (Ref: 559925) 
 aCCR7   PE (Ref: 552176) CD197 
PhD thesis: CMV and BKV immunity, Adrian Egli                                     44/196 
 aCD1a   APC (Ref: 559775) 
 aCD3    PerCP (Ref: 345766), PE (Ref: 345765), 
     FITC (Ref: 345763), APC (Ref: 555335) 
 aCD4    APC-Cy7 (Ref: 341115), APC (Ref:  
     555349), PerCP (Ref: 345770) 
 aCD8    PE-Cy7 (Ref: 335822), APC (Ref:  
     345775), PE (Ref: 555367) 
 aCD14   APC (Ref: 555399), APC-Cy7 (Ref:  
     333951), FITC (Ref: 555397)  
 aCD16   FITC (Ref: 335035), PE (Ref: 332779) 
 aCD19   APC (Ref: 345791) 
 aCD25   PE-Cy7 (Ref: 557741) Clone M-A251 
 aCD27   FITC (Ref: 340424) 
 aCD28   Pure (Ref: 348040). PE (Ref: 348047)  
 aCD45   PerCP (Ref: 345809) 
 aCD45RA   FITC (Ref: 555488), PE (Ref: 555489) 
 aCD45RO   APC (Ref: 340438), FITC (Ref: 555492) 
 aCD49d   pure (340976) 
 aCD56   FITC (REF: 345811), PE (Ref:345812) 
 aCD69   PE (Ref: 341652) 
 aCD80 
 aCD83   FITC (Ref: 556910), APC (Ref: 551073) 
 aCD86   PE (Ref: 555665) 
 aCD94   PE (Ref: 555889) 
 aCD107a   FITC (Ref: 555800) 
 aCD107b   FITC (Ref: 555804) 
 aCD279   PE (Ref: 557946), PD-1 
 aFoxP3   Biolegend PE (Ref:320108), FITC (Ref:  
     320106) Clone 206D 
 aGranzyme B  PE (Ref: 558132) 
 aIL2    FITC (Ref: 340448) 
 aIL10    PE (Ref: 559330) 
  aINFγ    APC (Ref: 341117), FITC (Ref: 340449), PE 
     (Ref: 340452) 
PhD thesis: CMV and BKV immunity, Adrian Egli                                      45/196 
 
 aNKB1   PE (Ref: 555967) 
 
Antigens 
 All peptides are from Eurogentec (Köln, Germany). A library of single 
 peptides (15 amino acid length with 11aa overlap) was ordered and 
 pooled. Pool and Sub-pools (with 10 peptides) were formed and used 
 for epitope mapping. 
 All virus lysates and cell culture control lysates from Virion (Rüschlikon, 
 Switzerland), except homemade BKV Lysate (lysate of vero-cells with 
 freezing and thawning and ultra-sonification). 
  
 BK LT pool 50ug/mL (dissolved in 85% DMSO) 
 BK VP1 pool 50ug/mL (dissolved in PBS) 
 BK agno pool 200ug/mL (dissolved in PBS) 
 BK LT cluster 25mer (see appendix) 
 BK LT cluster 15mer (see appendix) 
 BK LT cluster 9mer (see appendix) 
 BKV Lysate, wwNCCR, unknown conc. (dissolved in PBS) 
 BKV Lysate, rNCCR, insertion, unknown conc. (dissolved in PBS) 
 BLV Lysate, rNCCR, deletion, unknown conc. (dissolved in PBS) 
  
 CMV Lysate 1-3.5% 1mg/mL stock, (dissolved in PBS, EC 0.1mg/mL) 
 CMV Ctrl Lysate stock 
 CMV pp65 pool 50ug/mL (dissolved in 85% DMSO) 
 CMV pp72 pool 50ugmL (dissolved in PBS) 
  
 EBV Lysate 1-5% 
 EBV Ctrl Lysate 
 HSV1/2 Lysate 1-3% 
 HSV1/2 Ctrl Lysate 
  
 JC LT pool 50ug/mL (dissolved in PBS) 
 JC VP1 pool 50ug/mL (dissolved in PBS) 
 JC agno pool 200ug/mL (dissolved in PBS) 
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 RSV Lysate 1-2% 
 RSV Ctrl Lysate 
  
 SEB 100ug/mL dissolved in PBS (Ref: S4881-5MG), Sigma Aldrich 
  
 VZV Lysate 2-5% 
 VZV Ctrl Lysate 
  
BFA     (Ref: B7651-25MG), Sigma Aldrich (Buchs, 
     Switzerland) 
BSA     (Ref: A9647-500G), Sigma Aldrich 
Cryo tubes    CryoS tubes 2mL, Greiner Bio-one  
     (Frickenhausen, Germany) 
CPT tubes    Citrate Plasma (Ref: 362782), Becton  
     Dickinson 
Cytokines 
 IL2    Peprotech (Ref: 200-02-10) 
 IL4    Peprotech (Ref: 200-04-10) 
 GM-CSF   Peprotech (Ref: 300-3-10) 
 
DMSO    Fluka, >99.5%, (Ref: 41644) 
EDTA     (Ref: E-7889), Sigma Aldrich 
Elispot plates   Multiscreen HTS MSIPN4WSO, Millipore 
     (Molsheim, Germany) 
Elispot coating 
 human INFγ   mAB 1.D1K (Ref: 3420-3-5000), Mabtech 
 human Granzyme B  mAB GB10(Ref: 3845-3-1000) 
 human TNFα   mAB TNFα-I 
 human IL2   mAB IL2-I (Ref: 3440-3-1000) 
 human Perforin  mAB Pf80/164 (Ref: 3465-3-1000) 
Elispot catching 
 human INFγ-biotin  mAB 7-B6-1-biotin (Ref: 3420-6-1000) 
 human INFγ-ALP  mAB 7-B6-1-ALP 
 human Granzyme B-biotin mAB GBII-biotin (Ref: 3485-6-250) 
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 human TNFα-biotin  mAB TNFα-II 
 human Il2-biotin  mAB IL2-II-biotin (Ref: 3440-6-1000) 
 human Perforin-biotin mAB Pf344-biotin (Ref: 3465-6-250) 
Elispot development 
 Streptavidin-ALP  (Ref: 3300-10) 
 Streptavidin-HRP  (Ref:3310-9) 
Elispot staining 
 NBT    (Ref: 484235-250), VWR 
 BCIP    (Ref: 203788-100), VWR 
 NBT/BCIP mixture 
 TMB    Substrate (Ref: 3651-2), Mabtech 
Ethanol    >99.8% (Ref: 02860) 2.5l, Fluka, Sigma  
     Aldrich 
FACS tubes (blear)   5mL Polypropylene round bottom (Ref:  
     352063), Becton Dickinson (Allschwil,  
     Switzerland) 
FACS tubes (clear)   5mL Polystyrene round bottom (Ref:  
     352058), Becton Dickinson 
Falcon tubes 15ml   (Ref: 1888271), Becton Dickinson 
Falcon tubes 50ml   (Ref: 227261), Becton Dickinson 
FACS Flow    wash buffer for FACS machine, (Ref:  
     342003), Becton Dickinson 
FCS     Biochrom AG, 100% (Ref: S0115) 
Filters 
 mini for Elispot dilution Spartan 13 0.2 RC, (Ref: 10463040)  
     Whatman (Dassel, Germany) 
 large for cell medium Nalgene 500mL 0.4uM, (Rochester, USA) 
 Falcon   50mL, Millipore Steriflip (Ref: SCGP00525)  
FoxP3 Perm Buffer    (Ref: 421403), Biolegend 
Human sera    (Ref: H45200-100), Sigma Aldrich 
Immunosuppressive drugs 
 Tacrolimus   Alexis (Lausen, Switzerland) 
 Cyclosporin A  Alexis (Lausen, Switzerland) 
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 Leflunomide   A77 1726 Lef, 25mg, (Ref: 430-096- 
     M025) Alexis (Lausen, Switzerland) 
 Rapamycin   Alexis (Lausen, Switzerland) 
KCl     Sigma Aldrich 
KH2PO4    Sigma Aldrich 
L-Glutamine    (Ref: G7513-100), Sigma Aldrich 
 
MACS, magnetic separation micro beads 
 CD4    human (Ref: 120-000-440) 
 CD8    human (Ref: 120-000-244) 
 CD14    human (Ref: 120-000-305) 
NaCl     Sigma Aldrich 
Na2HPO4    Sigma Aldrich 
Penicillin Streptavidin  (Ref: P0781-100), 100mL, Sigma Aldrich 
 
Peptides (virus and other antigens) 
 see antigens 
 
RPMI-1640 cell medium  (Ref: B8758), Sigma Aldrich 
Saponin    (Ref: S7900-100G), Sigma 
Tryptan-blue 0.5% 
Tween 20    (Ref: 93773), Fluka, Sigma Aldrich 
 
 
3.2.2. Solutions 
 
Autologous cell media, store at 4° for 1 months 
25ml plasma from donor (heat inactivated, centrifuged 1650g 20’, EC 5%) 
500mL RPMI 
filtered with Millipore, 50mL, 0.45uM 
 
BFA, stored at -20° 
1mL 70% Ethanol 
1mg BFA (EC 1mg/mL) 
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BSA 20% stock solution, store at -20°C 
200mL PBS 
40g BSA (EC 20%) 
 
DC expansion medium, stored at 4° for max 1 month 
500mL RPMI 
25mL human sera (EC: 5%) 
5mL L-Glutamine (EC: 1%) 
5mL Penicillin Streptavidin (EC: 1%) 
125uL GMCSF (200ug/mL, EC: 50ng/mL) 
100uL IL4 (1mg/mL EC 0.2ug/mL or 1000U/mL) 
 
EDTA 500mM stock solution 
100mL PBS 
114.62g EDTA (EC: 500mM) 
 
Elispot antibody dissolving solution, stored at 4° 
995mL PBS 
5mL FCS (EC: 0.5%)  
 
Elispot developing solution, for immediate use 
11mL TRIS 
100uL NBT 
200uL BCIP 
 
Elispot wash for Elisa washer, store at 4° 
1000mL PBS 
0.5mL Tween 20 (EC: 0.05%) 
 
FACS Co-stimulation solution, stored at 4°C 
200uL aCD28 (1.0mg/mL, EC 100ug/mL) 
400uL aCD4+9d (0.5mg/mL, EC 100ug/mL) 
1400uL PBS 
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FACS wash, store at 4° 
950mL PBS 
50mL FCS (EC: 5%) 
5g BSA (EC: 0.5%) 
filtered with Millipore, 50mL, 0.45uM 
 
Freezing media, store at 4° 
900ml FCS 
100ml DMSO (EC: 10%) 
 
MACS solution, store at 4° 
485mL PBS 
12.5mL 20% BSA (EC 0.5%) 
2mL 500mM EDTA (EC 2mM) 
 
Permeabilizing solution, for immediate use 
99mL FACS buffer 
1mL Saponin 10% (EC: 0.1%) 
 
Phosphate buffered saline (PBS 10x stock, pH7.2), stored at RT 
80g NaCl 
2g KCl 
11.5g Na2HPO4 (or 14.41g Na2HPO4x2H20) 
2g KH2PO4 
 
R5 medium, stored at 4° for max 1 months 
465mL RPMI 
25mL human sera (EC: 5%) 
5mL Penicillin Streptavidin (EC: 1%) 
5mL L-Glutamin (EC: 1%) 
filtered with Millipore, 50mL, 0.45uM 
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R10 medium, stored at 4° for max 1months 
440mL RPMI  
50mL FCS (EC: 10%) 
5mL Penicillin Streptavidin (EC: 1%) 
5mL L-Glutamin (EC: 1%) 
filtered with Millipore, 50mL, 0.45uM 
 
Saponin 10%, store at 4° for max 1 week 
10mL PBS 
1g Saponin 
 
TRIS, store at room temperature 
121,1g Tris 
800mL MilliQ 
add HCl to pH (70mL for 7,4; 60mL for 7.6; 42mL for 8.0) 
 
3.2.3. Machines 
 
Centrifuges: 
 Eppendorf    5810R, large 
 Eppendorf   5415, small 
Elisa washer    Labsystem well-wash, Ascent, Bioconcept, 
     (Allschwill, Switzerland) 
Flow cytometer   Canto I, Becton Dickinson, (Allschwil,  
     Switzerland) 
     Calibur, Becton Dickinson, (Allschwil,  
     Switzerland) 
Elispot reader   CTL Ltd. (USA) 
Luminex    Bioplex 200, Biorad (Reinach, Switzerland) 
 
3.2.4. Software 
 
Adobe Photoshop CS, Version 8.0 
Adobe Illustrator CD, Version 11.0 
Ch3D Viewer, Version 4.1. 
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EndNote, Version 9.0 
Excel for Mac, Version 11.5.2. 
FACS Diva Software, Version 4.0 
Flow Jo, Version 3.4. 
Mac OS, Version 10.3.9. 
Powerpoint for Mac, Version 11.5.1. 
Prism, Version 5.0a 
SPSS, Version 13.0 
Swiss PdB Viewer, Version 3.9.b1 
Word for Mac, Version 11.5.0 
 
3.2.5. Websites 
 
http://www.ncbi.nlm.nih.gov/sites/entrez?otool=unibaslib 
http://www.ncbi.nlm.nih.gov/gv/mhc/main.cgi?cmd=init 
http://www.immuneepitope.org/home.do 
http://www.syfpeithi.de/ 
 
3.2.6. Biological specimen 
 
3.2.6.1. Urine and Plasma 
 
Native untreated urine was used for PCR detection. Aliquots of 4mL were 
stored at 4° for max two days or frozen at -20°, if batch-analysis was 
performed later.  
 
EDTA- or Citrate-Plasma was used for PCR detection and serology assays. 
EDTA-plasma was obtained from whole blood sample by centrifugation (10’ at 
3000g). Citrate-Plasma was obtained from CPT VacutainerTM tubes according 
to the manufacturers protocol. Plasma was stored at 4° or frozen at -20°, if 
batch-analysis was performed later. 
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3.2.6.2. Peripheral blood mononuclear cells (PMBC) 
 
Peripheral blood mononuclear cells (PBMC) were used for detection of virus-
specific T-cells. PBMCs could be either directly isolated using the CPT-
Vacutainer system or from EDTA whole blood with a ficoll gradient purification 
(detailed protocol see appendix). After counting PBMCs (Neubauer 0.1mm) 
were directly used or frozen at -80C° in freezing media. Within one week the 
cells were transferred to liquid nitrogen. 
 
3.3. Methods 
 
3.3.1. T-cell expansion cultures 
 
For a detailed comparison of the different expansion methods evaluated 
please see appendix or Figure 12. 
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Figure 12. Overview of expansion protocols. ActMono 9days (A), GMP 
approved expansion 29days (B) and separate expansion 21days (C)  
 
3.3.1.1. ActMono 9 days expansion protocol 
 
The concept of this method is to separately pulse activated monocytes 
(ActMono) with virus antigen preparation and add to PBMCs (restPBMC) in 
1:10 ratio for 9day. Virus-specific T-cells will amplify in a short expansion 
culture.  
At day -1: Three mL of the donor PBMC cell suspension (2 Mio/mL) were put 
into a 6 well plate. Activated monocytes adhered overnight to the well bottom. 
The following day: RestPBMCs were floating on top and removed. ActMono 
were detached by strong pipetting. Both populations were counted and 
concentrated to 4Mio per mL. ActMonos were pulsed for >3-4h with an 
antigen solution at a final concentration of 5ug/mL and washed afterwards. 
0.5mL of restPBMCs (4Mio/mL) were transferred into a 24well plate. After 
pulsing, ActMonos were added in a concentration of 1:10 in 500uL per well. 
RestPBMCs and ActMonos were incubated for 9days. After 7days medium 
starts turning yellow, indicating cell division. 
 
Figure 13 illustrates the cell subsets of adherent ActMonos and restPBMCs. 
Additionally the increasing amount of virus-specific T-cells is shown after 
9days of expansion. This expansion protocol was mainly used for Epitope 
mapping. 
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3.3.1.2. GMP-approved 28 days expansion protocol 
 
The concept of this method is to co-cultivate antigen and PBMCs during the 
expansion. With two stimulation phases and increasing antigen 
concentrations, a more balanced CD4+ and CD8+ T-cell expansion should be 
obtained. This protocol is based on GMP standards without antibiotics and 
only autologous cell medium. 
Two Mio PBMCs/well/mL are put into a 24 well plate. RPMI with  autologous 
plasma served as expansion medium. The antigen is added at a final 
concentration of 10ng/mL. 
After 10 days of expansion the cells are re-pulsed with irradiated PBMCs and 
100ng peptide/mL. Every third day, half of the old medium is replaced with 
fresh medium containing 20IE IL2 per mL. After 28days expanded cells can 
be used. 
 
3.3.1.3. Dendritic cell based 21 days expansion protocol 
 
The concept of this method is to separately expand CD4+ and CD8+ T-cell 
cultures and pulse them with mature dendritic cells (DC). T-cell cultures are 
stimulated and re-stimulated 3 times in total. 
 
At day-7: CD14 positive cells are isolated with magnetic beads. CD14 
negative fraction is frozen. CD14 positive fraction is put into culture with GM-
CSF and IL4 for one week. 
At day -1: LPS is added to finally mature DCs. 
At day 0: CD14- fraction is thawn and CD4+ and CD8+ T-cell fractions are 
magnetically separated. Mature DCs are checked in FACS (see Figure 14) 
and added at a ratio of 1:10 to the T-cells.  
 
At weekly intervals new matured DCs are used to re-stimulate the expanding 
T-cells. In a 3 and 4 day interval half of the medium is changed and fresh 
medium with 100IE IL2/mL added. 
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Figure 13. (A) CD3 and CD14 subsets after overnight adherence. (B) BK LT 
expansion over 9 days with re-challenging. 
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3.3.2. Detection of virus-specific T-cells 
 
3.3.2.1. FACS 
 
For virus-specific stimulation with FACS analysis 0.25 to 1x10e6 PBMCs were 
stimulated with positive controls (SEB or PHA), negative controls (medium, or 
cell lysate), virus peptides (BKV LT and VP1 pool, JCV LT and VP1 pool, and 
CMV pp65 and pp72 pool) or virus cell culture lysate for 6 hours or overnight 
in presence of Brefeldin A and of a co-stimulatory cocktail (aCD28 and 
aCD49). 
The stimulation was stopped with adding EDTA, followed by two washing 
steps. Cell were fixed and permeabilized (see protocol in appendix).  
As surface markers anti-CD3, anti-CD4, anti-CD8, anti-CD16/CD56, anti-
CD45RA, anti-CD45RO, anti-CCR7, and anti-PD1 for cell sub-typing was 
used. The activation state was determined with anti-CD69, anti-CD25, anti-
IL10, anti-IL2, and anti-INFγ. 
The measurement was done with a flow cytometer (For a detailed protocol 
see appendix). 
General concentration and time kinetic experiments are shown in Figure 15.  
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Figure 14. CD14+ and CD14- subsets after MACS separation 
 
In general 30’000-50’000 events (CD3 positive cells) were acquired and 
further analysed in a gating hierarchy (see Figure 16). Percent of INFγ or IL2 
and CD69 positive cells of all CD4+ helper or CD8+ cytotoxic T-cells is 
indicated. The mean fluorescence intensity indicates the amount antibody or 
cytokine per cell. Further details on the protocol can be found in the appendix. 
 
 
Figure 15. All experiments were performed with SEB on various healthy blood 
donors. Top left: BFA dilution (1mg/mL, stock) with different end-
concentrations into 500uL media and effect on INFγ production after 6h is 
shown; Top right: CD28/CD49d dilution (1mg/mL, stock) and co-stimulating 
effects on T-cells after 6h is shown; Bottom: and time kinetics of INFγ and 
CD69 expression.  
 
 
 
3.3.2.2. Elispot 
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Microtiter-plates were coated with anti-INFγ, anti-IL2, or anti TNFα for 
detection of the respective cytokine production of stimulated PBMCs. 
2.5x10^5 PBMCs and 1-2ug/mL peptide are added for 16-20h to each well of 
the microtiter-plate. Unspecific antibody bindings are washed away and a 
biotinylated secondary antibody was added for 2 hours. Afterwards the plate 
is washed again and an antibody with Streptavidin bound alkaline-
phosphatase is added for 1 hour and a chromogenic substrate (NBT/BCIP) 
induces a coloured spot corresponding to one cytokine producing T-cell. The 
plates were read in an Elispot reader (For a detailed protocol see appendix). 
The SFUs are normalized to 1Mio PBMCs per well for comparison. Figure 17 
explains the method. 
 
 
Figure 16. Gating strategy for virus-specific T-cells. 
 
3.3.2.3. Cell separation: CD4+ - CD8+ - CD14 
 
For specific expansion of CD4+/CD8+ T-cells or separation of T-cell subsets 
in leukemic patients magnetic separation of T-cells was used. 
An antibody against a phenotypic marker tagged with a magnetic bead is 
used to directly separate the corresponding T-cell subset (positive selection).  
Briefly, 10 Mio PBMCs are re-suspended in 1mL MACS buffer. 100ul of the 
magnetic beads are added, followed by incubation on ice for 20 minutes. The 
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non-marked cells are separated and the marked cells remain in a magnetic 
column. Finally, the attached marked cells of interest were eluted out with 
removing the magnetic field. Cell purity reached up to 99% (see Figure 14). 
 
 
 
Figure 17. Procedure of Elispot plate coating, stimulating and developing 
 
 
3.3.3. PCR protocols 
 
Several PCR protocols were used to determine copy numbers of CMV, BKV 
and JCV per mL of specimen. Additionally, Polyomavirus BK and JC NCCR 
were determined and rearrangements sequenced, BKV VP1 region was 
sequenced for serotype determination, and CMV UL97 phosphotransferase 
gene was sequenced for detection of GCV resistance. 
 
Table 4 gives an overview of all used PCR probes and primers. Detailed 
protocols can be found in the appendix part. 
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Table 4. Primer and probes for PCR protocols 
 
 
Description Sequence 
  
Quantification  
BKV-LT-forward 5’-TAGGTGCCAACCTATGGAACAGA-3’ 
BKV-LT-reverse 5’-GAAAGTCTTTAGGGTCTTCTACC-3’ 
BKV-probe FAM-CATTAAAGGAACTCCACCAGGACTCCCACTC-TAMRA 
  
JCV-LT-forward 5’-CTAAACACAGCTTGACTGAGGAATG-3’ 
JCV-LT-forward 5’-CATTTAATGAGAAGTGGGATGAAGAC-3’ 
JCV-probe FAM-TAGAGTGTTGGGATCCTGTGTTTTCATCATCACT-TAMRA 
  
CMV-IL10-forward 5’-TTTTTTCTAGGCGCTTCCGA-3’ 
CMV-IL10-reverse 5’-ACACTGCGGCTTTGTATTCTTTATC-3’ 
CMV-probe FAM-AGGCGAAGCCGGCGACGA-TAMRA 
  
CMV-UL97  
CMV outer1 5’-TGCTGCACAACGTCACGGTACATC-3’ 
CMV outer2 5’-AAACAGACTGAGGGGGCTACT-3’ 
CMV part1 forward 5’-CGTTGGCCGACGCTATCAAATTTC-3’ 
CMV part1 reverse 5’-ACAGCTCCGACATGCAATAACG-3’ 
CMV part2 forward 5’-GTGGGTAACGTGCTGGGCTTTTG-3’ 
CMV part2 reverse 5’-GTGGGTTTGTACCTTCTCTGTTGC-3’ 
  
NCCR   
BKV outer 1, BKTT5 5’-GAGCTCCATGGATTCTTC-3’ 
BKV outer 2, BKTT6 5’-CCAGTCCAGGTTTTACCA-3’ 
BKV inner 1, BKTT7 5’-CCCTGTTAAGAACTTTATCCATTT-3’ 
BKV inner 2, BKTT8 5’-AACTTTCACTGAAGCTTGTCGT-3’ 
  
JCV outer 1 5’-AGGCCTAATAAATCCATAAGCTCCA-3’ 
JCV outer 2 5’-GTTCCACTCCAGGTTTTACTAACTT-3’ 
JCV inner 1 5’-TTTTAGCTTTTTGCAGCAAAAAATTA-3’ 
JCV inner 2 5’-CCTGGCGAAGAACCATGGCCAG-3’ 
  
VP1 sequencing  
BKV outer 1 5’-GTGCAAGTGCCAAAACTACTAATAA-3’ 
BKV outer 2 5’-TGCATGAAGGTTAAGCATGCTAGT-3’ 
BKV inner 1 5’-CAACCAAAAGAAAAGGAGAGTGTC-3’ 
BKV inner 1 5’-TCCTCCACCATGCTCATGCACT-3’ 
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5. Summary and discussion of the key results 
 
5.1. Cytomegalovirus 
 
Effective control of CMV replication requires a sufficient CMV-specific cellular 
immune control through T-cells (Sester, Sester et al. 2001; Lacey, Gallez-
Hawkins et al. 2002; Bunde, Kirchner et al. 2005; Sester, Gartner et al. 2005). 
Reduction of CMV-specific T-cells may lead to uncontrolled CMV replication in 
kidney transplant recipients causing CMV-associated diseases in graft and 
recipient. To reduce virus replication and progression to disease in high-risk 
patients, a prophylactic or preemptive intervention strategy is common 
practice (see introduction). Long-term Ganciclovir application under persistent 
virus replication and immunosuppression increases the risk to select for GCV-
resistant CMV replication (UL54 or UL97 mutations) (Limaye, Corey et al. 
2000). 
 
5.1.1. Cytomegalovirus-specific T-cell responses and viral replication in 
kidney transplant recipients (Egli, Binet et al. 2008) 
 
Published immune assays vary according CMV antigen preparation used. We 
asked, which is best preparation to stimulate CMV-specific T-cells and, 
whether CMV-specific T-cells can be used after kidney transplantation to 
predict the risk of future CMV replication episodes and development of GCV-
resistant CMV replication. 
 
The aim was to compare the amount of INFγ producing CMV-specific T-cells 
in healthy blood donors versus kidney transplant recipients using several 
antigen preparations to detect CMV-specific T-cells (virus-lysate from cell 
culture and pp65/pp72 peptide pools). We further aimed to characterize R+ 
patients with or without concurrent CMV replication and GCV-resistance 
associated mutations. Follow-up of virus detection in blood revealed patients 
with future CMV replication 
 
We hypothesised, that kidney transplant patients show a lower amount of 
CMV-specific T-cells compared to healthy blood donors. Additionally, that R+ 
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kidney transplant recipients with low CMV-specific T-cells show a risk for 
concurrent and future CMV-replication and development of GCV-resistance. 
 
We examined 13 CMV-seronegative and 17 CMV-seropositive healthy 
donors, and 25 D+R- and 48 R+ kidney transplant (KT) patients. 
We determined CMV-specific CD4+ and CD8+ T-cell response to CMV lysate, 
pp65- and pp72-peptide pools (15mer library with 11aa overlap) with flow 
cytometry. Concurrent and future CMV replication was checked during the 
next 3 months with PCR and pp65-antigenemia. GCV-associated mutations 
were searched with sequencing the CMV-UL97 gene. 
 
CMV seropositive healthy blood donors showed significant higher CMV-
specific T-cell responses towards all tested antigen-preparations compared to 
R+ KT patients (see publication Table 2). CMV-lysate and CMV-pp65 
stimulated both CD4+ and CD8+ T-cells, whereas CMV-pp72 seemed to 
induce a stronger CD8+ response. 
As expected, R+ KT patients showed significant higher CMV-specific T-cell 
responses compared to D+R- KT patients (see Figure 18). 
 
 
 
Figure 18. CMV-lysate specific immune responses in R+ KT versus D+R- KT 
patients. 
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In total, 9/25 D+R- and 6/48 R+ kidney-transplant patients showed a 
concurrent CMV replication at time of sampling (see publication Table 1). 
Overall, R+ KT patients with concurrent CMV replication showed significant 
lower amounts of CMV-specific T-cells compared to patients without CMV 
replication (see Figure 19). For example median values of pp65-specific 
CD4+ T-cells in R+ patients with concurrent CMV replication: 0.00% versus 
without replication: 0.03%, p<0.0001 (MWU). 
 
 
 
Figure 19. R+ patients with and without concurrent CMV replication and 
corresponding immune responses. 
 
Receiver operating curve (Roc) analysis identified a cut-off value for the risk 
of concurrent and future CMV replication and development of GCV resistance. 
Patient with a CMV-pp65 specific CD4+ T-cell response < 0.03% CD4+ T-
cells showed significantly more often concurrent and future CMV replication 
within the following 8 weeks (p=0.036). Additionally, these patients developed 
more often GCV-resistance (p=0.041). For future replication the sensitivity 
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was 50% and the specificity 93%. The positive predictive value was 95% and 
the negative predictive value was 40% (see Figure 20). 
 
 
 
Figure 20. Roc analysis to define threshold of protection from concurrent 
CMV replication 
 
Bunde et al. reported that higher pp72-specific CD8+ T-cell frequencies were 
associated with a decreased risk of CMV disease during the first month after 
heart or lung transplantation (AUC 0.719, specificity 100%, sensitivity 50%, 
p=0.012) (Bunde, Kirchner et al. 2005). Sester et al. associated the amount of 
CMV-lysate specific CD4+ T-cell to episodes of CMV pneumonitis in lung 
transplant recipients, without defining a clear cut-off (Sester, Gartner et al. 
2005). Clearly, increasing calcineurin inhibitor levels, anti-rejection treatments 
particularly with anti-lymphocyte agents and steroid pulses are known to 
perturb antiviral immune control with lowered CMV-specific T-cell responses 
(Sester, Gartner et al. 2005; Lilleri, Zelini et al. 2007) and subsequent CMV 
replication (Dickenmann, Cathomas et al. 2001; Dickenmann, Kabulbayev et 
al. 2004). With this limitation in mind, CMV pp65-specific CD4+ T-cells might 
serve as a dynamic marker of protection for patients on stable 
immunosuppression complementing CMV load diagnostics in centers using a 
preemptive strategy. 
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We found 3 R+ patients (6.3%) with GCV resistance. Those were the first 
described cases in literature. We concluded that GCV resistant CMV 
replication in R+ may be an underestimated problem and determination of 
CMV-specific T-cells could help to identify patients at risk. This may be helpful 
to guide treatment duration of prophylactic or preemptive strategy, where 
decision on stopping of treatment may be difficult. 
 
5.1.2. Cytomegalovirus-associated chorioretinitis after liver transplantation: 
case report and review of the literature (Egli, Bergamin et al. 2008) 
 
In some HIV patients, despite of effective antiviral suppression of CMV after 
initiation of HAART worsening of CMV chorioretinitis is observed, This 
paradoxical clinical course is known as immune reconstitution inflammatory 
syndrome (IRS) and was linked to recovering CD4+ T-cell counts after 
effectively inhibiting HIV replication (Karavellas, Lowder et al. 1998; Hirsch, 
Kaufmann et al. 2004). Activation, expansion, and persistence of specific T-
cell clones are postulated as the patho-mechanism. 
 
We were confronted with the case of a 51-year old CMV D+R- liver 
transplanted women with primary CMV replication and development of GCV-
resistant CMV replication and progression to CMV colitis. Due to persistent 
GCV-resistant CMV replication, immunosuppression was significantly lowered 
and lymphocytes increased rapidly. Three weeks after successful viral 
clearance, the patient suddenly developed chorioretinitis. We wondered 
whether this could be due to an immune reconstitution syndrome and CMV-
specific T-cell associated collateral damage. 
 
Clinical examination of both eyes showed IRS-like chorioretinitis patterns. 
Still, 8 months after CMV clearance, we could detect an astonishing high 
amount of CMV-pp72 specific CD8+ T-cells. This high response slowly 
decreased over the next year of follow-up (Figure 21). We hypothesized that 
during CMV replication pp72-specific CD8+ T-cells clonally expanded and 
were weakly controlled.  
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Figure 21. Follow-up of CDM-specific immune responses posttransplant. 
 
We wondered, how often CMV-associated chorioretinitis occurs in post-liver 
transplantation and reviewed all PubMed accessible papers from 1987 to 
2007. In 12’653 liver transplant recipients included, CMV-replication was 
reported in 25.6% at 6.7±4.4 (mean, SD) weeks, CMV-syndrome in 2.1% at 
10.4±7.1 weeks, and organ invasive disease in 10.6% at 8.8±6.8 weeks post 
transplant, respectively (see publication Table 1). The leading entities were 
CMV hepatitis, pneumonitis, and enteritis. Instead, CMV-chorioretinitis was 
reported in only 14 patients (0.1%) and diagnosed at a mean of 101±127 
weeks (median 41.7 weeks, range 8-338) post transplant (see publication 
Table 2). Chorioretinitis occurred substantially later than other CMV diseases 
such as colitis or pneumonitis. Time of occurrence and course suggested that 
two patho-physiologic mechanisms might be operative. The first pattern had 
an earlier onset with considerable damage at the retina suggesting a strong 
virus-mediated cytopathic component and seemed to respond better to 
intravenous GCV. The second pattern was seen at later time points when 
immunosuppression is typically lower and responses to intravenous GCV 
seemed not as successful. 
So far, only for fungal infection IRS-like disease has been described in solid 
organ transplant recipients (Singh, Lortholary et al. 2005; Singh, Lortholary et 
al. 2005). We concluded that after significant reduction of immunosuppression 
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and unexpected CMV-like disease in the absence of viral replication IRS 
should also be considered in SOT patients. 
5.1.3. A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ 
T-cells across a wide range of HLA specificities (Provenzano, Sais et al. 
2008) 
 
As noted before, CMV-pp65 specific T-cell response seems to be valuable as 
marker to assess the risk for CMV replication. Identification of immuno-
dominant epitopes within CMV-pp65 may be helpful to improve diagnostic 
tests and further identify important virus regions for vaccine development. 
 
M. Provenzano and S. Spagnoli (university of Basel, Switzerland) computer 
predicted with Syfpeithi algorithm a 16mer sequence of pp65 with potential to 
stimulate various HLA types (RQYDPVAALFFFDIDL). Spagnoli’s group tested 
the peptide in healthy individuals. Our group aimed to examine the potential 
immune stimulating role in kidney transplant recipients. In total, we examined 
10 kidney transplant recipients (8 R+, 1 D-R- and 1 D+R- with primary 
infection). 
 
We expanded separately CD4+ and CD8+ RQY-specific T-cells with peptide 
pulsed DC over 3 weeks (see material and methods, and appendix). 
 
We could show, that the RQY 16mer was recognized by most kidney 
transplanted patients. Even more, RQY could stimulate both CD4+ and CD8+ 
T-cells. Single 9mer epitopes were identified for particular HLA types with 
showing a specific INFγ and IL2 production (See publication Table 3 A and B). 
We concluded, that RQY probably could be used as a immuno-dominant 
sequence together with other immuno-dominant peptides to improve current 
monitoring assays or to stimulate immune responses in adoptive T-cell 
transfer or vaccine development. 
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5.1.4. PD1-expression on CMV specific T-cell response and influence on 
cytokine profiles (unpublished results, Egli, Sester et Hirsch) 
 
Co-stimulatory signals are highly important to induce a antigen-specific T-cell 
response. Activating or inhibitory signals further modulate the immune 
response (introduction and Figure 3). Recently, co-stimulatory molecules 
became targets of immunosuppressive agents (introduction and Figure 7., 
(Sharpe and Abbas 2006; Vincenti and Kirk 2008)). However, a CD28-
blocking antibody showed unexpected stimulatory effects in a phase 1 trial 
with severe side-effects (Suntharalingam, Perry et al. 2006).  
The role of inhibiting co-stimulatory effects on the function of virus-specific T-
cells is a fascinating and yet weakly examined field of research. In latent virus 
infection the up-regulation of PD1 as an inhibitor of T-cell function seems to 
be an important escape pathway for viruses. During several viral infections 
such as Hepatitis B, LCMV, and HIV, PD1 was up-regulated on CD8+ virus-
specific T-cells and were associated with impaired T-cell function and even 
worse disease outcome (Barber, Wherry et al. 2006; Day, Kaufmann et al. 
2006; Urbani, Amadei et al. 2006). Blocking PD1 could theoretically lead to a 
restoration of T-cell function and probably clearance of virus replication and 
even elimination of latent infected cells. 
 
Sester et al. examined the effect of PD1-expression on IL2 and INFγ 
production of CMV-specific CD4+ T-cells in kidney transplant. Blockade of the 
PD1 molecule was induced with binding PD1 ligand to an inhibitory antibody. 
Beside, increasing INFγ and IL2 production of CMV-specific CD4+ T-cells, 
also a significant increase in cell-proliferation capacities was observed 
(Sester, Presser et al. 2008). 
 
We have extensively characterized the amount of INFγ and to some extend 
also IL2 production of CMV-specific T-cells. We wondered, what the role of 
other cytokines in kidney transplant patients is. Additionally, as cytokine 
profiling could help to further evaluate PD1 blockade as a potential anti-viral 
target, we decided to examine supernatant from T-cell expansion cultures and 
compare cytokine profile in PD1 blocked and non-blocked samples. 
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Supernatants of short-term expanded T-cell cultures stimulated with CMV 
lysate (for 5 days) or SEB (for 3 days) were harvested by Sester et al. 
(University of Saarland, Homburg, Germany). Baseline PD1 expression level 
was defined as either high or low, depending on the FACS mean florescence 
signal of the PD1 staining (Sester, Presser et al. 2008). 
In total we examined three healthy blood donors, four kidney transplant 
recipients with high PD1 expression and five with low PD1 expression. During 
expansion an inhibitory antibody binding to PD1-ligand and thereby blocking 
PD1 signalling and an isotype control without effect on PD1-ligand were 
added. We measured the amount of cytokines in the cell supernatant with a 
luminex technology. This method allows detecting 27 different cytokines per 
50uL of supernatant 
 
First we compared the amount of cytokines produced by different antigen 
preparations. SEB strongly induced cytokine production with significant higher 
amounts compared to CMV-lysate. However, IL-1ra, -8, -9, -10, -13, -17, IP10, 
INFγ, MIP1b, Rantes, and TNFα responded to CMV lysate. 
Then, we examined the general increase of cytokine production in different 
patient groups. Overall, the baseline production of cytokines (isotype treated 
samples) from CMV-specific T-cells was higher for healthy blood donors 
compared to kidney transplant patients (Figure 23). 
 
On the other, we observed a higher increase of almost all cytokine in kidney 
transplant patients with PD1 blockade. Cytokines such as, IL4, IL6, IL17, INFγ 
MCP1, MIP-1a/-1b and TNFα increased by more than 5 fold compared to non 
treated cell cultures. Even more, kidney transplant recipients with high PD1 
expression showed an even stronger fold increase of cytokine release (See 
Figure 22) compared to low PD1 expressing patients. 
 
We conclude that various cytokines may be stimulated with CMV lysate and 
SEB. PD1 inhibitory antibodies lead to an unselective increase of T-cell 
function, but interestingly only in CMV-specific T-cells. As a potential 
treatment for persistent virus, especially CMV replication in a transplant 
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setting, this needs to be very carefully evaluated, due to potential of graft 
rejection induction. 
 
The weakness of the so far done study certainly is the low number of persons 
examined. However, as kidney transplant recipients are very heterogeneous, 
further studies could be extremely expensive. Therefore we would based on 
the current results, focus on the key cytokines. 
 
 
 
Figure 22. Cytokine array. Colour indicates the fold increase or decrease 
after treatment with blocking PD1-ligand antibody. From bright green to blue 
increasing cytokine levels were measured. From orange to purple decreasing 
cytokine levels were measured. 
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Figure 23. Cytokine profile. healthy blood donors (HD), green; kidney 
transplant recipients (KTx) with high PD1 expression, red; KTx with low PD1 
expression, blue. Darker colour shaded bars indicate treatment with anti-PD1-
ligand antibody. 
 
5.1.5. Impact of immunosuppression on CMV-pp65 and BKV-LT specific T-
cells (unpublished results, Egli, Köhli et Hirsch) 
 
Prolonged and high levels of immunosuppression un-specifically down-
modulates the immune system’s function. Allo-reactive as well as virus-
specific T-cells are impaired in effector function as e.g. INFγ release or 
proliferation capacity (see introduction and Figure 7). Dosage of 
immunosuppression is based on clinical observations and measurement in 
plasma of through levels. Sester et al. showed, the impact of Calcineurin 
inhibitors on CMV-lysate specific T-cells. However, in their studies only 
calcineurin inhibitors were tested and the stimulating antigen was a whole 
virus-lysate from fibroblast cells (Sester, Gartner et al. 2005). 
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We wondered, what the impact of calineurin inhibitors (CsA and Tac) and anti-
proliferative drugs (Rapa and Lef) on CMV-pp65 specific T-cells and BKV-LT 
specific T-cells may be. 
 
PBMCs from healthy blood donors were isolated and pre-incubated for 3h 
with respective immunosuppressives at different concentrations. Treated cells 
were added to the antigen solutions (SEB, CMV-pp65 and BK-LT) in a 
standard Elispot or FACS assay overnight. The amount of virus-specific T-
cells on different dosages was assessed as T-cell reactivity. The value of INFγ 
releasing T-cells without immunosuppressive treatment was set as 100%. 
 
We first tested the direct effect of Calcineurin inhibitors (Tac and CsA) on 
SEB, CMV-pp65 and BKV-LT stimulated PBMCs. As shown in Figure 24, a 
significant dose dependent inhibition on virus-specific T-cell reactivity (INFγ 
production) could be observed for SEB, CMV-pp65 and BKV-LT. 
 
For anti proliferative agents, Rapamycin and Leflunomide no effect was 
observed for SEB and CMV-pp65. However, for BKV LT we found a dose-
dependent decrease (Figure 25). This effect could have been due to higher 
variance in a lower amount of BKV-specific T-cells compared to CMV-pp65 
specific T-cells or to a toxic effect of DMSO, which was the dilution medium 
for BKV LT. 
 
Previously, we tested the effect of DMSO on the production of INFγ. Above 
3% we found an inhibitory effect (data not shown). The concentration used in 
the Rapamycin and Leflunomide assays was always below 1%. To reduce 
assay variance due to a low amount of BKV LT specific T-cells, we used BKV-
LT expanded T-cells. With expanded BKV-specific T-cells no effect of 
Rapamycin and Leflunomide was found (Figure 26.). 
expansion 
 
We then tested the effect of rapamycin during expansion. A standard 
ActMono expansion was performed and during time of monocyte pulsing 
different concentrations of rapamycin were present in the 24well plate. After 
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9days, we observed a yellow medium only in wells with low rapamycin 
concentration, which indicates higher rate of cell division. Elispot assay was 
used to detect the amount of INFγ, IL2 and TNFα producing BKV-specific T-
cells (Figure 27). The amount of INFγ releasing BKV-specific T-cells 
expressed in SFUs/1Mio PBMCs could be reduced to half at 8ng/mL. With the 
same concentration IL2 decreased to 10%. This indicates a certain hierarchy 
among cytokines. The strong decrease of IL2 producing T-cells may have an 
impact on the CD8+ T-cell population as well. 
 
We confirmed that calcineurin inhibitors directly affect the INFγ release of 
CMV and BKV-specific T-cells. For CsA, a slight stronger decrease of INFγ 
release in BKV-LT-specific T-cells could be observed compared to CMV-pp65 
specific T-cells. Additionally, in the direct essay, we observed a rapamycin-
specific INFγ blockade of BKV LT-specific T-cells, but most probably due to a 
combined toxic effect. Rapamycin and Leflunomid, as antiproliferative 
substances, show in expanded T-cells no effect on INFγ release, but a clear 
effect in proliferation capacity over time. 
 
 
 
Figure 24. Dose dependant effect of calcineurin inhibitors on SEB, CMV-pp65 
and BKV-LT stimulated T-cells. 
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Figure 25. No dose dependant effect of rapamycin or leflunomide on SEB 
and CMV-pp65, but dose dependence on BKV-LT stimulated T-cell 
 
 
Figure 26. No dose dependent effect of rapamycin after BKV-LT specific  
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Figure 27. No significant dose dependent effect on amount of cytokine 
producing BKV-specific T-cells treated with rapamycin during expansion. 
 
Our laboratory examines the impact of rapamycin on BKV replication in 
infected RPTEC cells. A strong inhibitory effect with reduction by more than 1 
log could already be observed at 1ng/mL (M. Wernli, and Hans H. Hirsch 
unpublished results). As BKV-specific T-cell function is reduced at higher 
levels, this could have a high clinical impact. If confirmed with further 
experiments and in clinical studies, Rapamycin might become a choice of 
treatment of kidney transplant recipients with progressive and prolonged BKV 
replication. 
 
Guiding immunosuppressive therapy with levels of immunosuppressive drugs 
according to the risk of virus replication and rejection episodes is not sufficient 
(Sampson, Dunn et al. 2008). However measuring virus-specific T-cells could 
be more successful. Using the amount of virus-specific T-cells to measure the 
impact of immunosuppression requires knowledge of the particular through 
level. However, only a small fraction is unbound in blood. CsA has only 2% in 
a unbound fraction, whereas the rest is bound to proteins in blood or 
distributed in tissues (Akhlaghi and Trull 2002). This means that a higher 
concentration of immunosuppression may be present at various sites of virus 
replication. Even so during tissue inflammation the drug metabolism and 
thereby concentration may additionally change (Pellequer, Weissenborn et al. 
2007). Further studies should clearify the impact of tissue concentrations on 
T-cell functions. 
 
 
5.2 Polyomavirus BK 
 
Similar to CMV, control of BKV replication requires a sufficient BKV-specific 
cellular immune control through T-cells (Comoli, Basso et al. 2003; Chen, 
Trofe et al. 2006; Comoli, Binggeli et al. 2006; Hammer, Brestrich et al. 2006; 
Binggeli, Egli et al. 2007; Ginevri, Azzi et al. 2007; Egli, Dumoulin et al. 2008, 
in press). Reduction of BKV-specific T-cells may lead to uncontrolled and 
progressed BKV replication in kidney transplant recipients causing 
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Polyomavirus-associated nephropathy. As no specific antiviral treatment is 
available, the only treatment option is reduction of immunosuppression to 
regain BKV-specific effector T-cells. However, this harbour a significant risk 
for induction of graft rejection (Hirsch and Steiger 2003). 
5.2.1. Prevalence of polyomavirus BK and JC infection and replication in 400 
healthy blood donors (Egli, Infanti et al. 2008) 
 
Polyomavirus BK and JC primary infections happen in early age and latency 
in kidney is established there after (Knowles, Pipkin et al. 2003; Stolt, 
Sasnauskas et al. 2003). In healthy donors and immunosuppressed patients, 
the virus may reactivate and intermittent shedding in urine is observed. 
Studies on humoral factors and virus replication would give detailed insight in 
mechanisms of viral transmission and risk for reactivation and disease. 
Nevertheless, most studies examined humoral and shedding aspects only in 
transplant patients or weakly defined and questionable immunocompetent 
individuals. Our aim was to set the baseline characteristics of BKV and JCV 
serology and viral replication in healthy blood donors. 
 
We consecutively enrolled 400 healthy blood donors from the blood donation 
center Basel (SRK, Swiss Red Cross) from February 2007 to January 2008. 
Participants were enrolled into four age decades of 100 persons each 
consisting of 50 females and 50 males (age 20-29, 30-39, 40-49, and 50-59 
years, total 200 male and 200 females). IgM and IgG activity against BKV and 
JCV-VLP were determined as described before (Leuenberger, Andresen et al. 
2007). Standard PCR was used to determine the BKV and JCV loads (Hirsch, 
Knowles et al. 2002).  
 
Overall BKV seroprevalence and antibody activity was significant higher than 
JCV seroprevalence and antibody activity (82% vs. 57.7%, 0.6288OD vs 
0.4439OD) (Figure 28A). In contrast, viral shedding was more common for 
JCV and also with higher viral loads compared to BKV (18.8% vs. 7%, 4.644 
logs c/mL vs. 3.51 logs c/mL) (Figure 28A). Viral rearrangements of the non-
coding control region occur rarely (BKV 0%, JCV <1%). This supports our 
hypothesis of accumulation of rr-NCCR in immunosuppression (see 
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introduction). No virus was detected in plasma. The role of virus detection in 
PBMC was controversial (Dolei, Pietropaolo et al. 2000; Ling, Lednicky et al. 
2003). 
Assuming an average individual is producing one litre of urine a day 
containing 2’500 c/mL of BKV and 100’000 c/mL of JCV. In a large city with 
1’000’000 inhabitants for example Zurich in Switzerland, 2.5x1011 copies of 
BKV and 2x1013 copies of JCV would be shed daily. Indeed, human 
polyomaviruses can be found in various environmental compartments (Bofill-
Mas, Pina et al. 2000; Bofill-Mas, Formiga-Cruz et al. 2001; Bofill-Mas and 
Girones 2003). Due to the ubiquitary presence of those viruses, they could be 
used as marker for water quality control or to study human population history 
by analysing genome alterations (Sugimoto, Hasegawa et al. 2002; Ikegaya, 
Zheng et al. 2005). 
 
Female showed higher BKV IgG activities than men. Men more often shed 
both viruses, however viral loads were comparable. With increasing age, we 
observed a significant decrease of BKV seropositive individuals with 
significant BKV IgG activity. For JCV a strong opposite trend was found.  
 
A correlation of JC-VLP IgG activity and JCV loads in urine was found, 
whereas a trend was observed for BKV (Figure 28B). We concluded that IgG 
activity may serve as a marker for recent antigen exposure and serological 
immune response may not protect from virus shedding. This was also 
observed in kidney transplant recipients (Randhawa 2006; Ginevri, Basso et 
al. 2007; Leuenberger, Andresen et al. 2007). BKV and JCV sero-double 
positive individuals showed significant less JCV replication in urine compared 
to JCV single sero positive. This may indicate a cross-protective effect of 
BKV-specific immunity on JCV replication. For the cellular BKV-specific 
immune response cross recognition was shown for peptide pools and single 
epitopes (Egli, Dumoulin et al. 2008, in press). 
 
BKV specific IgG activity was significant lower in BKV non-serotype 1 
shedding individuals. This indicates the importance for serotype-specific 
humoral assays (Figure 28C). 
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Figure 28. BKV and JCV serologic IgG activities and BKV and JCV replication 
in urine is shown (A). Correlation of BKV and JCV activities and virus 
replication detected in urine is shown (B). Comparison of BKV IgG activities 
within the individuals shedding serotype 1 or non-serotype 1. 
 
5.2.2. Polyomavirus BK-specific cellular immune response to VP1 and Large 
T-Antigen in Kidney Transplant Recipients (Binggeli, Egli et al. 2007) 
 
Measurement of BKV-specific T-cells could allow to better profile the risk of 
kidney transplant patients to replicate BKV and develop PVAN. 
 
We aimed to compare healthy individuals to kidney transplant patients with 
increasing or decreasing BKV plasma loads. We wanted to compare as well 
BKV-VP1 and LT peptide pools, and the corresponding potential to expand T-
cells in culture. Finally, we were interested in examinations concerning the 
cross-reactive potential between BKV and JCV. 
 
In total, 10 healthy blood donors without BKV detection in urine or plasma, 
and 42 kidney transplant recipients (characteristics in publication Table 1) 
were examined in a cross-sectional study design. 
Healthy blood donors compared to kidney transplant recipients showed lower 
amounts of BKV-VP1 and -LT specific T-cells. This might be due to recent 
virus reactivation. Interestingly, the immune response in kidney transplant 
patients and especially against BKV-VP1 is widely scattered (Figure 29). The 
population of kidney transplant recipients is heterogeneous according basic 
diseases, amount of BKV loads, immunosuppression, etc. Especially for VP1, 
as postulated, infection with other serotypes or JCV might influence the 
immune response. Additionally, at the time-point of this study, we were not 
able to determine BKV serology. As 20% are sero negative, this might add to 
the scattered immune response. 
 
For CMV, a difference of virus proteins to stimulate either CD4+ or CD8+ T-
cells has been observed. We wondered, if the same is true for BKV. In a 
direct FACS analysis, in healthy individuals normally no BKV-specific T-cells 
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can be detected due to the sensitivity of the assay (data not shown). 
However, in transplant patients with recent reactivation, we observed a higher 
VP1-specific CD4+ T-cell response compared to CD8+ T-cells (Figure 30). 
 
 
Figure 29. BKV VP1 and LT specific T-cell responses in healthy blood donors 
and kidney transplant recipients. 
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Figure 30. FACS analysis of BKV-specific CD4+ and CD8+T-cells in kidney 
transplant recipients 
We grouped the patients according to their viral load dynamics. A change by 
more than 1.5 logs within 2 weeks was assessed to be significant. Patients 
with increasing or high viral loads showed significant lower BKV-specific T-
cells compared to patients with decreasing or cleared viral loads (LT: 22 vs. 
78 SFU/1Mio PBMC; VP1: 53 vs. 285 SFU/1Mio PBMC (Figure 31)). 
 
 
 
Figure 31. Comparison of patients with increasing (group 1) or decreasing 
(group 2) viral loads according to BKV LT and VP1 specific immune response. 
Interestingly, patients with a BKV LT specific immune response above 69 
SFU/1Mio PBMCs were significantly more often associated with decreasing 
BKV loads. A similar cut-off for VP1 could not be calculated. Suggesting that, 
BKV LT specific T-cell response more be more valuable as monitoring 
marker. 
 
We then checked the expansion potential of BKV-specific T-cells for 9days 
with ActMono protocol. The amount of expanded cells was compared to pre-
expansion amount. Both patient groups, with increasing and decreasing viral 
loads, showed a significant increase of BKV-specific immune responses in 
culture. This indicates, the presence of BKV-specific T-cells, probably due to 
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higher immunosuppression no sufficient immune response could be mounted 
in the direct assay. Interestingly re-challenging after 9 days showed that LT-
specific T-cell might have a higher expansion capacity. (Binggeli, Egli et al. 
2007) (Figure 32). Ginevri et al. examined in a prospective study the BKV-
specific immune response at different BKV-associated events, such as 
increasing, decreasing, or clearing BKV load in plasma. Interestingly, Ginevri 
et al. found no significant difference according INFγ production between BKV-
LT and VP1, however a significant stronger killing activity was seen for BKV-
LT specific T-cells. In their protocol used, BKV-specific T-cells were expanded 
before testing this could be an explanation for the difference to our results. 
During expansion probably CD8+ T-cells, which favour BKV LT show a higher 
killing activity. Whereas, BKV-VP1 stimulated T-cells as well to produce INFγ, 
however, more CD4+ T-cells without killing activity (Ginevri, Basso et al. 
2007). The role of BKV-specific CD4 T-cells with killing activities remains 
controversial (Zhou, Sharma et al. 2007). 
 
 
 
Figure 32. Direct Elispot versus 9day expanded BKV-specific T-cell cultures. 
 
In this study we have shown, that BKV LT and VP1 can be used to monitor 
BKV-specific immune responses. BKV LT specific immune response seems to 
be better correlated with protection from BKV replication. The amount of 
response is also associated with BKV load dynamics and might be used to 
predict future viral loads. 
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5.2.3. BKV epitop mapping (unpublished results, Egli et Hirsch) 
 
Epitope mapping is the identification of immunodominant regions (epitopes) 
within a larger antigen-sequence. The identified epitopes (9 or 15mer) are 
presented via MHC molecules in a strict HLA background to the T-cells (see 
introduction). Knowledge of the BKV epitopes will help to further improve our 
immunological BKV monitoring assays. Probably identified BKV epitopes 
could be used in a vaccine. 
 
Most vaccines nowadays in use were developed based on conventional 
techniques as for example repeated passages in various tissue cultures to 
reduce virulence (Ellis 2004). For the BKV large T protein, a safety issue may 
concern the biological activity of SV40-LT and its potential role in cancer 
development. Therefore, we avoid using the whole BKV-LT protein in a 
vaccine. Epitope mapping may reduce the sequence necessary to a 
minimum. 
 
Two methods of epitope mapping exist: (i) Computer algorithms to predict 
potential epitopes and (ii) experimental screening of peptide sub-pools with in 
vitro stimulation and detection of immuno dominant sub-pools and/or single 
peptide with INFγ detection assays. 
 
We have decided not only predicting single eptiope for single HLA types, as 
mostly HLA A0201 were identified so far, but focused to screen the whole LT 
protein for several HLA types. Cluster regions, covering more HLA types and 
inducing a CD4+ and CD8+ T-cell response would be of great value. 
 
Computer prediction 
Several computer prediction algorithms may be used to simulate in silico 
single or combined parts of the processing (see Introduction and Table 5). 
 
Name Description URL 
   
Antjien Binding to MHC ligands, TCR-MHC complexes, T cell epitopes, TAP http://www.jenner.ac.uk/antijen/ 
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BIMAS Predicts half-time of dissociation to HLA class I molecules http://www-bimas.cit.nih.gov 
CEP Conformational Eptiope Prediction Server http://202.41.70.74:8080/cgi-bin/cep.pl 
EpiMatrix  http://tbhiv.biomed.brown.edu// 
EpiMHC Peptides that bind to MHC molecules http://bio.dfci.harvard.edu/epimhc/ 
Epipredict Predicts HLA-class II restricted T-cell epitopes http://www.epipredict.de/index.html 
IEBD Integrating TAP, proteosomal cleavage, MHC http://www.immuneepitope.org 
JenPrep Immunological protein-peptide interactions http://www.jenner.ac.uk/JenPep/ 
MAPPP Possible antigenic peptides to be processed and finally presented on cell surfaces 
http://www.mpiib-
berlin.mpg.de/MAPPP/expertquery.html 
MHCBN MHC binding, non-binding peptides, epitopes 
MIF 
antigenicity Predicts antigenic sites in proteins http://immunax.dfci.harvard. 
NetChop Cleavage sites of the human proteasome http://www.cbs.dtu.dk/services/NetChop 
PapRoc Proteasomal cleavages http://www.paproc.de/ 
PreDep Genomic, transcriptomics and proteomic data http://margalit.huji.ac.il/ 
ProPred Predicts MHC Class-II binding regions http://www.imtech.res.in/raghava/mhcbn/ 
Superficial Identification of potential epitopes or binding sites http://bioinformatics.charite.de/superficial/ 
Syfpeithi T-cell epitope and MHC ligand publication http://www.syfpeithi.de 
   
 
Table 5. List of computer prediction algorithms 
 
For computer prediction, we decided to use a combination of proteasome 
cleavage, TAP processing and MHC class I loading. IEBD database 
(www.immuneepitope.org, (Peters, Sidney et al. 2005)) fulfilled these criteria. 
MHC II binding prediction was also calculated with IEBD database. Syfpeithi 
algorithm was used as a comparison to IEBD (www.syfpeithi.de). However, 
Syfpeithi only predicts the binding affinity between an amino acid sequence 
and a corresponding MHC molecule, which could be a disadvantage of this 
algorithm. 
 
As the HLA type is absolutely essential for the MHC presentation of immuno-
dominant peptide sequences, first, the HLA distribution of Europe, Basel, and 
the United states was analysed with the NCBI database 
(http://www.ncbi.nlm.nih.gov/gv/mhc) (Figure 33). For those HLA types above 
5% in population, the MHC I epitopes predicted would be of interest. 
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Figure 33. HLA distribution in Europe (blue), North American (red) and Basel, 
Switzerland (green). 
 
BKV LT protein prediction 
The amino acid sequence of BKV LT (695aa) was entered into the algorithm 
software and the HLA type of interest was chosen. The algorithm gives 
several scores to compare the identified epitopes with each other. We 
focused on the best 20 predicted epitopes with an integrative overall score 
(combination of proteosomal cleavage, Tap processing and MHC I binding). 
IEBD MHCII prediction is based only on MHC II binding affinity. Additionally, 
we also predicted the best 20 epitopes with the Syfpeithi algorithm. Syfpeithi 
as well is only based on MHC I binding affinity. 
 
The position of the first amino acid of a predicted epitope was entered into a 
excel file and a overlay of all identified epitopes for all possible HLA 
combinations was performed to find clusters of epitopes (See Figure 24 A-F 
for method). For 14 HLA A, 14 HLA B and 10 HLA DQ types the BK LT amino 
acid sequence was entered and the top 20 epitopes were considered for 
further analysis. 
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Then the clusters were aligned to find super clusters within HLA A, B or DR. 
Super clusters were defined as a region, where an epitope sequence 
recognizing more than 4 different HLA types. These regions covers a high 
variance of HLA types in the population and would be of value for monitoring 
and vaccine-development. 
 
A slight difference between Syfpeithi and IEBD prediction was found, 
especially when single amino acid sequences within a cluster of interest was 
compared. This might be of relevance when single tetramers are design for 
testing epitopes. However, over 80% of the predicted epitopes were identical 
by both algorithms (see Figure 34). Most predicted clusters lay within the 
DNA binding site and the p53-binding region. Rb and ATPase activity site was 
spared. 
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Figure 34. Prediceted epitopes for HLA A, B and DR with IEBD and Syfpeithi 
are shown. Last graphic shows an overlay analysis to identify super cluster 
regions. 
 
As longer sequences are not practical for production and harbour a certain 
danger on biological activities, we identified 15mer and 25mer amino acid 
sequences within super-cluster regions. Within the cluster-15 and 25mer we 
checked the amount of 9mer sequences representing particular single 
epitopes of HLA A and B. 15mer and longer corresponding 25-26meres were 
ordered for experimental verification of immune stimulation potential (see 
Table 6). Table 7 shows the predicted 9mers and recognized single HLA 
types, which we would use in a future checkerboard attempt. Table 8 shows 
potential tetramer peptides for single HLA types represented in the cluster 
regions identified. 
 
Position (aa) Sequence length region 
    
010 to 033 LERAAWGNLPLMRKA 15aa p300 
026 to 040 NLPLMRKAYLRKCKE 15aa p300 
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145 to 159 HQFLSQAVFSNRTLA 15aa DNA binding site 
153 to 167 FSNRTLACFAVYTTK 15aa DNA binding site 
172 to 186 ILYKKLMEKYSVTFI 15aa DNA binding site 
190 to 204 MCAGHNIIFFLTPHR 15aa DNA binding site 
212 to 226 NFCQKLCTFSFLICK 15aa DNA binding site 
222 to 235 FLICKGVNKEYLLYS 15aa DNA binding site 
232 to 246 YLLYSALTRDPYHTI 15aa DNA binding site 
281 to 295 ETKCEDVFLLLGMYL 15aa DNA binding site 
287 to 301 VFLLLGMYLEFQYNV 15aa DNA binding site 
357 to 371 MTREEMLTERFNHIL 15aa p53 binding site 
404 to 418 DSVIFDFLHCIVFNV 15aa p53 binding site 
565 to 579 LLEKRILQSGMTLLL 15aa p53 binding site 
573 to 587 SGMTLLLLLIWFRPV 15aa p53 binding site 
    
019 to 043 LERAAWGNLPLMRKAYLRKCKEFHP 25aa p300 
145 to 167 HQFLSQAVFSNRTLACFAVYTTKEK 25aa DNA binding site 
162 to 186 AVYTTKEKAQILYKKLMEKYSVTFI 25aa DNA binding site 
188 to 212 RHMCAGHNIIFFLTPHRHRVSAINN 25aa DNA binding site 
212 to 237 NFCQKLCTFSFLICKGVNKEYLLYSAL 27aa DNA binding site 
227 to 250 GVNKEYLLYSALTRDPYHTIEESI 24aa DNA binding site 
280 to 304 VETKCEDVFLLLGMYLEFQYNVEEC 25aa DNA binding site 
355 to 378 LHMTREEMLTERFNHILDKMDLIF 24aa p53 binding site 
402 to 426 KMDSVIFDFLHCIVFNVPKRRYWLF 25aa p53 binding site 
565 to 590 LLEKRILQSGMTLLLLLIWFRPVADF 26aa p53 binding site 
    
 
Table 6. Predicted superclusters, which cover different HLA types. Position 
within BKV LT protein, peptide length and function region is indicated 
 
Position Sequence Length HLA Type predicted Algorithm Region 
      
19 LERAAWGNL 9aa B4401 Syf p300 
21 RAAWGNLPL 9aa B0702, B5101, B4001 Syf, IEBD p300 
26 NLPLMRKAY 9aa A01, B4402, B1501 Syf p300 
27 LPLMRKAYL 9aa 
B5101, B08, B0702, B0801, B0801, 
B5101 Syf, IEBD p300 
28 PLMRKAYLR 9aa A03 Syf p300 
29 LMRKAYLRK 9aa A0301, A1101 Syf, IEBD p300 
32 KAYLRKCKE 9aa B5101 Syf p300 
33 AYLRKCKEF 9aa A2403, A2402,B4402 Syf, IEBD p300 
      
145 HQFLSQAVF 9aa 
A2403, B1501,B4002, B4001, B3501, 
B1501, B0702 Syf, IEBD DNA 
148 LSQAVFSNR 9aa A1101 Syf, IEBD DNA 
150 QAVFSNRTL 9aa B5101, B0702 Syf, IEBD DNA 
156 RTLACFAVY 9aa 
A0301, A0101, A1101, A03, B3501, 
B1501 Syf, IEBD DNA 
158 LACFAVYTT 9aa B5101 Syf DNA 
159 ACFAVYTTK 9aa A03 Syf DNA 
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165 TTKEKAQIL 9aa B08 Syf DNA 
166 TKEKAQILY 9aa A0101, A01 Syf, IEBD DNA 
167 KEKAQILYK 9aa none  DNA 
169 KAQILYKKL 9aa B5101 Syf DNA 
172 ILYKKLMEK 9aa A1101, A0301, A0201, A03 Syf, IEBD DNA 
173 LYKKLMEKY 9aa A01, B1501 Syf, IEBD DNA 
176 KLMEKYSVT 9aa A03 Syf DNA 
177 LMEKYSVTF 9aa A0202, A0101,B3501, B1501, B0801 Syf, IEBD DNA 
178 MEKYSVTFI 9aa B4402, B5101 Syf, IEBD DNA 
      
188 RHMCAGHNI 9aa A0203 IEBD DNA 
192 AGHNIIFFL 9aa A0202 IEBD DNA 
190 MCAGHNIIF 9aa B4403, B4001. B3501, B0801 IEBD DNA 
191 CAGHNIIFF 9aa B3501 IEBD DNA 
196 IIFFLTPHR 9aa A1101, A0301 IEBD DNA 
199 FLTPHRHRV 9aa A0201, A0202, A0203 Syf, IEBD DNA 
201 TPHRHRVSA 9aa B0702 IEBD DNA 
202 PHRHRVSAI 9aa A0203, B08 Syf, IEBD DNA 
      
212 NFCQKLCTF 9aa A0206, A2403, B4403, B0801, B3501 IEBD DNA 
214 CQKLCTFSF 9aa B1501 Syf, IEBD DNA 
216 KLCTFSFLI 9aa A0201, A0202, A0206, A2402 Syf, IEBD DNA 
218 CTFSFLICK 9aa A0301, A1101 Syf, IEBD DNA 
222 FLICKGVNK 9aa A0301, A03, A1101 Syf, IEBD DNA 
224 ICKGVNKEY 9aa A01 Syf DNA 
226 KGVNKEYLL 9aa A2402 Syf DNA 
227 GVNKEYLLY 9aa A0301, A1101, A01, B1501, B3501 Syf, IEBD DNA 
230 KEYLLYSAL 9aa B4001, B4002, B4402, B4403 Syf, IEBD DNA 
      
232 YLLYSALTR 9aa A0201, A03, A1101 Syf, IEBD DNA 
235 YSALTRDPY 9aa A01, A0101, B3501 Syf, IEBD DNA 
238 LTRDPYHTI 9aa B5101 Syf, IEBD DNA 
242 PYHTIEESI 9aa A2402 Syf DNA 
      
282 TKCEDVFLL 9aa A2402 Syf DNA 
283 KCEDVFLLL 9aa A2402, B0702, B4001 Syf DNA 
286 DVFLLLGMY 9aa A01, A0101, B1501 Syf, IEBD DNA 
287 VFLLLGMYL 9aa A0206, A2402 Syf, IEBD DNA 
289 LLLGMYLEF 9aa 
A0201, A03, B1501, B5101, B4002, 
B0801, B3501 Syf, IEBD DNA 
291 LGMYLEFQY 9aa 
A1101, A01, A0101, B5101, B4403, 
B3501 Syf, IEBD DNA 
293 MYLEFQYNV 9aa A1101, A0201 IEBD DNA 
      
355 LHMTREEML 9aa A0203, B0801 IEBD p53 
359 REEMLTERF 9aa A2403, B4403, B4002, B4001, B4402 Syf, IEBD p53 
362 MLTERFNHI 9aa 
A0201, A0202, A0203, A2402, B0801, 
B08 Syf, IEBD p53 
369 HILDKMDLI 9aa A2402, B08 Syf, IEBD p53 
      
402 KMDSVIFDF 9aa A0201, A0202 IEBD p53 
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403 MDSVIFDFL 9aa A0202, B0702 Syf, IEBD p53 
406 VIFSFLHCI 9aa A0203, A0206, A0201, B5101 Syf, IEBD p53 
410 FLHCIVFNV 9aa A0201, A0203, A0202 Syf, IEBD p53 
408 FDFLHCIVF 9aa B5101, B4002, B1501, B0801, B3501 Syf, IEBD p53 
414 IVFNVPKRR 9aa A1101 Syf, IEBD p53 
415 VFNVPKRRY 9aa none  p53 
417 NVPKRRYWL 9aa B0801, B0702 IEBD p53 
418 VPKRRYWLF 9aa B08. B5101, B0702 Syf, IEBD p53 
      
569 RILQSGMTL 9aa A0201 Syf, IEBD p53 
570 ILQSGMTLL 9aa A0201, A0203, A0202 Syf, IEBD p53 
571 LQSGMTLLL 9aa A0206, A0201, A0202, B4001 Syf, IEBD p53 
573 SGMTLLLLL 9aa A0202, B4001 Syf, IEBD p53 
574 GMTLLLLLI 9aa A0201 Syf, IEBD p53 
575 MTLLLLLIW 9aa A2403, B4403 IEBD p53 
576 TLLLLLIWF 9aa A0301, A0206, A0201, B4403 IEBD p53 
577 LLLLLIWFR 9aa A0201, A0301 IEBD p53 
579 LLLIWFRPV 9aa A0201, A0203, A0206 Syf, IEBD p53 
582 IWFRPVADF 9aa A2403, B4403, B1501, B2403 Syf, IEBD p53 
      
 
Table 7. Identified 9mers with corresponding predicted HLA types. In red 
already published epitopes. Prediction method and functional region is 
indicated. 
 
A0101 RATING A0201 RATING A0301 RATING 
NLPLMRKAY BB** ILYKKLMEK AA PLMRKAYLR AA 
RTLACFAVY AAA FLTPHRHRV AAA LMRKAYLRK BB** 
TKEKAQILY AAA KLCTFSFLI AA RTLACFAVY AA 
LYKKLMEKY BB** YLLYSALTR BB ACFAVYTTK AA 
LMEKYSVTF BBB LLLGMYLEF BB ILYKKLMEK AAA 
ICKGVNKEY BB** MYLEFQYNV BB KLMEKYSVT AA 
GVNKEYLLY BB** MLTERFNHI AA IIFFLTPHR BB** 
YSALTRDPY AA KMDSVIFDF BBB CTFSFLICK BBB 
DVFLLLGMY BB** VIFSFLHCI AAA * FLICKGVNK AAA 
LGMYLEFQY BB** FLHCIVFNV AAA * GVNKEYLLY BB** 
  RILQSGMTL AA YLLYSALTR AAA 
  ILQSGMTLL AAA * LLLGMYLEF AA 
  LQSGMTLLL BB TLLLLLIWF BB** 
  GMTLLLLLI AA LLLLLIWFR BB** 
  TLLLLLIWF BB   
  LLLLLIWFR BB   
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  LLLIWFRPV AAA ***   
 
 
A1101 RATING A2402 RATING B0702 RATING 
LMRKAYLRK AAA AYLRKCKEF AAA RAAWGNLPL BBB 
LSQAVFSNR AA  HQFLSQAVF BBB HQFLSQAVF BBB 
RTLACFAVY BBB KLCTFSFLI BB** QAVFSNRTL BBB 
ILYKKLMEK AAA KGVNKEYLL BB** TPHRHRVSA AA 
IIFFLTPHR AA PYHTIEESI AA  KCEDVFLLL BBB 
CTFSFLICK AAA TKCEDVFLL BB** NVPKRRYWL BBB 
FLICKGVNK AAA KCEDVFLLL BB** VPKRRYWLF AA ** 
GVNKEYLLY BBB VFLLLGMYL AA   
YLLYSALTR AA REEMLTERF BBB   
LGMYLEFQY BBB MLTERFNHI BB**   
MYLEFQYNV BBB HILDKMDLI BB**   
IVFNVPKRR AA MTLLLLLIW BBB   
  IWFRPVADF BBB   
      
 
 
B0801 RATING B3501 RATING B4001 RATING 
LPLMRKAYL AAA HQFLSQAVF BB** RAAWGNLPL BBB 
TTKEKAQIL AAA RTLACFAVY BB** HQFLSQAVF BBB 
LMEKYSVTF BBB LMEKYSVTF BB** MCAGHNIIF BBB 
MCAGHNIIF BBB MCAGHNIIF BB** KCEDVFLLL BBB 
PHRHRVSAI AA  CAGHNIIFF BB** REEMLTERF BBB 
NFCQKLCTF BB  NFCQKLCTF BB** LQSGMTLLL BBB 
LLLGMYLEF BB GVNKEYLLY BB** SGMTLLLLL BBB 
LHMTREEML BB YSALTRDPY BB**   
MLTERFNHI AA LLLGMYLEF BB**   
HILDKMDLI AA LGMYLEFQY BB**   
FDFLHCIVF BBB FDFLHCIVF BB**   
NVPKRRYWL AA     
VPKRRYWLF AAA     
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Table 8. Potential tetramer epitopes for single HLA types represented in 
cluster regions. Rating allows to decide on the particular binding affinity on a 
company algorithm (Proimmune, England, done by Sara Allwood.) AAA, 
highest probability to bind; AA, fair good probability; BB, could be tried; BBB, 
will not bind. ** Must provide supporting evidence of binding before 
acceptance of these rated sequences by ProImmune to attempt as pentamer; 
*** Successfully synthesised this specificity before; * Predicted binding similar 
to that of LLLIWFRPV (Previously made as pentamer). 
 
BKV agno protein prediction 
The potential role of BKV agno in replication was discussed in the 
introduction. We wondered if any potential epitope lay within one of the three 
potential phosphorylation sites of the protein (S7, S11 and T21) 
(Johannessen, Myhre et al. 2008). Therefore, we computer predicted epitopes 
for HLA A01 with wildtype agno and phophorylated agno. Phosphorylation of 
agno protein may influence the natural processing via MHC. Syfpeithi 
prediction revealed that several epitopes contain the S11 and T21 amino 
acids, but most epitopes lay within the second part of the agno protein (see 
Figure 35). 
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Figure 35. Wild type agno compared to phosphorylated agno and the 
influence on predicted epitopes. 
 
The MHC binding affinity scores predicted by Syfpeithi indicates a weak 
binding. This could be an explanation for the bad immuno induction potential. 
However, other HLA types should be predicted and set into context with the 
processing of other BKV epitopes. Additionally single patients with high agno 
responses should be compared to “ordinary” patients without a agno specific 
immune response. 
 
Experimental results and confirmation of predicted epitopes 
To verify, if the in silico predicted regions correlate with in vitro immunology, 
we checked the BK LT protein using a checkerboard approach. This would 
verify immuno-dominant sequences and reveal unpredicted regions, which 
would haven been probably missed by the computer prediction alone. 
 
First, laboratory personal was tested for humoral and cellular BKV- and JCV-
LT, -VP1 and -agno-specific immune response. PBMCs of BKV seropositive 
healthy individuals were isolated and BKV LT-specific T-cells were expanded 
for epitope mapping. Donor characteristics can be seen in Table 9.  
 
 
PhD thesis: CMV and BKV immunity, Adrian Egli                                      111/196 
 
Age 
 
Gender 
 
BKV 
serology 
JCV 
serology 
HLA A 
 
HLA B 
 
HLA DR 
 
       
31 
 
male 
 
+ 
 
(+) 
 
24/29 
 
44/55 
 
07/14 
 
30 
 
male 
 
+ 
 
- 
 
02/30 
 
13/35 
 
11/13 
 
34 
 
female 
 
+ 
 
+ 
 
02/03 
 
07/62 
 
04/15 
 
50 
 
male 
 
(+) 
 
+ 
 
01/02 
 
08/40 
 
11/13 
 
42 
 
male 
 
(+) 
 
+ 
 
02/11 
 
07/62 
 
04/15 
 
       
 
Table 9. Showing healthy donor characteristics for epitope mapping. (+) weak 
serological response. 
 
In principle the ActMono assay was used to amplify virus-specific T-cells (see 
material and methods and Figure 11A). 
 
Every sub-pool consists of 10 single peptides (see appendix for sub-pool 
specifications). Within the checkerboard, at the cross-points of sub-pools a 
higher immune response indicates immuno dominant peptides (Figure 36).  
 
 
Figure 36. Checkerboard design. Every sub-pool of the 15mer total library 
contained 10 single peptides. We had in total a sub-pool set from A to J 
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crossing with 1 to 10 and a set K to R crossing with 11 to 20. Sub-pool 
containment can be seen in the appendix. 
 
Another way to verify predicted clusters was comparison to already published 
epitopes. We found than 80% of published peptides were included in our 
cluster-regions. Two HLA DR1 epitopes (0901: TFSRMKYNICMGKCI AND 
0301: TLYKKMEQDVKVAHQ), and one HLA B08 epitope 
(IYLRKSLQNSEFLLE) were not in our super-cluster (Li, Melenhorst et al. 
2006). 
 
Phenotypic characteristics during expansions with BKV LT-pool 
Before expansion the amount of BKV -specific T-cells in the peripheral blood 
is low. In Elispot between 50 and 150 SFU/1Mio PBMCs can be detected, 
corresponding to 0.005% of PBMC. The sensitivity of flow cytometry normally 
is too low to detect any BKV specific response without expansion. Using the 
ActMono expansion method, the amplification efficacy was between 10 and 
100 fold. SFUs reached between 500 and 5000 SFUs/1Mio PBMC. In FACS 
analysis 0.2 to 3% of BKV LT-specific T-cells could be detected after 
expansion. CD4+ and CD8+ T-cells were in a ration of 2:1. However, further 
specific memory marker were not yet tested. 
 
Checkerboard approach for BK LT 15mer library 
BKV LT specific T-cells of 5 healthy individuals were expanded over nine days 
using a peptide pool containing the whole BK LT library (179 15mers). After 
expansion the virus-specific cells were frozen and new round of expansion 
with fresh blood was started. After having roughly 50 x 10e6 expanded T-cells 
we thawn the cells and pooled them for each individual. 
 
Elispot was performed according to standard protocol except using 100’000 
expanded T-cells per well. Content of peptide sub-pools can be seen in the 
appendix. Sub-pools were plated in duplicates onto the Elispot plate (see 
Figure 36 for an example).  
On every plate staphylococcal enterotoxin B and BK LT pool served as a 
positive control. Additionally, a background control with cell medium was run 
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in parallel. The double value of the mean background wells served as a 
definition for a positive immune response (green marked wells in Figure 37-
38).  
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Figure 37. Checkerboard of peptide sub-pools A-D and 1-10. 
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Figure 38. Checkerboard of peptide sub-pools E-H and 1-10. 
 
Checkerboard results of sub-pools I-J/1-10, K-N/11-20 and O-R/11-20 can be 
seen in the appendix part. The same approach was done for four other 
healthy individuals. 
 
Then, the database was again consulted to check, if the positive response 
was also computer predicted at a crossing sub-pools. If so, this single peptide 
was entered into a excel file and compared with other individuals with the 
same HLA type and also with the overall predicted peptides for this HLA type.  
For example in Figure 37, sub-pool B crossing with sub-pool 9 identified p107 
to be immunodominant with 790 SFU/1Mio PBMCs. Indeed this 15mere 
harbour the 9mere epitope WSSSEVPTY, which is immunodominant for HLA 
B3501 and matched with the HLA type of the blood donor. 
 
Overall a high concordance between the predicted IEBD and Syfpeithi 
epitopes and the in vitro generated data existed for various HLA types (Figure 
39). 
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Figure 39. Overlay of predicted Syfpeithi and IEBD epitopes and 
checkerboard peptides with high activity for different HLA types. 
 
Usage of predicted 15mer and 25mer peptides 
The next step was to test the predicted 9-, 15-, and 25mer peptides for 
functionality on expansion. The predicted 9-, 15-, and 25mers were pooled 
separately. We performed an ActMono expansion with pulsing the monocytes 
for 4h with the 15mers and 25mers pools. Re-challenging in Elispot and FACS 
was after 9days with the corresponding predicted 9-, 15-, and 25mers pools. 
 
Results from the flow cytometry indicated for individual RG (HLA A 02/11 B 
07/62) a strong induction of BKV-specific CD8+ T-cells, when challenged with 
the 9mers (See Figure 42). In this individual the re-challening with single 
predicted 15mers in Elispot revealed that 3 peptides were particular 
immunodominant (NLP, LER, MTR). Based on the CD8 response in FACS, 
these 15mer harbour HLA A or B epitopes. When compared with the 
database we could identify indeed 3 new not published epitopes: HLA A0201: 
MLTERFNHI; HLA B0702: RAAWGNLPL; HLA B0702: LPLMRKAY. Elispot 
plates can be seen in Figure 40. However, the RAAWGNLPL epitope is 
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accordning to the pro-immune house prediction assay no good epitope for 
binding to HLA B0702 MHC I molecules. 
 
Results from flow cytometry of individual AD (HLA A24/29 B44/55) a weaker 
BKV-specific CD8+ response compared to CD4+ response in flowcytometry 
(Figure 43). However, the 9mer pool in Elispot responded very strongly. Four 
single 15mers were strong positive, harbouring the 9meres for HLA A2402 or 
B4402: AYLRKCKEF, for A2402: PYHTIEESI, for A2403: HQFLSQAVF, and 
for DR0701: LPLMRKAY (Figure 41). 
 
9mer tetramers 
Tetra/Pentamer staining is a technique to measure the amount of T-cells 
binging to a particular epitope. The identified epitopes is artificially loaded on 
a nanoparticle coated with MHC molecule of a certain HLA type. A T-cell with 
a TCR specific for the epitope will bind to the tetramer, which is tagged with 
PE-fluorescence marker (introduction and Figure 5). In peripheral blood the 
spectra of specific T-cells should be highly biased, because only those T-
cells, which were previously stimulated will patrol. Stimulation, however, is 
based on the corresponding MHC with the particular HLA background. 
 
To further identify if epitope-specific T-cells were present in the expanded 
culture, we ordered pentamers (Proimmune, England) of the corresponding 
HLA types covering the 15mer and 25mer predicted region. However, so far 
these pentamers are not yet tested. Table 8 and 9 show a list of identified 
tetramers with the corresponding HLA type. 
 
In general, the HLA DR distribution was more focused on certain regions and 
not as widely spread than HLA A or B epitopes within the protein. Therefore 
certainly several HLA DR epitopes will be missed using more focused 
sequences. On the other hand, our laboratory and others have previously 
shown, that especially the BKV-LT specific CD8+ T-cells response seems to 
be important in controlling viral replication (Comoli, Binggeli et al. 2006; 
Hammer, Brestrich et al. 2006; Binggeli, Egli et al. 2007; Ginevri, Azzi et al. 
2007). Under this aspect, anyway we would favour HLA A or B epitopes. 
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Figure 40. Elispot after 9d expansion with predicted 15mer pool. Re-
challenging with predicted 9-, 15-, and 25mer pools and single 15mers. NLP, 
LER, MTR responded particular good. HLA A 02/11 B 07/62 
 
 
 
Figure 41. Elispot after 9d expansion with predicted 15mer pool. Re-
challenging with predicted 9-, 15-, and 25mer pools and single 15mers. NLP, 
LER, MTR responded particular good. HLA A24/29 B44/55 
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Figure 42. Flowcytometry analysis after expansion with 25mer pools and re-challenge with shorter fragments pools. 
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Figure 43. Flowcytometry analysis after expansion with 25mer pools and re-challenge with shorter fragments pools. 
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As the proteasome shows different cleavage specificities when it is interferon 
induced, another critical point could be the potential differences in epitopes 
processing during infection. During active BKV replication indeed the spectra 
of T-cell is wider scattered (Comoli, Basso et al. 2003). However, Gineveri et 
al. have shown, that BKV LT specific immune response after viral clearance 
shows highest killing activity (Ginevri, Azzi et al. 2007). Based on this we 
could assume that memory T-cell clones will persist recognizing the 
responsible epitopes. Our assays targets memory T-cells response should 
catch the important epitopes.. 
 
The high homology of more than 80% between BKV LT and JCV LT explains 
the high immunological cross-reactivity between both viruses. Binggeli et al. 
showed that BKV-specific expanded cells could be re-challenged with a JCV-
LT peptide library. For JCV LT a higher immune response was examined 
compared to BKV VP1 expanded T-cells re-challenged with JCV-VP1 
(Binggeli, Egli et al. 2007). This cross-reactive potential was more specifically 
examined on single epitope level. Indeed, four BKV LT epitopes have shown 
so far cross-.reactive potential to JCV LT (TFSTMKYNICMGKCI, 
IYLRKSLQNSEFLLE, LLIQFRPV, KSLQNSEFLLEKRIL) (Li, Melenhorst et al. 
2006; Randhawa, Popescu et al. 2006). 
Cross-reactivity could be a problem for a cellular immune assays, but most 
probably due to high double seropositivity, this cannot be avoided. However, a 
pre-serological testing could clarify BKV or JCV latent infection. In a vaccine, 
a cross protective effect could be beneficial.  
We have observed, that JCV and BKV double-seropositive individuals shed 
significantly less often JCV in urine compared to single JCV-seropositives 
blood donors (Egli, Infanti et al. 2008). However, the impact of this 
observation in kidney transplant recipients is yet not examined. 
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6. Conclusions 
 
During my PhD thesis several aspects of the interaction of Cytomegalovirus 
and Polyomavirus BK with the host’s immune system were examined (see list 
of publications). The overall aim was to compare immune response in healthy 
individuals and kidney transplant recipients with or without viral replication. 
 
In healthy individuals, Polyomaviruses BK and JC infect 80% and 60%, 
respectively. For CMV seroprevalences may reach up to 80%. Intermittent 
virus shedding in urine is observed for BKV in 7%, JCV in 19% and CMV in 
0%. However, no virus replication in plasma was detected. Posttransplant, 
mainly due to prolonged immune suppression the amount and function of 
CMV- and BKV-specific T-cells is impaired. Calcineurin inhibitors lead to a 
direct reduction of INFγ production of virus-specific T-cells, whereas anti-
proliferative immunosuppressives reduce the expansion capacity in a dose-
dependent manner. This may be a major reason for uncontrolled virus 
replication. 
 
The humoral response reflects the amount of recent antigen exposure and 
does not directly indicate protection from virus replication. Virus-specific 
cellular immune responses would probably allow to assessing the risk of 
future replication.  
Overall the importance of CMV and BKV specific T-cells posttransplant in 
controlling virus replication was examined. For both viruses we could 
calculate a protective threshold of virus-specific T-cells. CMV-pp65 specific 
CD4 T-cells above 0.03% were significantly associated with no CMV 
replication during the next eight weeks. Additionally, below this cut-off, CMV 
seropositive recipients developed more often GCV-resistant CMV replication. 
During BKV replication, patients with more than 69 BKV-LT specific T-cells 
per 1 Mio PBMCs were significantly more often showing decreasing BKV 
loads in plasma. 
 
As virus-specific T-cells seem to be crutial in reducing virus replication, and 
reduction of immune suppression harbours the risk of acute rejection, a 
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booster vaccine could be a new therapeutic option. A booster vaccine could 
probably elevate the amount of virus-specific T-cells above a critical threshold 
of protection from disease, despite effects of immune suppression. 
 
We tried to identify immunodominant regions with the CMV pp65 and BKV LT 
proteins. We used a combined approach of computer prediction algorithms 
and experimental verification. Epitope mapping of BKV LT with computer 
prediction revealed several clusters, which could be immunodominant and 
also potentially be processed and recognized in various HLA backgrounds. 
The identified cluster regions were synthesised as 15 and 25mers. Expansion 
and re-stimulation with predicted epitopes could so far confirm the HLA A and 
B-specific prediction of single 9mers covered by the larger 15 and 25mer 
sequences. However, other HLA types need to be tested for direct stimulation 
and expansion potential of the predicted epitopes. Additionally, tetramer 
staining should be performed for verification. 
Based on this research, we will be able to improve current immune monitoring 
and probably a high-specific peptide-based vaccine against BKV LT could be 
developed and be used to increase the amount of BKV-LT specific T-cells. 
 
Another potentially therapeutic agent could be the blockade of PD1 ligand. 
PD1 expression in chronic virus infection lead to impaired CD8+ T-cell 
function. CMV-specific CD4 T-cells treated with an inhibitory antibody against 
PD1 ligand, and thereby activating CD4+ T-cells, lead to a increase of the 
expansion capacity. We have shown, that the anti-PD1 ligand antibody 
increases various cytokines. This could be also tested for BK virus. 
 
Measurement of virus-specific T-cells may replace serological assays in the 
future, due to a better correlation to effective antiviral control, which can be 
used as monitoring tool during infection and post-vaccination. 
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6. Outlook 
 
 
6.1. PD1-expression on CMV specific T-cell response and influence on 
cytokine profiles 
 
Overall PD1 blockade, and thereby activation of CMV-specific T-cells seems 
to lead to an unspecific up-regulation of almost any cytokine. 
This could be a safety issue when an antibody blocking PD1 would be used 
therapeutically. There certainly is a theoretical risk for inducing graft rejection 
by stimulating and activating allo-reactive T-cells. Interestingly, only virus-
specific T-cell responded to the antibody treatment, whereas SEB treated 
cells did not up-regulate their cytokines. As SEB will stimulate a wide range of 
T-cells as well allo-reactive T-cells, we would conclude that anti-PD1 
treatment is only beneficial in virus-specific T-cells. However, this needs to be 
tested by stimulating T-cells with allo-antigen preparations. 
 
Virus infections may probably lead to an up-regulation of PD1-ligand 
expression on the host cell surface. This could be a general protective 
mechanism for viruses as they are thereby protected from T-cell killing. The 
exact patterns of PD1-ligand expression should be examined in various cell 
lines with and without virus infection such as CMV and BKV. In kidney 
biopsies with BKV nephropathy a significant up-regulation of PD1-ligand 
mRNA was observed (Starke, Lindenmeyer et al. 2008). 
 
We could use infected RPTECs as antigen presenting cells to CD8 T-cells 
and check the influence of PD1 blockade on killing of virus infected T-cells. 
 
If indeed the effect on virus-specific T-cells is dominating, a PD1 blockade 
could be tested in a mouse model to check for virus clearance. 
 
6.2. Effect of immunosuppression on CMV-pp65 specific and BKV-LT 
specific T-cells 
 
As shown in the ongoing research part, we first concentrated on virus-specific 
PBMCs and the influence of different immunosuppressive compounds. 
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However, many open aspects remain and even more questions were 
generated with this set of experiments. 
 
An interesting, although confusing observation was the dose dependent 
decrease of INFγ-release by BKV-LT specific T-cells with Rapamycin and 
Leflunomid, but not with SEB and pp65 stimulated T-cells. Possible 
explanations were: 
(i) An immunosuppressive effect of DMSO. (ii) The low amount of BKV-LT 
specific T-cells may influence the performance of the assay. Indeed, we noted 
no more dose depending effects when using expanded BKV-specific T-cells. 
(iii) Probably very speculative, BKV-specific T-cells behave differently and due 
to intracellular protein patterns more sensitive to mTOR. 
 
A new batch of BKV LT peptides should be ordered in a higher concentration, 
thereby further reducing DMSO concentration. 
To examine potential differences in mTOR profiles, a selection of BKV-
specific T-cell could be performed by FACS sorting. Then we could check for 
activation/expression state of several mTOR-associated proteins. 
 
We would like to examine the effect of immune suppression on several T-cell 
subtypes. First, we focus on ordinary subsets as CD4+ and CD8+ T-cells, and 
naïve and memory compartments. Then, we concentrate more specifically on 
T-cells with high co-stimulatory marker expressions as CD28 and PD1, as 
these cells may be particular important for immune control. 
 
When immunosuppression is too high, virus replication may happen 
uncontrolled. Measurement of trough levels of immunosuppressive drugs 
overall seem to be too unspecific for several reasons. First, trough levels are 
only an indirect marker, whereas T-cell function would be directly assessing 
the effects of immunosuppression. Plasma levels may additionally be highly 
dependent on individual patients characteristics, as e.g. age, gender, fat 
distribution, other drugs, kidney or liver function, liver enzyme patterns and/or 
polymorphisms. Therefore, we would like to use BKV and CMV-specific 
immune response as an immune marker for too much immune suppression in 
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the near future. On the other hand, a panel of HLA-graft matched antigens 
could be indicators for allo-reactivity and danger of graft rejection. This will 
allow to titrate the immune suppression not only on trough levels which may 
be different for single individuals but to set immune suppression on the real in 
vivo immune function. 
 
We have chosen INFγ as a common read out cytokine. However, hardly any 
data is available on influence of immunosuppression on other cytokine 
profiles. Especially IL2 and TNFα showed in our hands a dose dependent 
decrease, but faster than INFγ. Therefore, we would like to examine the 
hierarchy of cytokine production under immune suppression. 
 
6.3. BKV epitop mapping 
 
6.3.1. Further computer prediction 
 
With computer algorithms several mega- and super-cluster regions within the 
BK LT protein were predicted. JC LT epitopes could also be predicted and 
may possibly be at a similar position within the protein (p300, DNA-binding 
site, and p53-binding region). Dependent on the cross-recognition potential 
between two epitopes, a vaccine could thereby cover both polyomaviruses at 
once. 
Additionally the BKV-VP1 and BKV-agno protein could be further computer 
predicted. These new epitopes could be used in a combined immuno 
monitoring test or vaccine with early and late protein targets. As already 
discussed, a vaccine based on VP1 alone, may be more difficult to design. 
 
Potential side effects of a vaccine, especially unwanted induction of allo-
reactivity post-vaccination, could be discovered by a BLAST of the identified 
predicted sequences. This could reveal virus-epitope and host-protein-epitope 
similarities. This could be understood as a molecular mimicry and selective 
advantage of a virus, because, theoretically T-cell recognizing host-proteins 
should be positive selected. On the other side, this may open the field of 
virus-induced autoimmune diseases. 
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As BKV-LT specific IgG response correlates with virus clearance in plasma, 
we wonder, if this is a effect of neutralizing antibodies, or just a bias of 
selected antibodies, due to help of BKV-LT specific T-cells. As BKV-LT 
specific T-cells seem to be especially important for viral clearance, and 
infected host cells are killed, the new epitopes are more available for the 
immune system. Our ELISA assay uses different parts of BKV LT - LTD1, -D2 
and -D3, LT D1 is approximately 120aa (1-120), LT D2 100a (120-280), and 
LTD3 420aa (280-695). Interestingly, the antibody epitope prediction 
algorithm from IEBD revealed that the LT D1 showed highest potential to bind 
IgGs (Emini surface accessibility scale, Parker hydrophilicity prediction, and 
linear epitope prediction; results not shown). Leuenberger et al. confirmed this 
experimentally, where LT D1 showed highest antibody activity (Leuenberger, 
Andresen et al. 2007). When we would base ELISA assays designs on 
predicted antibody-antigen sequences, we could probably optimize our 
current assays and increase as well sensitivity and specificity. 
 
6.3.2. Further experimental testing 
 
Five healthy individuals spanning several HLA types have been so far epitope 
mapped with the 15mer sub-pools (A-R, 1-20, see appendix) from the whole 
LT-peptide pool in a checkerboard attempt. We compared predicted single 
epitopes of the corresponding HLA type with the checkerboard results and 
showed, that a high match between predicted activity and experimental 
results exists. However, we have planed to further check more different HLA 
combinations with this approach. 
This will not only improve our comparison of predicted and verify epitopes but 
also show if the identified super-clusters, which are our candidate sequences 
for a monitoring tool and vaccine, harbour enough relevant epitopes for a 
sufficient booster of the immune response. 
 
The next step would be to further use the computer predicted 15mer and 
25mer sequences. In two of five individuals the expansion with a pool of 
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predicted 15mer and 25mer sequences was preliminary tested. The re-
challenge with a 9mer pool and FACS analysis supported the potential of the 
predicted sequences to induce a CD8+ T-cell based immune response. 
We plan to further sub-pool the 9mers for a corresponding 15mer. Thereby we 
will be able to identify single 9mer epitopes for one HLA type. 
 
When we have identified single epitopes we would like to verify these with 
pentamer staining. This would allow to easily screening a larger patient 
collective for relevant epitopes. 
 
As we have tested so far only healthy blood donors, we would extend our 
examination also on blood sample from kidney transplant recipients at several 
stages of disease. We would compare patients with ongoing high, low and 
cleared BK viremia. Therefore we could further verify, which epitopes in a 
transplant recipient are more essential for successful virus control.  
 
Based on these results of the computer predicted and immunological 
experiments, we could design a vaccine-vector with either containing the 
genetic sequence of the identified BKV sequence or load DC with the 
peptides. 
 
In a phase-1 trial, we would test the vaccine preparations in a mouse model to 
check for side effects and immune response. 
In a phase-2 trial, we could vaccine a group of BKV seronegative healthy 
individuals and check for the induction of an immune response with our 
monitoring tools for humoral and cellular immune response. 
In a phase-3 trial, we would vaccine seronegative and seropositive kidney 
transplant recipients before transplantation with several vaccine schemes (3 
vs. 1 time point; several time intervals pre- and posttransplant).  We would 
compare the immune response and measure viral reactivation in a vaccinated 
group and compare it to a non-vaccinated group. 
In a second phase-3 trial, we could examine the long-term benefitial effect of 
such a protein vaccine. The main target would be to reduce PVAN. 
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10. Appendices 
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Direct T-cell measurement protocol - flow cytometry assay 
(Protocol Version 3.0, Dr. Adrian Egli, University of Basel) 
 
 
1. Peripheral blood mononuclear cells 
 
Gain PBMCs from CPT tubes (spin 1650g for 20’ and wash twice with PBS) or 
lymphprep separation (spin 800g 20’ and wash twice) as described in the 
manufactures protocols. 
 
2. Stimulation of the PBMCs 
 
Stimulation always in dull polypropylen FACS tubes 
 
Pre-lay 1ug/mL aCD28 and 1ug/mL aCD49d (10uL per tube) 
Per stimulation 0.5 - 2 Mio PBMCs dissolved in 500uL R5 are used 
 
Add antigen 
 
SEB (100ug/mL) neg peptides (100ug/mL) Lysate 
10uL per tube (ec 2ug/mL) - 10uL per tube (ec 2ug/mL) 16uL 
 
Caveat: Virus lysate often has a very varying concentration (1-5mg/mL) and 
batches should be tested out, as well as control lysates from corresponding 
cell cultures. 
If peptides are used add Brefeldin A right from the beginning (10ug/mL ec). 
Stock 500ug/mL, add 10uL per tube 
 
Vortex 
 
Incubation for 30’ 37°C at 7%CO2 
Vortex  
Spin 5’ at 1100rpm 
 
Incubation for 1h 30’ at 37°C at 7%CO2 
Add 10ug/mL (ec) BFA to lysate stimulated tubes 
 
Vortex 
 
Incubation overnight at 37°C at 7% CO2 
 
3. Fixation of the cells 
 
Prewarm 4% PFA 
Add 100uL per tube EDTA (20mM) 
Vortex each tube for 10’’(!) 
 
Incubation for 15’ at room temperature 
 
Add 2mL FACS wash 
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Spin 10’ 450g at RT 
 
Discard supernatent with vacuum 
 
Add 300uL 4% PFA to each tube for 5’ (!) 
 
Stop fixation by adding 3mL FACS wash 
 
Spin 10’ 450g at RT 
 
Discard supernatent with vacuum 
 
Dissolve pellet and rest fluid in 200uL 1% PFA 
 
4. Staining 
 
Put cells  into new clear FACS tubes 
 
Add 2mL of 0.1% Saponin (Permeabilizing solution) 
 Cave for FoxP3 staining specific perm solution from the company 
 should be used 
 
Incubate for 10’ at RT 
 
Spin 10’ 450g at RT 
 
Discard supernatent with vacuum 
 
Add antibody solution as indicated in the “staining modul” section. 
 
Incubate in dark at RT for 30-45’ 
 
Add 3mL FACS wash 
 
Spin 10’ 450g at RT 
 
Discard supernatent with vacuum 
 
Add 200uL 1%PFA 
 
Measurement at FACS or store at 4°C 
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Staining modules 
 
Standard (INFγ and IL2) 
 
CD3  (PerCP) 10uL 
CD4  (APC Cy7) 5uL 
CD8  (PE Cy7) 5uL 
CD69  (PE)  20uL 
INFγ  (APC)  10uL 
IL2  (FITC)  20uL 
Saponin 10%  1uL 
 
Memory marker (CD45RA and CCR7) 
 
CD3  (PerCP) 10uL 
CD4  (APC Cy7) 5uL 
CD8  (PE Cy7) 5uL 
CCR7  (PE)  20uL 
INFγ  (APC)  10uL 
CD45RA (FITC)  20uL 
Saponin 10%  1uL 
 
T regulatory cells (CD25 and IL10) 
 
CD3  (PerCP) 10uL 
CD4  (APC Cy7) 5uL 
CD25  (PE Cy7) 20uL 
INFγ  (APC)  10uL 
IL10  (PE)  20uL 
Saponin 10%  1uL 
 
Monocytes 
 
CD3  (PerCP) 10uL 
CD4  (APC Cy7) 5uL 
CD8  (PE Cy7) 5uL 
CD14  (APC)  10uL 
CD83  (FITC)  20uL 
CD86  (PE)  20uL 
Saponin 10%  1uL 
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Direct T-cell measurement protocol - Elispot assay 
 
(Protocol Version 3.0, Dr. Adrian Egli, University of Basel) 
 
1. Coating plate with primary antibody 
 
R5 medium= RPMI, +5% hi human sera, + 1% PenStrep (Gibco) +1% L-
Glutamine 
 
Pre-wet PVDF (Millipore MSIPN4510) plates with 40uL 50% EtOH 
Incubate for 30sec to 1min 
Wash plates 3x with 200ul sterile PBS 
 
Dilute INFγ antibody (Mabtech 1-D1K 1mg/mL) in sterile PBS 
=> 1:100 (10ug/mL) 
Add 100ul/well 
Tap plate 
Incubate plate at 4°C overnight (or >3h at 37°C) 
 
2. Blocking 
 
Remove antibody 1-D1L 
Wash plates 1x with 100ul sterile PBS 
Wash plates 3x with 200ul sterile PBS 
 
Add 200uL R5 medium 
Block 3h at 37°C 
Remove medium 
 
3. Stimulation 
 
Dilute Antigen according to table below 
Distribute 100il antigen per well into PVDF plate 
 
Pos Ctrl (1ug/ml, ec) neg Ctrl Antigen (2ug/mL, ec) Antigen (2ug/mL, ec) 
    
98ul R5 100ul R5 98ul R10 92ul R5 
2 ul SEB (100ug/mL)  2ul Antigen (200ug/mL) 8ul Antigen (50ug/mL) 
 
(Cave: if antigen is diluted in DMSO make a serial dilution to detect an 
inhibitory concentration cut-off level.) 
 
Dilute PBMCs to 2.5x10^6 cells /mL in R5 
Distribute 100ul cell suspension into PDVF plate 
 
Incubate at 37°C overnight for 15 to 24h 
Cave depending on cytokine release adapt incubation time 
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4. Secondary Antibody 
 
Remove cells 
Wash plates 5x in 200ul PBS + 0.05% Tween 20 
 
Dilute 2nd INFγ antibody (Mabtech 7-B6-Biotin 1mg/mL) 1:1000 (1ug/mL) in 
 PBS + 0.5% FCS 
Add 100ul per well 
Incubate 2-3h at room temperature 
 
Wash 5x in 200ul PBS + 0.05% Tween 20 
Dilute strepatvidin-AP 1:1000 (1ug/mL endconc) in PBS +0.5% FCS 
Add 100ul per well 
Incubate for 1h 
 
Wash 5x in 200ul in PBS + 0.05% Tween 20 
Peal off under-drain 
Rinse plate from both side with water 
Flick off water 
 
5. Development 
 
11ml Tris ph9.5 
200ul BCIP (Calbichem) 
100ul NBT (Calbiochem) 
Filter 0.45um 
 
Add 100ul per well 
Develop for 15min 
 
Stop reaction by rinsing the plate with water 
Rinse plate from both side 
Flick off water 
Air dry plates overnight in dark 
 
Analyse spots next day 
Responses are positive if they exceed 3x SD and mean of the negative ctrl. 
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T-cell expansion protocol - ActMono 
 
(Protocol Version 2.0, Dr. Adrian Egli, University of Basel) 
 
1. Day -1 
Monocyte Cultivation 
Resuspend PBMC in R5AB 
Distribute 3ml of 2x106 PBMC/ml in a 6 well plate 
 (or 1ml of 2x106 PBMC/ml in a 12 well plate). 
Incubate overnight at 37° in 5%CO2 atmosphere 
 
2. Day 0 
Seperation 
With 5ml pipette take supernatent away (=RestPBMC), wash once with R5AB 
 and also add it to the RestPBMC. 
 
With 1000ul pipette detache adherent cells (ActMono), wash once with R5AB 
 and also add it to the ActMono. Count both. 
Dilute RestPBMC (500ul = 106 RestPBMC) 
 
Monocyte pulsing 
Resuspend ActMono 4x106/ml 
 
Pulse 500ul of ActMono (=2x106 cells) with 
5ug/ml complete pool 10ug/ml peptide pool or single 
peptides 
50ul of 50ug/ml 25ul of 200ug/ml 
12.5ul of 200ug/ml  
 
Plate RestPBMC in 24well (at 4x106/ml) 500uL per well. 
Incubate in incubator until pulsed ActMonos are added. 
 
Incubate for 2h at 37° at 5% CO2 
Wash in R5AB about 6ml 
Centrifuge at RT, 450g, 5min 
Resuspend pellet in 5000ul R5AB (=100’000ActMono/500ml) 
 
Stimulation 
Transfer 500ul ActMono into 24well plate 
Add 500ul RestPBMC (=106 cells) -> 1:10 dilution ratio 
Incubate für 9d at 37° at 5% CO2 
 
3. Day 9 
Elispot 
Transfer cells into 15ml Falcon 
Wash the cell with R5AB 
 
Count them. Dilute them according to viral peptides used. 
CMV normally has a very well expansion: 100'000 PBMC/well 
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T-cell expansion protocol - Expansion protocol “Provenzano” 
 
(Protocol Version 2.0, Dr. Adrian Egli, University of Basel - adapted from M. 
Provenzano, Zurich, Switzerland) 
 
1. Dendritic cell culture 
 
Always 7 days before pulsing T-cells 
Day -7 Magnetic separation 
 
Transfer 10 Mio PBMCs in 15mL Falcon tube 
Spin 10’ 450g at 4°C 
 
Add 900uL MACS wash solution 
Add 100uL aCD14 MACS beads 
 
Incubate on ice for 20’ 
 slightly shake after 10’ 1x 
 
Add 10mL of MACS wash solution 
 
Spin 10’ 450g at 4°C 
 
Dissolve pelett in 5mL 
 
Magnetic separation: 
Use MACS separation columns (LS) in MACS separator 
 
Pre-wet columns with 3mL 
Load 5mL of magnetic bead-tagged cell solution on to columns 
 tip: wash again with 5mL to harvest the rest in the Falcon tube 
Wash with another 5mL of MACS wash solution 
= CD14 negative fraction 
 
Remove magnetic field 
 
Wash LS columns 2x with 5mL MACS wash solution 
Use two times punching tool to remove attached cells 
= CD14 positive fraction 
 
Spin 10’ 450g 10min at RT 
 
Dissolve in 2mL R5 medium 
Count 
 
Freeze CD14 negative fraction for usage at Day 0 
 
CD14 positive fraction: 
2Mio CD14+ in 4mL DC medium in 6 well plate 
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Incubate for 7 days at 37°C 7%CO2 
 
Check for CD14 maturation at day 0 and 7. 
 
Day -1 
 
Add 4uL LPS (1mg/mL) per well 
Slightly shake 
 
 
2. Peptide loading on mDCs 
 
Day 0 
Harvest mature DCs for loading with peptides 
 
Transfer into a 15mL Falcon 
Pulse 5x10^6 CD14+ cells with 10ug/mL single peptides or 5ug/mL peptide 
 pool for 4 h at 37°C 7%CO2 
 
After pulsing irradiate DCs 2500rad 610’’ 
 
Prepare for Day +7 new DC culture with autologous fresh DCs 
(same protocol) 
 
3. Stimulation of virus-specific T-cells 
 
Thawn CD14 negative fraction from week before 
 
Repeat magnetic separation with aCD4 and aCD8 magnetic bead antibodies 
as performed with aCD14 
 
Count CD4 positive and CD8 positive cell fractions 
 
Put 1Mio CD4 or CD8 into a 24 well plate. 1Mio per well per mL R5 medium 
 
Add 0.1-0.2 Mio pulsed DCs to each well. 
 
Remove at Day 4, 5, 6: 50% of medium and add fresh medium with 20U 
IL2/mL 
At day 6: add 4uL LPS to new DC culture 
 
Day 7: Repeat pulsing of expanding T-cell cultures with mDCs 
 
Remove at Day 10, 11, 12: 50% medium and add fresh medium with 100U 
IL2/mL 
 
Use cells at Day 14: 
Count and perform FACS or Elispot analysis 
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T-cell expansion protocol - Expansion protocol “Comoli” 
 
(Protocol Version 2.0, Dr. Adrian Egli, University of Basel - adapted from P. 
Comoli, Pavia, Italy) GMP approved 
 
1. Day 0 
 
2 Mio PBMC/well/mL in autologous RPMI (standard R5 except 10% heat 
 inactivated and 1700g centrifuged donor plasma) in 24 well plate 
Add 10ng/mL (end concentration) of peptide pool into the culture 
 
Incubation for 10days at 37° with 5% CO2 
 
2. Day 10 
Repulse with 1Mio PBMCs (irradiated at 3500rad). 
Add 100ng/mL (end concentration) of peptide pool into the culture 
 
Remove 50% of old medium by pipetting half away 
Add fresh fresh medium with IL2 (ec 20IE/mL) 
 
3. Day 15, 19, 22, 26 
 
Remove half of medium and add fresh medium with IL2 (ec 20IE/mL) 
 
4. Day 29 
 
Harvest cells at day 29 
Use INFγ detection assay 
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Cytomegalovirus proteins: 
 
CMV pp65 peptide library (15aa long peptides, 11aa overlap) 
 
 EGT code N-term Sequence C-term 
     
1 P0510130 H2N MESRGRRCPEMISVL CONH2 
2 P0510131 H2N GRRCPEMISVLGPIS CONH2 
3 P0510132 H2N PEMISVLGPISGHVL CONH2 
4 P0510133 H2N SVLGPISGHVLKAVF CONH2 
5 P0510134 H2N PISGHVLKAVFSRGD CONH2 
6 P0510135 H2N HVLKAVFSRGDTPVL CONH2 
7 P0510136 H2N AVFSRGDTPVLPHET CONH2 
8 P0510137 H2N RGDTPVLPHETRLLQ CONH2 
9 P0510138 H2N PVLPHETRLLQTGIH CONH2 
10 P0510139 H2N HETRLLQTGIHVRVS CONH2 
11 P0510140 H2N LLQTGIHVRVSQPSL CONH2 
12 P0510141 H2N GIHVRVSQPSLILVS CONH2 
13 P0510142 H2N RVSQPSLILVSQYTP CONH2 
14 P0510143 H2N PSLILVSQYTPDSTP CONH2 
15 P0510144 H2N LVSQYTPDSTPCHRG CONH2 
16 P0510145 H2N YTPDSTPCHRGDNQL CONH2 
17 P0510146 H2N STPCHRGDNQLQVQH CONH2 
18 P0510147 H2N HRGDNQLQVQHTYFT CONH2 
19 P0510148 H2N NQLQVQHTYFTGSEV CONH2 
20 P0510149 H2N VQHTYFTGSEVENVS CONH2 
21 P0510150 H2N YFTGSEVENVSVNVH CONH2 
22 P0510151 H2N SEVENVSVNVHNPTG CONH2 
23 P0510152 H2N NVSVNVHNPTGRSIC CONH2 
24 P0510153 H2N NVHNPTGRSICPSQE CONH2 
25 P0510154 H2N PTGRSICPSQEPMSI CONH2 
26 P0510155 H2N SICPSQEPMSIYVYA CONH2 
27 P0510156 H2N SQEPMSIYVYALPLK CONH2 
28 P0510157 H2N MSIYVYALPLKMLNI CONH2 
29 P0510158 H2N VYALPLKMLNIPSIN CONH2 
30 P0510159 H2N PLKMLNIPSINVHHY CONH2 
31 P0510160 H2N LNIPSINVHHYPSAA CONH2 
32 P0510161 H2N SINVHHYPSAAERKH CONH2 
33 P0510162 H2N HHYPSAAERKHRHLP CONH2 
34 P0510163 H2N SAAERKHRHLPVADA CONH2 
35 P0510164 H2N RKHRHLPVADAVIHA CONH2 
36 P0510165 H2N HLPVADAVIHASGKQ CONH2 
37 P0510166 H2N ADAVIHASGKQMWQA CONH2 
38 P0510167 H2N IHASGKQMWQARLTV CONH2 
39 P0510168 H2N GKQMWQARLTVSGLA CONH2 
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40 P0510169 H2N WQARLTVSGLAWTRQ CONH2 
41 P0510170 H2N LTVSGLAWTRQQNQW CONH2 
42 P0510171 H2N GLAWTRQQNQWKEPD CONH2 
43 P0510172 H2N TRQQNQWKEPDVYYT CONH2 
44 P0510173 H2N NQWKEPDVYYTSAFV CONH2 
45 P0510174 H2N EPDVYYTSAFVFPTK CONH2 
46 P0510175 H2N YYTSAFVFPTKDVAL CONH2 
47 P0510176 H2N AFVFPTKDVALRHVV CONH2 
48 P0510177 H2N PTKDVALRHVVCAHE CONH2 
49 P0510178 H2N VALRHVVCAHELVCS CONH2 
50 P0510179 H2N HVVCAHELVCSMENT CONH2 
51 P0510180 H2N AHELVCSMENTRATK CONH2 
52 P0510181 H2N VCSMENTRATKMQVI CONH2 
53 P0510182 H2N ENTRATKMQVIGDQY CONH2 
54 P0510183 H2N ATKMQVIGDQYVKVY CONH2 
55 P0510184 H2N VIGDQYVKVYLESF CONH2 
56 P0510185 H2N DQYVKVYLESFCEDV CONH2 
57 P0510186 H2N KVYLESFCEDVPSGK CONH2 
58 P0510187 H2N ESFCEDVPSGKLFMH CONH2 
59 P0510188 H2N EDVPSGKLFMHVTLG CONH2 
60 P0510189 H2N SGKLFMHVTLGSDVE CONH2 
61 P0510190 H2N FMHVTLGSDVEEDLT CONH2 
62 P0510191 H2N TLGSDVEEDLTMTRN CONH2 
63 P0510192 H2N DVEEDLTMTRNPQPF CONH2 
64 P0510193 H2N DLTMTRNPQPFMRPH CONH2 
65 P0510194 H2N TRNPQPFMRPHERNG CONH2 
66 P0510195 H2N PFMRPHERNGFTVL CONH2 
67 P0510196 H2N RPHERNGFTVLCPKN CONH2 
68 P0510197 H2N RNGFTVLCPKNMIIK CONH2 
69 P0510198 H2N TVLCPKNMIIKPGKI CONH2 
70 P0510199 H2N PKNMIIKPGKISHIM CONH2 
71 P0510200 H2N IIKPGKISHIMLDVA CONH2 
72 P0510201 H2N GKISHIMLDVAFTSH CONH2 
73 P0510202 H2N HIMLDVAFTSHEHFG CONH2 
74 P0510203 H2N DVAFTSHEHFGLLCP CONH2 
75 P0510204 H2N TSHEHFGLLCPKSIP CONH2 
76 P0510205 H2N HFGLLCPKSIPGLSI CONH2 
77 P0510206 H2N LCPKSIPGLSISGNL CONH2 
78 P0510207 H2N SIPGLSISGNLLMNG CONH2 
79 P0510208 H2N LSISGNLLMNGQQIF CONH2 
80 P0510209 H2N GNLLMNGQQIFLEVQ CONH2 
81 P0510210 H2N MNGQQIFLEVQAIRE CONH2 
82 P0510211 H2N IFLEVQAIRETVEL CONH2 
83 P0510212 H2N EVQAIRETVELRQYD CONH2 
84 P0510213 H2N IRETVELRQYDPVAA CONH2 
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85 P0510214 H2N VELRQYDPVAALFFF CONH2 
86 P0510215 H2N YDPVAALFFFDIDL CONH2 
87 P0510216 H2N VAALFFFDIDLLLQR CONH2 
88 P0510217 H2N FFFDIDLLLQRGPQY CONH2 
89 P0510218 H2N IDLLLQRGPQYSEHP CONH2 
90 P0510219 H2N LQRGPQYSEHPTFTS CONH2 
91 P0510220 H2N PQYSEHPTFTSQYRI CONH2 
92 P0510221 H2N EHPTFTSQYRIQGKL CONH2 
93 P0510222 H2N FTSQYRIQGKLEYRH CONH2 
94 P0510223 H2N YRIQGKLEYRHTWDR CONH2 
95 P0510224 H2N GKLEYRHTWDRHDEG CONH2 
96 P0510225 H2N YRHTWDRHDEGAAQG CONH2 
97 P0510226 H2N WDRHDEGAAQGDDDV CONH2 
98 P0510227 H2N DEGAAQGDDDVWTSG CONH2 
99 P0510228 H2N AQGDDDVWTSGSDSD CONH2 
100 P0510229 H2N DDVWTSGSDSDEELV CONH2 
101 P0510230 H2N TSGSDSDEELVTTER CONH2 
102 P0510231 H2N DSDEELVTTERKTPR CONH2 
103 P0510232 H2N ELVTTERKTPRVTGG CONH2 
104 P0510233 H2N TERKTPRVTGGGAMA CONH2 
105 P0510234 H2N TPRVTGGGAMAGAST CONH2 
106 P0510235 H2N TGGGAMAGASTSAGR CONH2 
107 P0510236 H2N AMAGASTSAGRKRKS CONH2 
108 P0510237 H2N ASTSAGRKRKSASSA CONH2 
109 P0510238 H2N AGRKRKSASSATACT CONH2 
110 P0510239 H2N RKSASSATACTSGVM CONH2 
111 P0510240 H2N SSATACTSGVMTRGR CONH2 
112 P0510241 H2N ACTSGVMTRGRLKAE CONH2 
113 P0510242 H2N GVMTRGRLKAESTVA CONH2 
114 P0510243 H2N RGRLKAESTVAPEED CONH2 
115 P0510244 H2N KAESTVAPEEDTDED CONH2 
116 P0510245 H2N TVAPEEDTDEDSDNE CONH2 
117 P0510246 H2N EEDTDEDSDNEIHNP CONH2 
118 P0510247 H2N DEDSDNEIHNPAVFT CONH2 
119 P0510248 H2N DNEIHNPAVFTWPPW CONH2 
120 P0510249 H2N HNPAVFTWPPWQAGI CONH2 
121 P0510250 H2N VFTWPPWQAGILARN CONH2 
122 P0510251 H2N PPWQAGILARNLVPM CONH2 
123 P0510252 H2N AGILARNLVPMVATV CONH2 
124 P0510253 H2N ARNLVPMVATVQGQN CONH2 
125 P0510254 H2N VPMVATVQGQNLKYQ CONH2 
126 P0510255 H2N ATVQGQNLKYQEFFW CONH2 
127 P0510256 H2N GQNLKYQEFFWDAND CONH2 
128 P0510257 H2N KYQEFFWDANDIYRI CONH2 
129 P0510258 H2N FFWDANDIYRIFAEL CONH2 
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130 P0510259 H2N ANDIYRIFAELEGVW CONH2 
131 P0510260 H2N YRIFAELEGVWQPAA CONH2 
132 P0510261 H2N AELEGVWQPAAQPKR CONH2 
133 P0510262 H2N GVWQPAAQPKRRRHR CONH2 
134 P0510263 H2N PAAQPKRRRHRQDAL CONH2 
135 P0510264 H2N PKRRRHRQDALPGPC CONH2 
136 P0510265 H2N RHRQDALPGPCIAST CONH2 
137 P0510266 H2N DALPGPCIASTPKKH CONH2 
138 P0510267 H2N GPCIASTPKKHRG COOH 
     
 
 
CMV pp72 peptide library (15aa long peptides, 11aa overlap) 
 
 EGT code N-term Sequence C-term 
     
1 P0510821 H2N MESSAKRKMDPDNPD CONH2 
2 P0510822 H2N AKRKMDPDNPDEGPS CONH2 
3 P0510823 H2N MDPDNPDEGPSSKVP CONH2 
4 P0510824 H2N NPDEGPSSKVPRPET CONH2 
5 P0510825 H2N GPSSKVPRPETPVTK CONH2 
6 P0510826 H2N KVPRPETPVTKATTF CONH2 
7 P0510827 H2N PETPVTKATTFLQTM CONH2 
8 P0510828 H2N VTKATTFLQTMLRKE CONH2 
9 P0510829 H2N TTFLQTMLRKEVNSQ CONH2 
10 P0510830 H2N QTMLRKEVNSQLSLG CONH2 
11 P0510831 H2N RKEVNSQLSLGDPLF CONH2 
12 P0510832 H2N NSQLSLGDPLFPELA CONH2 
13 P0510833 H2N SLGDPLFPELAEESL CONH2 
14 P0510834 H2N PLFPELAEESLKTFE CONH2 
15 P0510835 H2N ELAEESLKTFEQVTE CONH2 
16 P0510836 H2N ESLKTFEQVTEDCNE CONH2 
17 P0510837 H2N TFEQVTEDCNENPEK CONH2 
18 P0510838 H2N VTEDCNENPEKDVLA CONH2 
19 P0510839 H2N CNENPEKDVLAELVK CONH2 
20 P0510840 H2N PEKDVLAELVKQIKV CONH2 
21 P0510841 H2N VLAELVKQIKVRVDM CONH2 
22 P0510842 H2N LVKQIKVRVDMVRHR CONH2 
23 P0510843 H2N IKVRVDMVRHRIKEH CONH2 
24 P0510844 H2N VDMVRHRIKEHMLKK CONH2 
25 P0510845 H2N RHRIKEHMLKKYTQT CONH2 
26 P0510846 H2N KEHMLKKYTQTEEKF CONH2 
27 P0510847 H2N LKKYTQTEEKFTGAF CONH2 
28 P0510848 H2N TQTEEKFTGAFNMMG CONH2 
29 P0510849 H2N EKFTGAFNMMGGCLQ CONH2 
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30 P0510850 H2N GAFNMMGGCLQNALD CONH2 
31 P0510851 H2N MMGGCLQNALDILDK CONH2 
32 P0510852 H2N CLQNALDILDKVHEP CONH2 
33 P0510853 H2N ALDILDKVHEPFEEM CONH2 
34 P0510854 H2N LDKVHEPFEEMKCIG CONH2 
35 P0510855 H2N HEPFEEMKCIGLTMQ CONH2 
36 P0510856 H2N EEMKCIGLTMQSMYE CONH2 
37 P0510857 H2N CIGLTMQSMYENYIV CONH2 
38 P0510858 H2N TMQSMYENYIVPEDK CONH2 
39 P0510859 H2N MYENYIVPEDKREMW CONH2 
40 P0510860 H2N YIVPEDKREMWMACI CONH2 
41 P0510861 H2N EDKREMWMACIKELH CONH2 
42 P0510862 H2N EMWMACIKELHDVSK CONH2 
43 P0510863 H2N ACIKELHDVSKGAAN CONH2 
44 P0510864 H2N ELHDVSKGAANKLGG CONH2 
45 P0510865 H2N VSKGAANKLGGALQA CONH2 
46 P0510866 H2N AANKLGGALQAKARA CONH2 
47 P0510867 H2N LGGALQAKARAKKDE CONH2 
48 P0510868 H2N LQAKARAKKDELRRK CONH2 
49 P0510869 H2N ARAKKDELRRKMMYM CONH2 
50 P0510870 H2N KDELRRKMMYMCYRN CONH2 
51 P0510871 H2N RRKMMYMCYRNIEFF CONH2 
52 P0510872 H2N MYMCYRNIEFFTKNS CONH2 
53 P0510873 H2N YRNIEFFTKNSAFPK CONH2 
54 P0510874 H2N EFFTKNSAFPKTTNG CONH2 
55 P0510875 H2N KNSAFPKTTNGCSQA CONH2 
56 P0510876 H2N FPKTTNGCSQAMAAL CONH2 
57 P0510877 H2N TNGCSQAMAALQNLP CONH2 
58 P0510878 H2N SQAMAALQNLPQCSP CONH2 
59 P0510879 H2N AALQNLPQCSPDEIM CONH2 
60 P0510880 H2N NLPQCSPDEIMAYAQ CONH2 
61 P0510881 H2N CSPDEIMAYAQKIFK CONH2 
62 P0510882 H2N EIMAYAQKIFKILDE CONH2 
63 P0510883 H2N YAQKIFKILDEERDK CONH2 
64 P0510884 H2N IFKILDEERDKVLTH CONH2 
65 P0510885 H2N LDEERDKVLTHIDHI CONH2 
66 P0510886 H2N RDKVLTHIDHIFMDI CONH2 
67 P0510887 H2N LTHIDHIFMDILTTC CONH2 
68 P0510888 H2N DHIFMDILTTCVETM CONH2 
69 P0510889 H2N MDILTTCVETMCNEY CONH2 
70 P0510890 H2N TTCVETMCNEYKVTS CONH2 
71 P0510891 H2N ETMCNEYKVTSDACM CONH2 
72 P0510892 H2N NEYKVTSDACMMTMY CONH2 
73 P0510893 H2N VTSDACMMTMYGGIS CONH2 
74 P0510894 H2N ACMMTMYGGISLLSE CONH2 
PhD thesis: CMV and BKV immunity, Adrian Egli                                      169/196 
 
75 P0510895 H2N TMYGGISLLSEFCRV CONH2 
76 P0510896 H2N GISLLSEFCRVLCCY CONH2 
77 P0510897 H2N LSEFCRVLCCYVLEE CONH2 
78 P0510898 H2N CRVLCCYVLEETSVM CONH2 
79 P0510899 H2N CCYVLEETSVMLAKR CONH2 
80 P0510900 H2N LEETSVMLAKRPLIT CONH2 
81 P0510901 H2N SVMLAKRPLITKPEV CONH2 
82 P0510902 H2N AKRPLITKPEVISVM CONH2 
83 P0510903 H2N LITKPEVISVMKRRI CONH2 
84 P0510904 H2N PEVISVMKRRIEEIC CONH2 
85 P0510905 H2N SVMKRRIEEICMKVF CONH2 
86 P0510906 H2N RRIEEICMKVFAQYI CONH2 
87 P0510907 H2N EICMKVFAQYILGAD CONH2 
88 P0510908 H2N KVFAQYILGADPLRV CONH2 
89 P0510909 H2N QYILGADPLRVCSPS CONH2 
90 P0510910 H2N GADPLRVCSPSVDDL CONH2 
91 P0510911 H2N LRVCSPSVDDLRAIA CONH2 
92 P0510912 H2N SPSVDDLRAIAEESD CONH2 
93 P0510913 H2N DDLRAIAEESDEEEA CONH2 
94 P0510914 H2N AIAEESDEEEAIVAY CONH2 
95 P0510915 H2N ESDEEEAIVAYTLAT CONH2 
96 P0510916 H2N EEAIVAYTLATAGVS CONH2 
97 P0510917 H2N VAYTLATAGVSSSDS CONH2 
98 P0510918 H2N LATAGVSSSDSLVSP CONH2 
99 P0510919 H2N GVSSSDSLVSPPESP CONH2 
100 P0510920 H2N SDSLVSPPESPVPAT CONH2 
101 P0510921 H2N VSPPESPVPATIPLS CONH2 
102 P0510922 H2N ESPVPATIPLSSVIV CONH2 
103 P0510923 H2N PATIPLSSVIVAENS CONH2 
104 P0510924 H2N PLSSVIVAENSDQEE CONH2 
105 P0510925 H2N VIVAENSDQEESEQS CONH2 
106 P0510926 H2N ENSDQEESEQSDEEE CONH2 
107 P0510927 H2N QEESEQSDEEEEEGA CONH2 
108 P0510928 H2N EQSDEEEEEGAQEER CONH2 
109 P0510929 H2N EEEEEGAQEEREDTV CONH2 
110 P0510930 H2N EGAQEEREDTVSVKS CONH2 
111 P0510931 H2N EEREDTVSVKSEPVS CONH2 
112 P0510932 H2N DTVSVKSEPVSEIEE CONH2 
113 P0510933 H2N VKSEPVSEIEEVAPE CONH2 
114 P0510934 H2N PVSEIEEVAPEEEED CONH2 
115 P0510935 H2N IEEVAPEEEEDGAEE CONH2 
116 P0510936 H2N APEEEEDGAEEPTAS CONH2 
117 P0510937 H2N EEDGAEEPTASGGKS CONH2 
118 P0510938 H2N AEEPTASGGKSTHPM CONH2 
119 P0510939 H2N TASGGKSTHPMVTRS CONH2 
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120 P0510940 H2N GKSTHPMVTRSKADQ COOH 
     
 
 
CMV pp65 RQY 16mer 
 
RQYDPVAALFFFDIDL 
 
 
CMV pp65 RQY spanning 9mers 
 
RQYDPVAAL 
QYDPVAALF 
YDPVAALFF 
DPVAALFFF 
PVAALFFFD 
VAALFFFDI 
AALFFFDID 
ALFFFDIDL 
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Polyomavirus BK proteins: 
 
BKV LT peptide library (15aa long peptides, 11aa overlap) 
 
 EGT N-term Sequence C-term 
     
89 P0510627 H2N MDKVLNREESMELMD CONH2 
90 P0510628 H2N LNREESMELMDLLGL CONH2 
91 P0510629 H2N ESMELMDLLGLERAA CONH2 
92 P0510630 H2N LMDLLGLERAAWGNL CONH2 
93 P0510631 H2N LGLERAAWGNLPLMR CONH2 
94 P0510632 H2N RAAWGNLPLMRKAYL CONH2 
95 P0510633 H2N GNLPLMRKAYLRKCK CONH2 
96 P0510634 H2N LMRKAYLRKCKEFHP CONH2 
97 P0510635 H2N AYLRKCKEFHPDKGG CONH2 
98 P0510636 H2N KCKEFHPDKGGDEDK CONH2 
99 P0510637 H2N FHPDKGGDEDKMKRM CONH2 
100 P0510638 H2N KGGDEDKMKRMNTLY CONH2 
101 P0510639 H2N EDKMKRMNTLYKKME CONH2 
102 P0510640 H2N KRMNTLYKKMEQDVK CONH2 
103 P0510641 H2N TLYKKMEQDVKVAHQ CONH2 
104 P0510642 H2N KMEQDVKVAHQPDFG CONH2 
105 P0510643 H2N DVKVAHQPDFGTWSS CONH2 
106 P0510644 H2N AHQPDFGTWSSSEVP CONH2 
107 P0510645 H2N DFGTWSSSEVPTYGT CONH2 
108 P0510646 H2N WSSSEVPTYGTEEWE CONH2 
109 P0510647 H2N EVPTYGTEEWESWWS CONH2 
110 P0510648 H2N YGTEEWESWWSSFNE CONH2 
111 P0510649 H2N EWESWWSSFNEKWDE CONH2 
112 P0510650 H2N WWSSFNEKWDEDLFC CONH2 
113 P0510651 H2N FNEKWDEDLFCHEDM CONH2 
114 P0510652 H2N WDEDLFCHEDMFASD CONH2 
115 P0510653 H2N LFCHEDMFASDEEAT CONH2 
116 P0510654 H2N EDMFASDEEATADSQ CONH2 
117 P0510655 H2N ASDEEATADSQHSTP CONH2 
118 P0510656 H2N EATADSQHSTPPKKK CONH2 
119 P0510657 H2N DSQHSTPPKKKRKVE CONH2 
120 P0510658 H2N STPPKKKRKVEDPKD CONH2 
121 P0510659 H2N KKKRKVEDPKDFPSD CONH2 
122 P0510660 H2N KVEDPKDFPSDLHQF CONH2 
123 P0510661 H2N PKDFPSDLHQFLSQA CONH2 
124 P0510662 H2N PSDLHQFLSQAVFSN CONH2 
125 P0510663 H2N HQFLSQAVFSNRTLA CONH2 
126 P0510664 H2N SQAVFSNRTLACFAV CONH2 
127 P0510665 H2N FSNRTLACFAVYTTK CONH2 
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128 P0510666 H2N TLACFAVYTTKEKAQ CONH2 
129 P0510667 H2N FAVYTTKEKAQILYK CONH2 
130 P0510668 H2N TTKEKAQILYKKLME CONH2 
131 P0510669 H2N KAQILYKKLMEKYSV CONH2 
132 P0510670 H2N LYKKLMEKYSVTFIS CONH2 
133 P0510671 H2N LMEKYSVTFISRHMC CONH2 
134 P0510672 H2N YSVTFISRHMCAGHN CONH2 
135 P0510673 H2N FISRHMCAGHNIIFF CONH2 
136 P0510674 H2N HMCAGHNIIFFLTPH CONH2 
137 P0510675 H2N GHNIIFFLTPHRHRV CONH2 
138 P0510676 H2N IFFLTPHRHRVSAIN CONH2 
139 P0510677 H2N TPHRHRVSAINNFCQ CONH2 
140 P0510678 H2N HRVSAINNFCQKLCT CONH2 
141 P0510679 H2N AINNFCQKLCTFSFL CONH2 
142 P0510680 H2N FCQKLCTFSFLICKG CONH2 
143 P0510681 H2N LCTFSFLICKGVNKE CONH2 
144 P0510682 H2N SFLICKGVNKEYLLY CONH2 
145 P0510683 H2N CKGVNKEYLLYSALT CONH2 
146 P0510684 H2N NKEYLLYSALTRDPY CONH2 
147 P0510685 H2N LLYSALTRDPYHTIE CONH2 
148 P0510686 H2N ALTRDPYHTIEESIQ CONH2 
149 P0510687 H2N DPYHTIEESIQGGLK CONH2 
150 P0510688 H2N TIEESIQGGLKEHDF CONH2 
151 P0510689 H2N SIQGGLKEHDFSPEE CONH2 
152 P0510690 H2N GLKEHDFSPEEPEET CONH2 
153 P0510691 H2N HDFSPEEPEETKQVS CONH2 
154 P0510692 H2N PEEPEETKQVSWKLI CONH2 
155 P0510693 H2N EETKQVSWKLITEYA CONH2 
156 P0510694 H2N VSWKLITEYAVETK CONH2 
157 P0510695 H2N KLITEYAVETKCEDV CONH2 
158 P0510696 H2N EYAVETKCEDVFLLL CONH2 
159 P0510697 H2N ETKCEDVFLLLGMYL CONH2 
160 P0510698 H2N EDVFLLLGMYLEFQY CONH2 
161 P0510699 H2N LLLGMYLEFQYNVEE CONH2 
162 P0510700 H2N MYLEFQYNVEECKKC CONH2 
163 P0510701 H2N FQYNVEECKKCQKKD CONH2 
164 P0510702 H2N VEECKKCQKKDQPYH CONH2 
165 P0510703 H2N KKCQKKDQPYHFKYH CONH2 
166 P0510704 H2N KKDQPYHFKYHEKHF CONH2 
167 P0510705 H2N PYHFKYHEKHFANAI CONH2 
168 P0510706 H2N KYHEKHFANAIIFAE CONH2 
169 P0510707 H2N KHFANAIIFAESKNQ CONH2 
170 P0510708 H2N NAIIFAESKNQKSIC CONH2 
171 P0510709 H2N FAESKNQKSICQQAV CONH2 
172 P0510710 H2N KNQKSICQQAVDTVL CONH2 
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173 P0510711 H2N SICQQAVDTVLAKKR CONH2 
174 P0510712 H2N AVDTVLAKKRVDTL CONH2 
175 P0510713 H2N TVLAKKRVDTLHMTR CONH2 
176 P0510714 H2N KKRVDTLHMTREEML CONH2 
177 P0510715 H2N DTLHMTREEMLTERF CONH2 
178 P0510716 H2N MTREEMLTERFNHIL CONH2 
179 P0510717 H2N EMLTERFNHILDKMD CONH2 
180 P0510718 H2N ERFNHILDKMDLIFG CONH2 
181 P0510719 H2N HILDKMDLIFGAHGN CONH2 
182 P0510720 H2N KMDLIFGAHGNAVLE CONH2 
183 P0510721 H2N IFGAHGNAVLEQYMA CONH2 
184 P0510722 H2N HGNAVLEQYMAGVAW CONH2 
185 P0510723 H2N VLEQYMAGVAWLHCL CONH2 
186 P0510724 H2N YMAGVAWLHCLLPKM CONH2 
187 P0510725 H2N VAWLHCLLPKMDSVI CONH2 
188 P0510726 H2N HCLLPKMDSVIFDFL CONH2 
189 P0510727 H2N PKMDSVIFDFLHCIV CONH2 
190 P0510728 H2N SVIFDFLHCIVFNVP CONH2 
191 P0510729 H2N DFLHCIVFNVPKRRY CONH2 
192 P0510730 H2N CIVFNVPKRRYWLFK CONH2 
122 P0510731 H2N NVPKRRYWLFKGPID CONH2 
123 P0510732 H2N RRYWLFKGPIDSGKT CONH2 
124 P0510733 H2N LFKGPIDSGKTTLAA CONH2 
125 P0510734 H2N PIDSGKTTLAAGLLD CONH2 
126 P0510735 H2N GKTTLAAGLLDLCGG CONH2 
127 P0510736 H2N LAAGLLDLCGGKALN CONH2 
128 P0510737 H2N LLDLCGGKALNVNLP CONH2 
129 P0510738 H2N CGGKALNVNLPMERL CONH2 
130 P0510739 H2N ALNVNLPMERLTFEL CONH2 
131 P0510740 H2N NLPMERLTFELGVAI CONH2 
132 P0510741 H2N ERLTFELGVAIDQYM CONH2 
133 P0510742 H2N FELGVAIDQYMVVFE CONH2 
134 P0510743 H2N VAIDQYMVVFEDVKG CONH2 
135 P0510744 H2N YMVVFEDVKGTGAE CONH2 
136 P0510745 H2N VFEDVKGTGAESKDL CONH2 
137 P0510746 H2N VKGTGAESKDLPSGH CONH2 
138 P0510747 H2N GAESKDLPSGHGINN CONH2 
139 P0510748 H2N KDLPSGHGINNLDSL CONH2 
140 P0510749 H2N SGHGINNLDSLRDYL CONH2 
141 P0510750 H2N INNLDSLRDYLDGSV CONH2 
142 P0510751 H2N DSLRDYLDGSVKVNL CONH2 
143 P0510752 H2N DYLDGSVKVNLEKKH CONH2 
144 P0510753 H2N GSVKVNLEKKHLNKR CONH2 
145 P0510754 H2N VNLEKKHLNKRTQIF CONH2 
146 P0510755 H2N KKHLNKRTQIFPPGL CONH2 
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147 P0510756 H2N NKRTQIFPPGLVTMN CONH2 
148 P0510757 H2N IFPPGLVTMNEYPV CONH2 
149 P0510758 H2N PGLVTMNEYPVPKTL CONH2 
150 P0510759 H2N TMNEYPVPKTLQARF CONH2 
151 P0510760 H2N YPVPKTLQARFVRQI CONH2 
152 P0510761 H2N KTLQARFVRQIDFRP CONH2 
153 P0510762 H2N ARFVRQIDFRPKIYL CONH2 
154 P0510763 H2N RQIDFRPKIYLRKSL CONH2 
155 P0510764 H2N FRPKIYLRKSLQNSE CONH2 
156 P0510765 H2N IYLRKSLQNSEFLLE CONH2 
157 P0510766 H2N KSLQNSEFLLEKRIL CONH2 
158 P0510767 H2N NSEFLLEKRILQSGM CONH2 
159 P0510768 H2N LLEKRILQSGMTLLL CONH2 
160 P0510769 H2N RILQSGMTLLLLLIW CONH2 
161 P0510770 H2N SGMTLLLLLIWFRPV CONH2 
162 P0510771 H2N LLLLLIWFRPVADFA CONH2 
163 P0510772 H2N LIWFRPVADFATDIQ CONH2 
164 P0510773 H2N RPVADFATDIQSRIV CONH2 
165 P0510774 H2N DFATDIQSRIVEWKE CONH2 
166 P0510775 H2N DIQSRIVEWKERLDS CONH2 
167 P0510776 H2N RIVEWKERLDSEISM CONH2 
168 P0510777 H2N WKERLDSEISMYTFS CONH2 
169 P0510778 H2N LDSEISMYTFSRMKY CONH2 
170 P0510779 H2N ISMYTFSRMKYNICM CONH2 
171 P0510780 H2N TFSRMKYNICMGKCI CONH2 
172 P0510781 H2N MKYNICMGKCILDIT CONH2 
173 P0510782 H2N ICMGKCILDITREED CONH2 
174 P0510783 H2N KCILDITREEDSETE CONH2 
175 P0510784 H2N DITREEDSETEDSGH CONH2 
176 P0510785 H2N EEDSETEDSGHGSST CONH2 
177 P0510786 H2N ETEDSGHGSSTESQS CONH2 
178 P0510787 H2N SGHGSSTESQSQCSS CONH2 
179 P0510788 H2N SSTESQSQCSSQVSD CONH2 
180 P0510789 H2N SQSQCSSQVSDTSAP CONH2 
181 P0510790 H2N CSSQVSDTSAPAEDS CONH2 
182 P0510791 H2N VSDTSAPAEDSQRSD CONH2 
183 P0510792 H2N SAPAEDSQRSDPHSQ CONH2 
184 P0510793 H2N EDSQRSDPHSQELHL CONH2 
185 P0510794 H2N RSDPHSQELHLCKGF CONH2 
186 P0510795 H2N HSQELHLCKGFQCFK CONH2 
187 P0510796 H2N LHLCKGFQCFKRPKT CONH2 
188 P0510797 H2N KGFQCFKRPKTPPPK CONH2 
189 P0510798 H2N DTSAPAEDSQRSDPH CONH2 
190 P0510799 H2N APAEDSQRSDPHSQE CONH2 
191 P0510800 H2N EDSQRSDPHSQELHL CONH2 
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192 P0510801 H2N RSDPHSQELHLCKG CONH2 
193 P0510802 H2N DPHSQELHLCKGFQC CONH2 
194 P0510803 H2N SQELHLCKGFQCFKR CONH2 
195 P0510804 H2N LHLCKGFQCFKRPKT CONH2 
196 P0510805 H2N CKGFQCFKRPKTPPP CONH2 
197 P0510806 H2N FQCFKRPKTPPPK COOH 
     
 
 
BKV LT peptide library sub-pools A-R, 1-20 
 
 
 
BKV VP1 peptide library (15aa long peptides, 11aa overlap) 
 
 EGT N-term Sequence C-Term 
     
1 P0510539 H2N MAPTKRKGECPGAAP CONH2 
2 P0510540 H2N KRKGECPGAAPKKPK CONH2 
3 P0510541 H2N ECPGAAPKKPKEPVQ CONH2 
4 P0510542 H2N AAPKKPKEPVQVPKL CONH2 
5 P0510543 H2N KPKEPVQVPKLLIKG CONH2 
6 P0510544 H2N PVQVPKLLIKGGVEV CONH2 
7 P0510545 H2N PKLLIKGGVEVLEVK CONH2 
8 P0510546 H2N IKGGVEVLEVKTGVD CONH2 
BKV-LT 10x10 Pool (100 ug/ml) 
POOL 1 2 3 4 5 6 7 8 9 10 
A 89 90 91 92 93 94 95 96 97 98 
B 99 100 101 102 103 104 105 106 107 108 
C 109 110 111 112 113 114 115 116 117 118 
D 119 120 121 122 123 124 125 126 127 128 
E 129 130 131 132 133 134 135 136 137 138 
F 139 140 141 142 143 144 145 146 147 148 
G 149 150 151 152 153 154 155 156 157 158 
H 159 160 161 162 163 164 165 166 167 168 
I 169 170 171 172 173 174 175 176 177 178 
J 179 180 181 182 183 184 185 186 187 188 
           
BKV-LT 10x10 Pool (100 ug/ml) 
POOL 11 12 13 14 15 16 17 18 19 20 
K 189 190 191 192 193 194 195 196 197 198 
L 199 200 201 202 203 204 205 206 207 208 
M 209 210 211 212 213 214 215 216 217 218 
N 219 220 221 222 223 224 225 226 227 228 
O 229 230 231 232 233 234 235 236 237 238 
P 239 240 241 242 243 244 245 246 247 248 
Q 249 250 251 252 253 254 255 256 257 258 
R 259 260 261 262 263 264 265 266 267 268 
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9 P0510547 H2N VEVLEVKTGVDAITE CONH2 
10 P0510548 H2N EVKTGVDAITEVECF CONH2 
11 P0510549 H2N GVDAITEVECFLNPE CONH2 
12 P0510550 H2N ITEVECFLNPEMGDP CONH2 
13 P0510551 H2N ECFLNPEMGDPDENL CONH2 
14 P0510552 H2N NPEMGDPDENLRGFS CONH2 
15 P0510553 H2N GDPDENLRGFSLKLS CONH2 
16 P0510554 H2N ENLRGFSLKLSAEND CONH2 
17 P0510555 H2N GFSLKLSAENDFSSD CONH2 
18 P0510556 H2N KLSAENDFSSDSPER CONH2 
19 P0510557 H2N ENDFSSDSPERKMLP CONH2 
20 P0510558 H2N SSDSPERKMLPCYST CONH2 
21 P0510559 H2N PERKMLPCYSTARIP CONH2 
22 P0510560 H2N MLPCYSTARIPLPNL CONH2 
23 P0510561 H2N YSTARIPLPNLNEDL CONH2 
24 P0510562 H2N RIPLPNLNEDLTCGN CONH2 
25 P0510563 H2N PNLNEDLTCGNLLMW CONH2 
26 P0510564 H2N EDLTCGNLLMWEAVT CONH2 
27 P0510565 H2N CGNLLMWEAVTVQTE CONH2 
28 P0510566 H2N LMWEAVTVQTEVIGI CONH2 
29 P0510567 H2N AVTVQTEVIGITSML CONH2 
30 P0510568 H2N TEVIGITSMLNLHA CONH2 
31 P0510569 H2N IGITSMLNLHAGSQK CONH2 
32 P0510570 H2N SMLNLHAGSQKVHEH CONH2 
33 P0510571 H2N LHAGSQKVHEHGGGK CONH2 
34 P0510572 H2N SQKVHEHGGGKPIQG CONH2 
35 P0510573 H2N HEHGGGKPIQGSNFH CONH2 
36 P0510574 H2N GGKPIQGSNFHFFAV CONH2 
37 P0510575 H2N IQGSNFHFFAVGGEP CONH2 
38 P0510576 H2N NFHFFAVGGEPLEMQ CONH2 
39 P0510577 H2N FAVGGEPLEMQGVLM CONH2 
40 P0510578 H2N GEPLEMQGVLMNYRS CONH2 
41 P0510579 H2N EMQGVLMNYRSKYPD CONH2 
42 P0510580 H2N VLMNYRSKYPDGTIT CONH2 
43 P0510581 H2N YRSKYPDGTITPKNP CONH2 
44 P0510582 H2N YPDGTITPKNPTAQS CONH2 
45 P0510583 H2N TITPKNPTAQSQVMN CONH2 
46 P0510584 H2N KNPTAQSQVMNTDHK CONH2 
47 P0510585 H2N AQSQVMNTDHKAYLD CONH2 
48 P0510586 H2N VMNTDHKAYLDKNNA CONH2 
49 P0510587 H2N DHKAYLDKNNAYPVE CONH2 
50 P0510588 H2N YLDKNNAYPVECWVP CONH2 
51 P0510589 H2N NNAYPVECWVPDPSR CONH2 
52 P0510590 H2N PVECWVPDPSRNENA CONH2 
53 P0510591 H2N WVPDPSRNENARYFG CONH2 
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54 P0510592 H2N PSRNENARYFGTFTG CONH2 
55 P0510593 H2N ENARYFGTFTGGENV CONH2 
56 P0510594 H2N YFGTFTGGENVPPVL CONH2 
57 P0510595 H2N FTGGENVPPVLHVTN CONH2 
58 P0510596 H2N ENVPPVLHVTNTATT CONH2 
59 P0510597 H2N PVLHVTNTATTVLLD CONH2 
60 P0510598 H2N VTNTATTVLLDEQGV CONH2 
61 P0510599 H2N ATTVLLDEQGVGPLC CONH2 
62 P0510600 H2N LLDEQGVGPLCKADS CONH2 
63 P0510601 H2N GVGPLCKADSLYVS CONH2 
64 P0510602 H2N PLCKADSLYVSAADI CONH2 
65 P0510603 H2N ADSLYVSAADICGLF CONH2 
66 P0510604 H2N YVSAADICGLFTNSS CONH2 
67 P0510605 H2N ADICGLFTNSSGTQQ CONH2 
68 P0510606 H2N GLFTNSSGTQQWRGL CONH2 
69 P0510607 H2N NSSGTQQWRGLARYF CONH2 
70 P0510608 H2N TQQWRGLARYFKIRL CONH2 
71 P0510609 H2N RGLARYFKIRLRKRS CONH2 
72 P0510610 H2N RYFKIRLRKRSVKNP CONH2 
73 P0510611 H2N IRLRKRSVKNPYPIS CONH2 
74 P0510612 H2N KRSVKNPYPISFLLS CONH2 
75 P0510613 H2N KNPYPISFLLSDLIN CONH2 
76 P0510614 H2N PISFLLSDLINRRTQ CONH2 
77 P0510615 H2N LLSDLINRRTQRVDG CONH2 
78 P0510616 H2N LINRRTQRVDGQPMY CONH2 
79 P0510617 H2N RTQRVDGQPMYGMES CONH2 
80 P0510618 H2N VDGQPMYGMESQVEE CONH2 
81 P0510619 H2N PMYGMESQVEEVRVF CONH2 
82 P0510620 H2N MESQVEEVRVFDGTE CONH2 
83 P0510621 H2N VEEVRVFDGTERLPG CONH2 
84 P0510622 H2N RVFDGTERLPGDPDM CONH2 
85 P0510623 H2N GTERLPGDPDMIRYI CONH2 
86 P0510624 H2N LPGDPDMIRYIDKQG CONH2 
87 P0510625 H2N PDMIRYIDKQGQLQT CONH2 
88 P0510626 H2N RYIDKQGQLQTKML COOH 
     
 
 
BKV agno peptide library (15aa long peptides, 11aa overlap) 
 
 EGT N-Term Sequence C-Term 
     
198 P0510807 H2N MVLRQLSRQASVKVG CONH2 
199 P0510808 H2N LSRQASVKVGKTWT CONH2 
200 P0510809 H2N ASVKVGKTWTGTKK CONH2 
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201 P0510810 H2N KVGKTWTGTKKRAQR CONH2 
202 P0510811 H2N TWTGTKKRAQRIFIF CONH2 
203 P0510812 H2N TKKRAQRIFIFILEL CONH2 
204 P0510813 H2N AQRIFIFILELLLEF CONH2 
205 P0510814 H2N FIFILELLLEFCRGE CONH2 
206 P0510815 H2N LELLLEFCRGEDSVD CONH2 
207 P0510816 H2N LEFCRGEDSVDGKNK CONH2 
208 P0510817 H2N RGEDSVDGKNKSTTA CONH2 
209 P0510818 H2N SVDGKNKSTTALPAV CONH2 
210 P0510819 H2N KNKSTTALPAVKDSV CONH2 
211 P0510820 H2N TTALPAVKDSVKDS COOH 
     
 
 
BKV LT predicted 15 mere 
 
Pos N-Term Sequence C-Term 
    
010 to 033 H2N LERAAWGNLPLMRKA CONH2 
026 to 040 H2N NLPLMRKAYLRKCKE CONH2 
145 to 159 H2N HQFLSQAVFSNRTLA CONH2 
153 to 167 H2N FSNRTLACFAVYTTK CONH2 
172 to 186 H2N ILYKKLMEKYSVTFI CONH2 
190 to 204 H2N MCAGHNIIFFLTPHR CONH2 
212 to 226 H2N NFCQKLCTFSFLICK CONH2 
222 to 235 H2N FLICKGVNKEYLLYS CONH2 
232 to 246 H2N YLLYSALTRDPYHTI CONH2 
281 to 295 H2N ETKCEDVFLLLGMYL CONH2 
287 to 301 H2N VFLLLGMYLEFQYNV CONH2 
357 to 371 H2N MTREEMLTERFNHIL CONH2 
404 to 418 H2N DSVIFDFLHCIVFNV CONH2 
565 to 579 H2N LLEKRILQSGMTLLL CONH2 
573 to 587 H2N SGMTLLLLLIWFRPV CONH2 
    
 
 
BKV LT predicted 25mer 
 
Pos N-Term Sequence C-Term 
    
019 to 043 H2N LERAAWGNLPLMRKAYLRKCKEFHP CONH2 
145 to 167 H2N HQFLSQAVFSNRTLACFAVYTTKEK CONH2 
162 to 186 H2N AVYTTKEKAQILYKKLMEKYSVTFI CONH2 
188 to 212 H2N RHMCAGHNIIFFLTPHRHRVSAINN CONH2 
212 to 237 H2N NFCQKLCTFSFLICKGVNKEYLLYSAL CONH2 
227 to 250 H2N GVNKEYLLYSALTRDPYHTIEESI CONH2 
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280 to 304 H2N VETKCEDVFLLLGMYLEFQYNVEEC CONH2 
355 to 378 H2N LHMTREEMLTERFNHILDKMDLIF CONH2 
402 to 426 H2N KMDSVIFDFLHCIVFNVPKRRYWLF CONH2 
565 to 590 H2N LLEKRILQSGMTLLLLLIWFRPVADF CONH2 
    
 
 
BKV LT predicted 9mer 
 
Position N-Term Sequence C-Term 
    
19 H2N LERAAWGNL COOH 
21 H2N RAAWGNLPL COOH 
26 H2N NLPLMRKAY COOH 
27 H2N LPLMRKAYL COOH 
28 H2N PLMRKAYLR COOH 
29 H2N LMRKAYLRK COOH 
32 H2N KAYLRKCKE COOH 
33 H2N AYLRKCKEF COOH 
    
145 H2N HQFLSQAVF COOH 
148 H2N LSQAVFSNR COOH 
150 H2N QAVFSNRTL COOH 
156 H2N RTLACFAVY COOH 
158 H2N LACFAVYTT COOH 
159 H2N ACFAVYTTK COOH 
    
165 H2N TTKEKAQIL COOH 
166 H2N TKEKAQILY COOH 
167 H2N KEKAQILYK COOH 
169 H2N KAQILYKKL COOH 
172 H2N ILYKKLMEK COOH 
173 H2N LYKKLMEKY COOH 
176 H2N KLMEKYSVT COOH 
177 H2N LMEKYSVTF COOH 
178 H2N MEKYSVTFI COOH 
    
188 H2N RHMCAGHNI COOH 
192 H2N AGHNIIFFL COOH 
190 H2N MCAGHNIIF COOH 
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191 H2N CAGHNIIFF COOH 
196 H2N IIFFLTPHR COOH 
199 H2N FLTPHRHRV COOH 
201 H2N TPHRHRVSA COOH 
202 H2N PHRHRVSAI COOH 
    
212 H2N NFCQKLCTF COOH 
214 H2N CQKLCTFSF COOH 
216 H2N KLCTFSFLI COOH 
218 H2N CTFSFLICK COOH 
222 H2N FLICKGVNK COOH 
224 H2N ICKGVNKEY COOH 
226 H2N KGVNKEYLL COOH 
227 H2N GVNKEYLLY COOH 
230 H2N KEYLLYSAL COOH 
    
232 H2N YLLYSALTR COOH 
235 H2N YSALTRDPY COOH 
238 H2N LTRDPYHTI COOH 
242 H2N PYHTIEESI COOH 
    
282 H2N TKCEDVFLL COOH 
283 H2N KCEDVFLLL COOH 
286 H2N DVFLLLGMY COOH 
287 H2N VFLLLGMYL COOH 
289 H2N LLLGMYLEF COOH 
291 H2N LGMYLEFQY COOH 
293 H2N MYLEFQYNV COOH 
    
355 H2N LHMTREEML COOH 
359 H2N REEMLTERF COOH 
362 H2N MLTERFNHI COOH 
369 H2N HILDKMDLI COOH 
    
402 H2N KMDSVIFDF COOH 
403 H2N MDSVIFDFL COOH 
406 H2N VIFSFLHCI COOH 
410 H2N FLHCIVFNV COOH 
408 H2N FDFLHCIVF COOH 
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414 H2N IVFNVPKRR COOH 
415 H2N VFNVPKRRY COOH 
417 H2N NVPKRRYWL COOH 
418 H2N VPKRRYWLF COOH 
    
569 H2N RILQSGMTL COOH 
570 H2N ILQSGMTLL COOH 
571 H2N LQSGMTLLL COOH 
573 H2N SGMTLLLLL COOH 
574 H2N GMTLLLLLI COOH 
575 H2N MTLLLLLIW COOH 
576 H2N TLLLLLIWF COOH 
577 H2N LLLLLIWFR COOH 
579 H2N LLLIWFRPV COOH 
582 H2N IWFRPVADF COOH 
    
 
 
Polyomavirus JC proteins: 
 
JCV LT peptide library (15aa long peptides, 11aa overlap) 
 
 EGT N-Term Sequence C-Term 
     
240 P0510369 H2N MDKVLNREESMELMD CONH2 
241 P0510370 H2N LNREESMELMDLLGL CONH2 
242 P0510371 H2N ESMELMDLLGLDRSA CONH2 
243 P0510372 H2N LMDLLGLDRSAWGNI CONH2 
244 P0510373 H2N LGLDRSAWGNIPVMR CONH2 
245 P0510374 H2N RSAWGNIPVMRKAYL CONH2 
246 P0510375 H2N GNIPVMRKAYLKKCK CONH2 
247 P0510376 H2N VMRKAYLKKCKELHP CONH2 
248 P0510377 H2N AYLKKCKELHPDKGG CONH2 
249 P0510378 H2N KCKELHPDKGGDEDK CONH2 
250 P0510379 H2N LHPDKGGDEDKMKRM CONH2 
251 P0510380 H2N KGGDEDKMKRMNFLY CONH2 
252 P0510381 H2N EDKMKRMNFLYKKME CONH2 
253 P0510382 H2N KRMNFLYKKMEQGVK CONH2 
254 P0510383 H2N FLYKKMEQGVKVAHQ CONH2 
255 P0510384 H2N KMEQGVKVAHQPDFG CONH2 
256 P0510385 H2N GVKVAHQPDFGTWNS CONH2 
257 P0510386 H2N AHQPDFGTWNSSEVP CONH2 
258 P0510387 H2N DFGTWNSSEVPTYGT CONH2 
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259 P0510388 H2N WNSSEVPTYGTDEWE CONH2 
260 P0510389 H2N EVPTYGTDEWESWWN CONH2 
261 P0510390 H2N YGTDEWESWWNTFNE CONH2 
262 P0510391 H2N EWESWWNTFNEKWDE CONH2 
263 P0510392 H2N WWNTFNEKWDEDLFC CONH2 
264 P0510393 H2N FNEKWDEDLFCHEEM CONH2 
265 P0510394 H2N WDEDLFCHEEMFASD CONH2 
266 P0510395 H2N LFCHEEMFASDDENT CONH2 
267 P0510396 H2N EEMFASDDENTGSQH CONH2 
268 P0510397 H2N ASDDENTGSQHSTPP CONH2 
269 P0510398 H2N ENTGSQHSTPPKKKK CONH2 
270 P0510399 H2N SQHSTPPKKKKKVED CONH2 
271 P0510400 H2N TPPKKKKKVEDPKDF CONH2 
272 P0510401 H2N KKKKVEDPKDFPVDL CONH2 
273 P0510402 H2N VEDPKDFPVDLHAFL CONH2 
274 P0510403 H2N KDFPVDLHAFLSQAV CONH2 
275 P0510404 H2N VDLHAFLSQAVFSNR CONH2 
276 P0510405 H2N AFLSQAVFSNRTVAS CONH2 
277 P0510406 H2N AVFSNRTVASFAVY CONH2 
278 P0510407 H2N SNRTVASFAVYTTKE CONH2 
279 P0510408 H2N VASFAVYTTKEKAQI CONH2 
280 P0510409 H2N AVYTTKEKAQILYKK CONH2 
281 P0510410 H2N TKEKAQILYKKLMEK CONH2 
282 P0510411 H2N AQILYKKLMEKYSVT CONH2 
283 P0510412 H2N YKKLMEKYSVTFISR CONH2 
284 P0510413 H2N MEKYSVTFISRHGFG CONH2 
285 P0510414 H2N SVTFISRHGFGGHNI CONH2 
286 P0510415 H2N ISRHGFGGHNILFFL CONH2 
287 P0510416 H2N GFGGHNILFFLTPHR CONH2 
288 P0510417 H2N HNILFFLTPHRHRVS CONH2 
1 P0510418 H2N FFLTPHRHRVSAINN CONH2 
2 P0510419 H2N PHRHRVSAINNYCQK CONH2 
3 P0510420 H2N RVSAINNYCQKLCTF CONH2 
4 P0510421 H2N INNYCQKLCTFSFLI CONH2 
5 P0510422 H2N CQKLCTFSFLICKGV CONH2 
6 P0510423 H2N CTFSFLICKGVNKEY CONH2 
7 P0510424 H2N FLICKGVNKEYLFYS CONH2 
8 P0510425 H2N KGVNKEYLFYSALCR CONH2 
9 P0510426 H2N KEYLFYSALCRQPYA CONH2 
10 P0510427 H2N FYSALCRQPYAVVEE CONH2 
11 P0510428 H2N LCRQPYAVVEESIQG CONH2 
12 P0510429 H2N PYAVVEESIQGGLKE CONH2 
13 P0510430 H2N VEESIQGGLKEHDFN CONH2 
14 P0510431 H2N IQGGLKEHDFNPEEP CONH2 
15 P0510432 H2N LKEHDFNPEEPEETK CONH2 
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16 P0510433 H2N DFNPEEPEETKQVSW CONH2 
17 P0510434 H2N EEPEETKQVSWKLVT CONH2 
18 P0510435 H2N ETKQVSWKLVTQYAL CONH2 
19 P0510436 H2N VSWKLVTQYALETKC CONH2 
20 P0510437 H2N LVTQYALETKCEDVF CONH2 
21 P0510438 H2N YALETKCEDVFLLMG CONH2 
22 P0510439 H2N TKCEDVFLLMGMYLD CONH2 
23 P0510440 H2N DVFLLMGMYLDFQEN CONH2 
24 P0510441 H2N LMGMYLDFQENPQQC CONH2 
25 P0510442 H2N YLDFQENPQQCKKCE CONH2 
26 P0510443 H2N ENPQQCKKCEKKDQ CONH2 
27 P0510444 H2N CKKCEKKDQPNHF CONH2 
28 P0510445 H2N KCEKKDQPNHFNHHE CONH2 
29 P0510446 H2N KDQPNHFNHHEKHYY CONH2 
30 P0510447 H2N NHFNHHEKHYYNAQI CONH2 
31 P0510448 H2N HHEKHYYNAQIFADS CONH2 
32 P0510449 H2N HYYNAQIFADSKNQK CONH2 
33 P0510450 H2N AQIFADSKNQKSICQ CONH2 
34 P0510451 H2N ADSKNQKSICQQAVD CONH2 
35 P0510452 H2N NQKSICQQAVDTVAA CONH2 
36 P0510453 H2N ICQQAVDTVAAKQRV CONH2 
37 P0510454 H2N AVDTVAAKQRVDSIH CONH2 
38 P0510455 H2N VAAKQRVDSIHMTRE CONH2 
39 P0510456 H2N RVDSIHMTREEMLV CONH2 
40 P0510457 H2N SIHMTREEMLVERFN CONH2 
41 P0510458 H2N TREEMLVERFNFLLD CONH2 
42 P0510459 H2N MLVERFNFLLDKMDL CONH2 
43 P0510460 H2N RFNFLLDKMDLIFGA CONH2 
44 P0510461 H2N LLDKMDLIFGAHGNA CONH2 
45 P0510462 H2N MDLIFGAHGNAVLEQ CONH2 
46 P0510463 H2N FGAHGNAVLEQYMAG CONH2 
47 P0510464 H2N GNAVLEQYMAGVAWI CONH2 
48 P0510465 H2N LEQYMAGVAWIHCLL CONH2 
49 P0510466 H2N MAGVAWIHCLLPQMD CONH2 
50 P0510467 H2N AWIHCLLPQMDTVIY CONH2 
51 P0510468 H2N CLLPQMDTVIYDFLK CONH2 
52 P0510469 H2N MDTVIYDFLKCIVL CONH2 
53 P0510470 H2N VIYDFLKCIVLNIPK CONH2 
54 P0510471 H2N FLKCIVLNIPKKRYW CONH2 
55 P0510472 H2N IVLNIPKKRYWLFKG CONH2 
56 P0510473 H2N IPKKRYWLFKGPIDS CONH2 
57 P0510474 H2N RYWLFKGPIDSGKTT CONH2 
58 P0510475 H2N FKGPIDSGKTTLAAA CONH2 
59 P0510476 H2N IDSGKTTLAAALLDL CONH2 
60 P0510477 H2N KTTLAAALLDLCGGK CONH2 
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61 P0510478 H2N AAALLDLCGGKSLNV CONH2 
62 P0510479 H2N LDLCGGKSLNVNMPL CONH2 
63 P0510480 H2N GGKSLNVNMPLERLN CONH2 
64 P0510481 H2N LNVNMPLERLNFELG CONH2 
65 P0510482 H2N MPLERLNFELGVGID CONH2 
66 P0510483 H2N RLNFELGVGIDQFMV CONH2 
67 P0510484 H2N ELGVGIDQFMVVFED CONH2 
68 P0510485 H2N GIDQFMVVFEDVKGT CONH2 
69 P0510486 H2N FMVVFEDVKGTGAES CONH2 
70 P0510487 H2N FEDVKGTGAESRDLP CONH2 
71 P0510488 H2N KGTGAESRDLPSGHG CONH2 
72 P0510489 H2N AESRDLPSGHGISNL CONH2 
73 P0510490 H2N DLPSGHGISNLDCLR CONH2 
74 P0510491 H2N GHGISNLDCLRDYLD CONH2 
75 P0510492 H2N SNLDCLRDYLDGSVK CONH2 
76 P0510493 H2N CLRDYLDGSVKVNLE CONH2 
77 P0510494 H2N YLDGSVKVNLERKHQ CONH2 
78 P0510495 H2N SVKVNLERKHQNKRT CONH2 
79 P0510496 H2N NLERKHQNKRTQVFP CONH2 
80 P0510497 H2N KHQNKRTQVFPPGIV CONH2 
81 P0510498 H2N KRTQVFPPGIVTMNE CONH2 
82 P0510499 H2N VFPPGIVTMNEYSVP CONH2 
83 P0510500 H2N GIVTMNEYSVPRTLQ CONH2 
84 P0510501 H2N MNEYSVPRTLQARFV CONH2 
85 P0510502 H2N SVPRTLQARFVRQID CONH2 
86 P0510503 H2N TLQARFVRQIDFRPK CONH2 
87 P0510504 H2N RFVRQIDFRPKAYLR CONH2 
88 P0510505 H2N IDFRPKAYLRKSLS CONH2 
89 P0510506 H2N RPKAYLRKSLSCSEY CONH2 
90 P0510507 H2N YLRKSLSCSEYLLEK CONH2 
91 P0510508 H2N SLSCSEYLLEKRILQ CONH2 
92 P0510509 H2N SEYLLEKRILQSGMT CONH2 
93 P0510510 H2N LEKRILQSGMTLLLL CONH2 
94 P0510511 H2N ILQSGMTLLLLLIWF CONH2 
95 P0510512 H2N GMTLLLLLIWFRPVA CONH2 
96 P0510513 H2N LLLLIWFRPVADFAA CONH2 
97 P0510514 H2N IWFRPVADFAAAIHE CONH2 
98 P0510515 H2N PVADFAAAIHERIVQ CONH2 
99 P0510516 H2N FAAAIHERIVQWKER CONH2 
100 P0510517 H2N IHERIVQWKERLDLE CONH2 
101 P0510518 H2N IVQWKERLDLEISMY CONH2 
102 P0510519 H2N KERLDLEISMYTFST CONH2 
103 P0510520 H2N DLEISMYTFSTMKAN CONH2 
104 P0510521 H2N SMYTFSTMKANVGMG CONH2 
105 P0510522 H2N FSTMKANVGMGRPIL CONH2 
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106 P0510523 H2N KANVGMGRPILDFPR CONH2 
107 P0510524 H2N GMGRPILDFPREEDS CONH2 
108 P0510525 H2N PILDFPREEDSEAED CONH2 
109 P0510526 H2N FPREEDSEAEDSGHG CONH2 
110 P0510527 H2N EDSEAEDSGHGSSTE CONH2 
111 P0510528 H2N AEDSGHGSSTESQSQ CONH2 
112 P0510529 H2N GHGSSTESQSQCFSQ CONH2 
113 P0510530 H2N STESQSQCFSQVSEA CONH2 
114 P0510531 H2N SQCFSQVSEASGAD CONH2 
115 P0510532 H2N FSQVSEASGADTQEN CONH2 
116 P0510533 H2N SEASGADTQENCTFH CONH2 
117 P0510534 H2N GADTQENCTFHICKG CONH2 
118 P0510535 H2N ENCTFHICKGFQCF CONH2 
119 P0510536 H2N TFHICKGFQCFKKPK CONH2 
120 P0510537 H2N CKGFQCFKKPKTPPP CONH2 
121 P0510538 H2N CFKKPKTPPPK COOH 
     
 
 
JCV VP1 peptide library (15aa long peptides, 11aa overlap) 
 
 EGT N-Term Sequence C-Term 
     
139 P0510268 H2N MAPTKRKGERKDPVQ CONH2 
140 P0510269 H2N KRKGERKDPVQVPKL CONH2 
141 P0510270 H2N ERKDPVQVPKLLIRG CONH2 
142 P0510271 H2N PVQVPKLLIRGGVEV CONH2 
143 P0510272 H2N PKLLIRGGVEVLEVK CONH2 
144 P0510273 H2N IRGGVEVLEVKTGVD CONH2 
145 P0510274 H2N VEVLEVKTGVDSITE CONH2 
146 P0510275 H2N EVKTGVDSITEVECF CONH2 
147 P0510276 H2N GVDSITEVECFLTPE CONH2 
148 P0510277 H2N ITEVECFLTPEMGDP CONH2 
149 P0510278 H2N ECFLTPEMGDPDEHL CONH2 
150 P0510279 H2N TPEMGDPDEHLRGFS CONH2 
151 P0510280 H2N GDPDEHLRGFSKSIS CONH2 
152 P0510281 H2N EHLRGFSKSISISDT CONH2 
153 P0510282 H2N GFSKSISISDTFESD CONH2 
154 P0510283 H2N SISISDTFESDSPNR CONH2 
155 P0510284 H2N SDTFESDSPNRDMLP CONH2 
156 P0510285 H2N ESDSPNRDMLPCYSV CONH2 
157 P0510286 H2N PNRDMLPCYSVARIP CONH2 
158 P0510287 H2N MLPCYSVARIPLPNL CONH2 
159 P0510288 H2N YSVARIPLPNLNEDL CONH2 
160 P0510289 H2N RIPLPNLNEDLTCGN CONH2 
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161 P0510290 H2N PNLNEDLTCGNILMW CONH2 
162 P0510291 H2N EDLTCGNILMWEAVT CONH2 
163 P0510292 H2N CGNILMWEAVTLKTE CONH2 
164 P0510293 H2N LMWEAVTLKTEVIGV CONH2 
165 P0510294 H2N AVTLKTEVIGVTSLM CONH2 
166 P0510295 H2N KTEVIGVTSLMNVHS CONH2 
167 P0510296 H2N IGVTSLMNVHSNGQA CONH2 
168 P0510297 H2N SLMNVHSNGQATHDN CONH2 
169 P0510298 H2N VHSNGQATHDNGAGK CONH2 
170 P0510299 H2N GQATHDNGAGKPVQG CONH2 
171 P0510300 H2N HDNGAGKPVQGTSFH CONH2 
172 P0510301 H2N AGKPVQGTSFHFFSV CONH2 
173 P0510302 H2N VQGTSFHFFSVGGEA CONH2 
174 P0510303 H2N SFHFFSVGGEALELQ CONH2 
175 P0510304 H2N FSVGGEALELQGVLF CONH2 
176 P0510305 H2N GEALELQGVLFNYRT CONH2 
177 P0510306 H2N ELQGVLFNYRTKYPD CONH2 
178 P0510307 H2N VLFNYRTKYPDGTIF CONH2 
179 P0510308 H2N YRTKYPDGTIFPKNA CONH2 
180 P0510309 H2N YPDGTIFPKNATVQS CONH2 
181 P0510310 H2N TIFPKNATVQSQVMN CONH2 
182 P0510311 H2N KNATVQSQVMNTEHK CONH2 
183 P0510312 H2N VQSQVMNTEHKAYLD CONH2 
184 P0510313 H2N VMNTEHKAYLDKNKA CONH2 
185 P0510314 H2N EHKAYLDKNKAYPVE CONH2 
186 P0510315 H2N YLDKNKAYPVECWVP CONH2 
187 P0510316 H2N NKAYPVECWVPDPTR CONH2 
188 P0510317 H2N PVECWVPDPTRNENT CONH2 
189 P0510318 H2N WVPDPTRNENTRYFG CONH2 
190 P0510319 H2N PTRNENTRYFGTLTG CONH2 
191 P0510320 H2N ENTRYFGTLTGGENV CONH2 
192 P0510321 H2N YFGTLTGGENVPPVL CONH2 
193 P0510322 H2N LTGGENVPPVLHITN CONH2 
194 P0510323 H2N ENVPPVLHITNTATT CONH2 
195 P0510324 H2N PVLHITNTATTVLLD CONH2 
196 P0510325 H2N ITNTATTVLLDEFGV CONH2 
197 P0510326 H2N ATTVLLDEFGVGPLC CONH2 
198 P0510327 H2N LLDEFGVGPLCKGDN CONH2 
199 P0510328 H2N FGVGPLCKGDNLYLS CONH2 
200 P0510329 H2N PLCKGDNLYLSAVDV CONH2 
201 P0510330 H2N GDNLYLSAVDVCGMF CONH2 
202 P0510331 H2N YLSAVDVCGMFTNRS CONH2 
203 P0510332 H2N VDVCGMFTNRSGSQQ CONH2 
204 P0510333 H2N GMFTNRSGSQQWRGL CONH2 
205 P0510334 H2N NRSGSQQWRGLSRYF CONH2 
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206 P0510335 H2N SQQWRGLSRYFKVQL CONH2 
207 P0510336 H2N RGLSRYFKVQLRKRR CONH2 
208 P0510337 H2N RYFKVQLRKRRVKNP CONH2 
209 P0510338 H2N VQLRKRRVKNPYPIS CONH2 
210 P0510339 H2N KRRVKNPYPISFLLT CONH2 
211 P0510340 H2N KNPYPISFLLTDLIN CONH2 
212 P0510341 H2N PISFLLTDLINRRTP CONH2 
213 P0510342 H2N LLTDLINRRTPRVDG CONH2 
214 P0510343 H2N LINRRTPRVDGQPMY CONH2 
215 P0510344 H2N RTPRVDGQPMYGMDA CONH2 
216 P0510345 H2N VDGQPMYGMDAQVEE CONH2 
217 P0510346 H2N PMYGMDAQVEEVRVF CONH2 
218 P0510347 H2N MDAQVEEVRVFEGTE CONH2 
219 P0510348 H2N VEEVRVFEGTEELPG CONH2 
220 P0510349 H2N RVFEGTEELPGDPDM CONH2 
221 P0510350 H2N GTEELPGDPDMMRYV CONH2 
222 P0510351 H2N LPGDPDMMRYVDKYG CONH2 
223 P0510352 H2N PDMMRYVDKYGQLQT CONH2 
224 P0510353 H2N RYVDKYGQLQTKML COOH 
     
 
 
JCV agno peptide library (15aa long peptides, 11aa overlap) 
 
 EGT n-term Sequence C-term 
     
225 P0510354 H2N MVLRQLSRKASVKVS CONH2 
226 P0510355 H2N LSRKASVKVSKTWS CONH2 
227 P0510356 H2N KASVKVSKTWSGTKK CONH2 
228 P0510357 H2N KVSKTWSGTKKRAQR CONH2 
229 P0510358 H2N TWSGTKKRAQRILIF CONH2 
230 P0510359 H2N TKKRAQRILIFLLEF CONH2 
231 P0510360 H2N AQRILIFLLEFLLDF CONH2 
232 P0510361 H2N LIFLLEFLLDFCTGE CONH2 
233 P0510362 H2N LEFLLDFCTGEDSVD CONH2 
234 P0510363 H2N LDFCTGEDSVDGKKR CONH2 
235 P0510364 H2N TGEDSVDGKKRQRHS CONH2 
236 P0510365 H2N SVDGKKRQRHSGLTE CONH2 
237 P0510366 H2N KKRQRHSGLTEQTYS CONH2 
238 P0510367 H2N RHSGLTEQTYSALPE CONH2 
239 P0510368 H2N LTEQTYSALPEPKAT COOH 
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Figure 26. Checker-board of peptide sub-pools I-J and 1-10. 
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Figure 27. Checker-board of peptide sub-pools K-N and 11-20. 
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Figure 28. Checker-board for peptide pools O-R and 11-20 
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